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Obesity is a serious global threat to public health causing serious chronic metabolic diseases. The 
drug Orlistat has been used for obesity treatment; however, orlistat causes unpleasant 
gastrointestinal side-effects. Recent research has investigated bioactive compounds from seaweeds, 
like alginate, as pancreatic lipase inhibitors to modulate fat digestion and reduce caloric intake. 
Previous work has shown that certain alginates can inhibit pancreatic lipase activity in vitro by up 
to 72%. 
The aim of this thesis is to investigate the effect of alginate on lipase activity in vitro, using three 
different approaches: turbidimetric assay, a kinetic assay and a synthetic model gut system.  
The turbidimetric assay for pancreatic lipase showed alginates can inhibit pancreatic lipase, with 
the level of inhibition depending on alginate structure and concentration. Alginate with a high 
content of guluronate residues can inhibit pancreatic lipase activity more than alginate rich in 
mannuronate residues.  
Kinetic analysis showed that alginates act as mixed inhibitors that can bind to both the free enzyme 
and the enzyme-substrate complex.  
Alginate passed through the gastric phase of the synthetic model gut reduced glyceryl trioctanoate 
digestion, but not the digestion of olive or sunflower oil. However, alginate added at the small 
intestinal phase reduced olive oil digestion. The regulatory effect of alginate was affected by gastric 
pH resulting in gel formation and precipitation, reducing or preventing the release of free alginate 
and reducing lipase inhibition.  
Alginate bread was digestible within the synthetic model with most alginate release occurring in 
the small intestinal phase. Alginate incorporated into bread did not reduce fat digestion, which may 
be due to alginate fragmentation resulting from high temperatures during the cooking process.  
The capacity of unfragmented alginates to inhibit pancreatic lipase activity in vitro supports future 
investigations of alginate in vivo as a pancreatic lipase inhibitor to reduce fat digestion and 
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Chapter 1: General Introduction 
1.1  Overview of obesity 
Obesity can be defined as a body mass index (BMI) of greater than or equal to 30 kg/m2, and it 
occurs due to an imbalance between the amounts of energy intake and output [1]. Excessive fat is 
stored in adipose tissue [2]; therefore, obesity can be indicated by an excess of triacylglyceride 
storage in adipose tissue[3]. Fat metabolism must be balanced to maintain homeostasis, and thus 
prevents the development of obesity [4]. The design and development of drugs for obesity treatment 
accounts for 2-6% of the total medical care costs in most developed countries, and it is expected 
that there will be a continuous increase in the market for anti-obesity drugs due to the global spread 
of obesity [4].  Moreover, the same study reported that more than one billion adults are overweight, 
and, according to the clinical diagnosis, more than 300 million of those are classified as obese [4]. 
In one study, it was estimated that by 2030, 86.3% of adults in the USA will be overweight, and 
more than half of these will be obese. Consequently, there will be a twofold increase in medical 
care costs every ten years until 2030, accounting for approximately 16-18% of the total costs of 
medical care in the USA [5]. It has been reported that obesity affects more than a third of people 
globally [6, 7]. It is has been estimated that by 2030, 38% of worldwide adults will be overweight 
and also another 20% of adults around the world will be obese [8]. According to data obtained from 
a pooled analysis of BMI from people in 200 countries, the worldwide obesity would exceed 6% 
in males and 9% in females by 2015 [9]. The health hazards of obesity include the development of 
serious chronic diseases such as type 2 diabetes, atherosclerosis, and hypertension. In addition, 
there is an increased risk of developing fatal coronary heart disease. Therefore, anti-obesity agents 
which control the process of gastrointestinal lipolysis have been used to protect against or treat 
obesity-related diseases [4, 10]. 
 
1.2 Overview of the digestive processes 
The digestive system has four main functions: ingestion, digestion, absorption, and elimination. 
Ingestion is the process of food consumption. Digestion is a multi-step process of mechanical and 
chemical actions in which ingested macromolecules are broken down into smaller molecules that 




torn and ground into smaller fragments referred to as boluses. After mastication, the food boluses 
move to the stomach via the esophagus where the ingested material is churned by stomach muscles 
and mixed with acidic gastric secretions that further breaks down the food matrix. This material, 
the chyme, in turn moves into the duodenum through the pyloric sphincter where the bile has an 
emulsifying effect, breaking large fat droplets to smaller droplets. Digestion also includes the 
hydrolytic effects of digestive enzymes (Table 1.1). Protein and carbohydrate macronutrients in 
consumed food largely consist of long chain polymers which are broken down by proteases and 
carbohydrases respectively for absorption in the small intestine. Ingested fat consists 
predominantly of triglyceride molecules which must be broken down to monoglycerides and fatty 
acids which are absorbed through micellar uptake. The absorption process includes the transport 
of digested food from the gut lumen into blood and lymphatic circulation. The elimination process 
involves removing waste and undigested foods such as some fibres (water-insoluble fibres) which 
are indigestible by bacteria in the colon [11-13]. Carbohydrate, protein, and fat macromolecules 
are digested by substrate specific digestive enzymes and there are more than a hundred enzymes 














 Enzyme Enzyme function Enzyme source 
Carbohydrate    α- amylase 
 
Breaks down α 1→4 glycosidic 
bonds in starch into smaller chains 
of glucose molecules 
Produced by salivary glands       





Separates the disaccharide sucrose 
into monosaccharides glucose and 
fructose. 
 
Produced in the small intestine. 
 Lactase Splits the disaccharides lactose 
into glucose and galactose. 
 
Produced in the small intestine. 
 Maltase Separates maltose into two        
molecules of glucose. 
Produced in the small intestine. 
Fat Lipase Breaks down fats into fatty acids 
and glycerol. 
Produced in salivary glands        
(lingual lipase), the stomach    
(gastric lipase), and the pancreas 
(pancreatic lipase). The action of 
lipase is enhanced by bile. 
Protein Pepsin Separates proteins into shorter 
chains of amino acids 




 Trypsin Separates short chains of amino 
acids into molecules containing 
one, two, or three amino acids 
Produced by the pancreas 




1.2.1  Carbohydrate digestion and absorption 
Starch, maltose, sucrose, and lactose are the major constitutes of the digestible carbohydrates. 
Digestion of starch begins in the mouth by the action of salivary α-amylase produced from the 
salivary glands; however, starch undergoes only partial digestion in the mouth. In the stomach, α-
amylase lacks hydrolytic activity due to the low pH environment [13]. However, it has been 
suggested that α-amylase can be protected within the bolus from gastric acid and pepsin 
inactivation by its substrate starch polymers, and therefore recover activity when the pH level rises 
in the small intestine [15]. Both salivary and pancreatic α-amylase are classified as endosaccharides 
which exclusively cleave the internal α-1,4 glyosidic bonds, however, α-1,6 and α-1,4 glyosidic 
bonds of glucose molecules at the branched points or at the terminus are not cleavable by these 
endosaccharides [16]. The digestion of starch restarts in the small intestine by the action of 
pancreatic amylase and the brush border enzymes. Pancreatic α-amylase continues the breakdown 
of starch molecules into glucose and maltose. The brush border enzymes complete the digestion of 
carbohydrates for absorption. The brush border enzymes include lactase, sucrase, maltase, maltose-
glucoamylase and isomaltase (α-dextrinase), and they hydrolyse disaccharide molecules to simple 
sugars. Disaccharide maltose undergoes hydrolysis by maltase into two molecules of glucose, 
whereas isomaltase breaks down the α (1→ 6) bond in isomaltose, which is the product of 
amylopectin incomplete hydrolysis, into two molecules of glucose. Sucrase breaks the disaccharide 
sucrose into glucose and fructose, while lactase converts disaccharides lactose into the 
monosaccharides, glucose and galactose. The absorption of monosaccharides into the intestinal 
epithelial cell is achieved by either of two transport mechanisms: active transport or facilitated 
diffusion. Both glucose and galactose are absorbed by the enterocytes via the Na+-coupled 
secondary active transport symporter, Na+-glucose transporter 1 (SGLT1), which has a high affinity 
for Na+ ions. The binding of two Na+ ions to the SGLT 1 symporter, changes the symporter shape 
and allows the sugar molecule to bind to the symporter with high affinity. SGLT1 transports glucose 
(or galactose) and Na+ ions from outside the cell to inside the cell.  The movement of each molecule 
of D-glucose down its concentration gradient by SGLT1 is coupled with the transport of two Na+ 
ions. The cell possesses internal ion concentrations which are low in Na+ and high in K+ due to the 
action of sodium potassium ATPase. The concentration of Na+ outside of the cell is higher than the 
concentration of Na+ ions inside the cell, in contrast, the concentration of K+ ions outside the cell 
is lower than inside the cell. The Na+ which arrives inside the cell through secondary active 




the reduction in the affinity of the transporter for the glucose.  The process of glucose transport to 
enterocytes requires energy because lipid bilayers have a low permeability to glucose, and this 
energy is provided through the Na+ ion gradient produced by basolateral K+/Na+-ATPase. Then, 
the glucose moves from the cell on the basolateral side of enterocyte where the glucose 
concentration is high to a low concentration outside the cell through the facilitated diffusion 
transporter Glucose transporter 2 (GLUT2), which creates a central aqueous channel for the 
transport of monosaccharides (glucose, galactose or fructose) through the lipid bilayer to the 
bloodstream. However, unlike glucose and galactose which are absorbed by the enterocytes 
through the SGLT1 symporter, fructose is absorbed by enterocytes through a specific facilitated 
diffusion carrier called GLUT5. Inside the enterocyte cell, the fructose is converted to glucose and 
lactic acid which in turn reduces its intracellular concentration, helping in its continuous transport 
from the intestinal lumen through facilitated diffusion. Then, these mono-saccharides (glucose 
molecules) are moved to interstitial fluid via GLUT2 where they are released to the blood 
capillaries, then to the liver through the portal vein where they can be stored as glycogen [13, 16, 
17] 
 
1.2.2 Protein digestion and absorption 
 Digestion of dietary proteins is achieved through a range of proteolytic enzymes with each of the 
enzymes having different peptide bond specificity. Exopeptidases break down the protein chain 
one amino acid at a time from the carboxy or amino end of the protein or polypeptide while 
endopeptidases cleave specific internal bonds producing large polypeptides [16]. The majority of 
protein digestion starts in the stomach, where about 10-20 % of proteins are digested by the action 
of an endopeptidase pepsin [17]. Gastric hydrochloric acid has the ability to denature proteins, 
allowing the digestive enzymes to attack peptide bonds. Additionally, hydrochloric acid provides 
the appropriate acidic environment at which active pepsin is formed from its inactive proenzyme 
pepsinogen. The conformation of inactive pepsinogen is changed by the effect of HCl produced by 
the parietal cells. Pepsinogen is stable at pH between 6 and 9, but at pH equal to or less than 6, 
pepsinogen undergoes autocatalytic activation and is converted to the active pepsin in the stomach 
[16, 18, 19]. The optimum pH for pepsin activity is pH 2.0 [18]. In the stomach, pepsin is at its 




polypeptide chains. Pepsins possess a relatively wide specificity; however, they favour peptide 
bonds that attached to a sequence composed of large hydrophobic/aromatic amino acids such as 
phenylalanine, tyrosine, tryptophan, and leucine [16, 20]. Protein digestion continues in the lumen 
of the small intestine. The entry of partially digested proteins and polypeptides into the duodenum 
of the small intestine activates release of cholecystokinin (CCK) from duodenal I cells into the 
bloodstream which activates the pancreas to produce intestinal proteases (trypsin, chymotrypsin, 
proelastase and carboxypeptidase A and B) in their inactive forms (zymogens) trypsinogen, 
chymotrypsinogen, elastase and procarboxypeptidase A and B, respectively, along with pancreatic 
bicarbonate. Active trypsin is produced from the cleavage of trypsinogen by the action of a brush-
border enzyme enterokinase. Then, this active trypsin stimulates the proteolytic enzyme cascade, 
with the cleavage of chymotrypsinogen, elastase and procarboxypeptidase A and B to produce their 
active forms. The bicarbonate starts to neutralise the gastric acid and produce an optimum pH at 
which the intestinal proteases can break down the polypeptide chains into chains of three or fewer 
of amino acids (tripeptides and dipeptides) as well as amino acids. Trypsin, chymotrypsin, and 
elastase are serine proteases which function as endopeptidases. Trypsin favours to attack the 
peptide bonds adjacent to lysine or arginine residue. Chymotrypsin tends to cleave the peptide bond 
attached to hydrophobic amino acids, whereas elastase cleaves elastin and peptide bonds attached 
to alanine, serine, and glycine [16].  
The brush border peptidases cleave the tripeptides and dipeptides, releasing free amino acids. 
Additionally, the intracellular peptidases are responsible for the cleavage of some tripeptides and 
dipeptides which are absorbed via di- and tripeptide cotransporter 1 (PEPT 1), releasing free amino 
acids. The absorption process of the free amino acids into the epithelial cell in the small intestine 
is achieved by facilitated diffusion or secondary active transport via specific transport proteins 
mainly coupled to Na+ uptake [13, 17, 18, 21]. The amino acid transporters are stereospecific 
transporters which transport L-isomer of amino acid rather than D-isomer. Also, many amino acid 
transporters have wide substrate specificity, hence, many amino acids can be carried by one 
transporter. Additionally, the specificity of amino acid transporter overlaps where the amino acids 
can access several transporters. Therefore, the amino acid transporters can be identified by the type 
of amino acid carried (acidic, basic, neutral, or zwitterionic) and the mechanism by which the 
amino acid is carried (facilitated diffusion or secondary active transport). Information about the 




if required, the kind of transport mechanism, and their positions in epithelial cells (apical or 
basolateral membrane) are summarised in Table 1.2. The neutral L-amino acids are transported 
across the apical side of enterocyte through the secondary active Na+-dependent cotransporter 
(referred to as system B), and then they are transported across the basolateral side of enterocyte to 
the bloodstream via sodium ion-independent facilitated diffusion. 
 
 
Table 1.2. Common transporters for amino acids and peptides in the epithelial cells of small intestine. 
Copied from Goodman, (2010) [16]. 
  
The free amino acids are moved from the basolateral side of the enterocyte into the bloodstream 
via three amino acid transporters independent of Na+ ions (asc, L, and y transport systems). 
However, two amino acid transporters (A and ASC transport systems) which are dependent on Na+ 
ions carry amino acids from the bloodstream into the enterocyte to supply the cell with nutrients 
[16].  
The di- and tripeptides are transported through the apical membrane of the enterocyte by PEPT 1 
coupled with H+ ions. The pH of the unstirred water layer which bathes the brush border is around 
6.0 while the intracellular pH of the enterocyte is about 7.4, indicating a difference in the 
concentrations of H+ ion between the two regions. The H+ electrochemical gradient is produced and 




ATPases. The PEPT 1 transporter takes advantage of H+ electrochemical gradient from the lumen 
to the cytoplasm of enterocyte [16, 22]. The di- and tripeptides which are carried to the enterocytes 
undergo further hydrolysis by intracellular peptidases inside the cells, producing free amino acids 
which are transported to the bloodstream through facilitated diffusion. However, not all the di- and 
tripeptides are broken down to amino acids and some are transported out via a basolateral peptide 
transporter [16]. 
 
1.2.3 Fat digestion and absorption 
Dietary fats include triglycerides, phospholipids (e.g., phosphatidylcholine) and sterols (e.g., 
cholesterol). The majority of these dietary fats from either animal or plant sources are hydrolysed 
by digestive enzymes to their basic structures before being absorbed. Moreover, these dietary fats 
are hydrophobic macromolecules, and therefore they must undergo emulsification to allow their 
hydrolysis by the digestive enzymes into smaller molecules which can be absorbed easily by the 
body [23].  Triglycerides constitute the majority of ingested dietary fats where they form 90-95% 
of the whole energy obtained from dietary fats [16, 24]. Fat digestion starts in the mouth by the 
action of lingual lipase produced by lingual glands. Fat digestion continues in the stomach by the 
action of gastric lipase produced by Chief cells in the stomach where 10-30% of dietary fats 
(triglycerides) are digested [25]. However, the complete digestion of dietary triglycerides occurs 
in the small intestine by pancreatic lipase.  
The arrival of fat into the intestinal duodenum activates the pancreas to produce lipases and 
esterases and triggers contraction of the gallbladder with the relaxation of the hepatopancreatic 
sphincter via the action of CCK to liberate bile. The bile contains bile salts which play a crucial 
role in fat digestion and absorption. Emulsification of dietary fats starts by cooking the food, 
continues with the action of crunching in the mouth, and mixing and peristalsis in the stomach [26]. 
The emulsion droplets which come from the stomach comprise triglycerides and diglycerides in 
their centre and are surrounded by polar lipids, phospholipids, fatty acids, triglycerides, cholesterol, 
denatured proteins, oligosaccharides, and bile salts are added in the intestinal duodenum. In the 
small intestine, large fat droplets undergo an emulsification process in which bile salts disperse 
them, leading to an increase in their surface area, thus allowing the digestive enzymes to hydrolyse 




number of pancreatic lipase molecules at oil/water interface of the substrate.  
Triglyceride hydrolysis by pancreatic lipase requires the presence of colipase. Pancreatic colipase 
is a protein coenzyme which is produced as an inactive procolipase which is then converted to the 
active colipase by the action of trypsin. The colipase has the ability to bind to both dietary 
triglyceride and to the lipase itself, enabling the access of the triglyceride to the active site of the 
lipase enzyme to undergo lipolysis. Also, the presence of colipase is necessary to avoid this 
inactivation. Pancreatic lipase attacks the ester bonds of triglyceride releasing two free fatty acids 
and a 2-mononacylglycerol molecule [16, 21, 27]. Dietary cholesterol esters undergo digestion by 
the action of pancreatic esterase releasing fatty acids and cholesterol. Dietary phospholipids are 
digested by phospholipase A2, producing a lysophospholipid and a free fatty acid.   
The lipid-soluble products produced from digestion of dietary fats undergo a solubilisation process 
by bile salts within the mixed micelles in the lumen of small intestine. Mixed micelles comprise 
bile and mixed lipids such as fatty acids, monoglycerides, cholesterol, lysophospholipids, and fat-
soluble vitamins. The mixed micelles are transported through the unstirred water layer bathing the 
brush-border membrane of the enterocytes where the pH is low at this region due to Na+/H+ 
exchange at the apical membrane of the enterocyte. The fatty acids inside the mixed micelles are 
protonated and released from the mixed micelles to move across the lipid bilayer membranes 
through simple diffusion. Due to their solubility in water, medium-chain free fatty acids containing 
4 to 12 carbon atoms can move through the unstirred water layer before being transported through 
the lipid bilayer to the enterocyte by simple diffusion [16]. They are then carried to the bloodstream 
where they are carried to the liver bound to albumin proteins. Other products resulting from lipid 
digestion are carried through the lipid bilayer and enter the enterocytes through simple diffusion. 
Once absorbed into the enterocytes, triglycerides are reformed in the cytoplasm of the enterocyte 
from monoglyceride molecules and fatty acids, and then the triglycerides are incorporated into 
chylomicrons which are then released to lymph and pass into the blood stream through the thoracic 





1.3 Overview of the digestive enzymes 
1.3.1 Αlpha-amylase structure and activity 
Alpha-amylase, which is also known as α-1, 4 glucan-4-glucanohydrolase (EC3.2.1.1), is a 
digestive enzyme found in mammals, micro-organisms and plants [28]. This enzyme cleaves α-D-
(1, 4) glycosidic bonds of starch (plant), glycogen (animal) and different oligosaccharides. In 
mammals, there are two types of α-amylase, salivary amylase and pancreatic amylase [28]. In 1987, 
Buisson et al. studied the three-dimensional structure of porcine pancreatic α-amylase at 2.9 Å 
resolution using x-ray crystallography and divided the N-terminal domain, which consists of amino 
acids 1-410, into two domains A and B, suggesting that the porcine pancreatic α-amylase was 
composed of three domains (A, B, and C). Domain A is the largest domain composed of 330 amino 
acids (1 -100 and 169 -407) and located in the centre between domains B and C. Domain A 
possesses a structure of usual parallel-stranded alpha-beta barrel (α/β)8. Domain B, which is smaller 
than domain A, is composed of amino acids 101-168, and consists of two anti-parallel beta sheets 
as well as a long loop with less fixed inner structure. The domain B is located between the third 
beta-strand and the third alpha-helix of the central domain A and it links to domain A mostly 
through a disulfide bridge (Cys 70-Cys 115) and through Ca2+, indicating that the enzyme is Ca2+ 
dependent. Domain C includes amino acids 408-496 and makes a spherical unit where the chain 
bends to eight anti-parallel β- strands. Domain C is linked to domain A via a single polypeptide 






Figure 1.1. Solid ribbon representation of the alpha-carbon chain of porcine pancreatic amylase using the 
software developed by M. Carson (1987). Domain A with the (a/ β)8 barrel structure is shown in dark blue 
(helices) and light blue (β-sheets and random coil), domain B in yellow and domain C in green. The arrow 
points to the active site cleft between domains A and B. Adapted from Buisson et al., (1987) [28].  
 
 
According to Buisson (1987), the active site of pancreatic alpha-amylase is present in a cleft inside 
the central N-terminal domain, at the carboxy-end of the β-strands of the (α/β) 8 barrel. The same 
study reported that a pair of aspartic acid residues (Asp 197 and Asp 300) are involved in the 
catalytic mechanism of porcine pancreatic α-amylase [28]. Other amino acids bind to the substrate 
through hydrogen bonds and hydrophobic interactions. Alpha-amylase has specificity for interior 
α-D-(1, 4) glycosidic bonds of starch, glycogen and oligosaccharides converting them into smaller 
chains of glucose molecules. Salivary α-amylase hydrolyses 40% of ingested starch [29]. Salivary 
amylase is active at pH ranges from 6.6 to 6.8; however, it loses activity rapidly in the stomach due 
to the acidic environment [30]. When carbohydrates arrive into the small intestine, pancreatic 
amylase continues the carbohydrate digestion [31]. Human pancreatic amylase is stable at pH 
between 5.0 and 10.5, however, the optimum pH for pancreatic amylase is 7.1 [32]. Valle and his 
colleagues (1959) reported that calcium ions are crucial, and each α-amylase molecule needs at 
least one calcium ion to conserve the catalytic activity and tertiary structure of the enzyme [33]. 
Buisson, (1987) reported that the calcium ions are very important for conformational stability of 




calcium binding site produces an ionic bridge between the two domains [28]. As a result, the cleft 
of the catalytic site which exists between the domains A and B will be stabilised through this ionic 
bridge.   
In porcine pancreatic amylase, four amino acids, Asn 100, His 201, Arg 158 and Asp 167, act to 
bind calcium ions [34]. The catalytic mechanism of glycoside hydrolases usually occurs at an 
anomeric carbon (C1), the carbon forming the glycosidic bond, and this anomeric carbon possesses 
two conformations (α and β). The catalytic mechanism of theses enzymes is either an inverting or 
retaining mechanism. An inverting mechanism is where the primary conformation of the anomeric 
carbon is altered after cleavage of the glycosidic bond. In contrast, a retaining mechanism is where 
the initial conformation of the anomeric carbon remains unchanged after the cleavage of glycosidic 
bond.  
Pinto et al. (2015) used computational techniques, quantum mechanic (QM) and molecular 
mechanic (MM) methods to define the catalytic mechanism of human pancreatic α-amylase (HPA) 
[35].  They reported that three residues, Asp 197, Glu233, and Asp300, are involved in the catalytic 
mechanism of HPA. This mechanism involves two steps: glycosylation and deglycosylation. 
During the glycosylation step, the glyosidic bond is cleaved, and this step is catalysed by carboxylic 
acids of Asp197 and Glu233 residues which act as nucleophilic and proton donor residues, 
respectively, to produce a covalent intermediate. The Asp197 nucleophilic residue attacks the 
anomeric carbon (C1), breaking the glycosidic bond. Subsequently, a proton is transferred from 
Glu233 to the glycosidic oxygen forming a hydrogen bond between the Glu233 and the substrate, 
hence, the anomeric carbon atom attaches to Asp197 through a hydrogen bond. In the 
deglycosylation step, the covalent intermediate produced from the first step (glycosylation) 
undergoes a nucleophilic attack by the hydroxyl group of the water molecule located at the active 
site close to anomeric carbon (C1), producing enzyme/substrate covalent intermediate, carrying out 
the sugar hydrolysis. The nucleophilic attack of the hydroxyl group of the water molecule activates 
deglycosylation through the breakdown of glycosidic bond and sequential transfer of a proton to 
the Glu233 residue through the glycosidic oxygen, hence, Glu233 will retain its protons that it had 
at the beginning of the catalytic reaction (Figure 1.2 and Figure 1.3). According to Pinto et al. 
(2015),  the Asp 300 residue is essential for stability of the water molecule, which functions as a  
nucleophile for the second step, since the Asp300 enables the water molecule to be close enough 




earlier occupied by the glycosidic oxygen, enabling the nucleophilic attack of the C1 of the sugar 
residue by the water molecule [35].  
 
 
Figure 1.2. Conformation of α-amylase /substrate based on quantum mechanics (QM) layers. D197, 
D300, E233 represent aspartate 197, aspartate 300, and glutamate 233, respectively. C1 represents an 
















Figure 1.3. Catalytic mechanism for human pancreatic α-amylase (HPA). Residues and substrate are in 





1.3.2 Pepsin structure and activity 
Pepsin is a member of a widespread aspartate super-family (EC 3.4.23.) which exists in different 
species including humans, plants, retroviruses, yeast and fungi. Pepsin is the main proteolytic 
enzyme in protein digestion. There are five types of pepsins, A, B, C, F, and Y, however, in humans, 
only pepsins A and C are present, and these pepsins are the active forms of the two immunological 
groups of pepsinogens PGI and PGII in human, respectively. PGI pepsinogen is minimally 
composed of pepsinogens 1-5, and it is produced by oxyntic glands of the fundus. PGII pepsinogen 
has only pepsinogens 6 and 7 and it is produced by the antrum pyloric glands, the fundus oxyntic 
glands, and the tissues of the proximal duodenum [19].  
The first crystallisation for pepsin was achieved by John Northrop in 1930, and then the molecular 
and crystal structures of purified pepsin was determined in 1990 by Sielecki and his colleagues [36, 
37]. The three-dimensional structure of pepsin (Figure 1.4) shows that it is made up of two lobes, 
N-terminal lobe and C-terminal lobe, which are almost identical in structure and size, producing a 
double symmetry composed mainly of β-sheets stablised by hydrogen bonds [38, 39]. In porcine 
pepsin, the N-terminal lobe includes amino acids 1 to 175, whereas the C-terminal lobe includes 
amino acids 176 to 326 [40]. The pepsin active site is made up of a pair of aspartate residues (Asp32 
and Asp215) which exist in a deep cleft located between the two lobes. The cleft length is about 
30Å (angstrom), and it is enclosed by a flexible flap, made up of 30-90 amino acids, bulging from 
the N-terminal section of the pepsin enzyme. The flap is made up of two antiparallel strands L71-
G82 and it restricts the access of substrate to active site cleft [41]. Both Ser 35 and Thr 218 residues 
are involved in the hydrogen bonding network which links the Asp 32 and Asp 215 residues [19].  
Seventeen water molecules are essential for supporting the shape, geometry and function of active 
sites and conserving the stability of the flexible flap during the binding of substrate to the active 
site cleft [42]. Eliminating these essential water molecules from pepsin by water miscible organic 
solvents such as ethanol results in its permanent inactivation [43]. The presence of water molecules 
within the hydrogen bonding network, which links the Asp32 and Asp215, enables nucleophilic 
attack by the hydroxyl group of the water molecule on the carbonyl carbon of the peptide bond to 
produce –NH2 and COOH [19, 20]. Six stranded antiparallel beta sheets present between the N- 
and C terminal domains creates the active binding site of the substrate which is located at the 




active binding site for the substrate [19]. The catalytic diad Asp32 and Asp215 function as an acid 
and base, respectively, in the catalytic mechanism of pepsin. The carboxyl group of Asp215 
protonates the oxygen atom on the scissile peptide bond, whereas the Asp32 carboxyl group as 
anion (-COO-) acts as a nucleophile and attacks the carbonyl carbon of amide, which was 
protonated previously by Asp215, producing a tetrahedral intermediate complex. Then, the 
produced tetrahedral intermediate goes through a reversible four-center reaction to release the free 
acid as a product and the amino enzyme intermediate. This intermediate then undergoes a reaction 
with a water molecule producing the free amide as a product and regenerating the active pepsin 
enzyme [19, 44]. Asp32 has to have a low pKa at the highly acidic pH to maintain the negative 
charge on carbonyl group (-COO-), and the extensive hydrogen bonding is responsible for 
maintaining the negative charge of the Asp32 carboxyl group, allowing the pepsin enzyme to act 
at this low pH [19]. 
 
 





Pepsin, which is an endopeptidase, cleaves interior peptide bonds of the protein, producing large 
polypeptides. Pepsin has a high affinity for peptides bound to aromatic amino acids such as Phe, 
Tryp, and Tyr. Pepsin is produced in the stomach as an inactive zymogen, pepsinogen, which is 
then converted to the active pepsin by an autocatalytic mechanism in the acidic pH environment 
caused by the secretion of gastric HCl. The primary structure of pepsinogen is similar to pepsin but 
in addition has 44 residues, the propeptide covalently linked to the N-terminus of the protein. 
Pepsinogen remains stable at pH ranged between 7 and 9, however, the pepsinogen undergoes 
irreversible denaturation at pH above 9 [19]. At low pH (<5.0), the carboxyl groups of pepsinogen 
are protonated spontaneously through an auto-catalytic mechanism which is controlled by the pH, 
leading to removal of the propeptides and producing pepsin. Pepsin has optimum pH 1.6 to 2.5.  
[36, 45]. Pepsin becomes permanently inactivated at pH above 7. However, it has been shown that 
the pH of inactivation relies on the concentration of pepsin as well as the environment where 
purified pepsin at concentrations between 0.1 and 1 mg/ml experienced a permanent inactivation 
at pH 7.0, whereas pepsin in gastric juice repelled permanent denaturation until pH ranged between 
the 7.5 and 7.7 [19, 46]. 
 
1.3.3 Pancreatic lipase structure and activity 
Pancreatic lipase, which is also known as triacylglycerol acyl hydrolase (EC3.1.1.3), is present in 
the majority of adult vertebrates [47]. Human, pancreatic lipase is composed of 449 amino acid 
residues, and it contains two distinct domains linked together via a hinge region. The N-terminal 
domain, which is larger than C-terminal domain, is composed of amino acids 1 to 335 amino acids. 
The N-terminal domain has a usual alpha/beta structure which is controlled by a central parallel β-
sheet. The N-domain contains the active site with a catalytic triad generated from the three amino 
acids Ser 152, Asp 176, and His 263. This catalytic triad is protected by a surface loop (lid) which 
does not allow access of solvent or substrate molecule.  
The smaller C-domain is composed of amino acids 336 to 499, and it possesses a binding site for 
co-lipase. The C-domain consists of two β-sheet layers, giving a β-sandwich style. Each single beta 
sheet is composed of four anti-parallel strands (Figure 1.5) [48]. Lipase’s catalytic triad site is 
surrounded by a short amphipathic lid between the disulphide-linked residues 237 and 261, 




hydrophilic external side, and internal hydrophobic side which is facing to the active site. 
Pancreatic lipase must undergo interfacial activation in which the lid covering the enzyme catalytic 
site is opened, allowing the entry of substrate into the active site of enzyme. The 3-D structures of 
lipase-procolipase complex and lipase-procolipase-bile salts-phospholipid shows that the 
procolipase binds to the C-terminal domain of lipase. However, in the case of mixed bile salts-
phospholipid micelles, some alterations occur in the shape of the lid covering the lipase catalytic 
site where the hydrophobic side of the lid is exposed, whereas the hydrophilic side is buried, 
consequently the active site of lipase becomes accessible for the substrate. In its new open shape, 
the two lipase domains slightly turn around the hinge region, allowing binding of the N-terminal 
domain to procolipase through the open lid [48-51]. 
 
 
Figure 1.5. Schematic diagram of 3D-structure of the closed conformation of human pancreatic lipase. 
Arrows indicate β-strands, whereas coils indicate α-helix. The N- and C- terminal domains, the lid, and the 
side chains of Phe227 and Phe335, which are the chymotryptic cleavage site, are indicated. Taken from 
Aoubala et al., (1995) [51].  




enzyme retains substantial activity at pH 6.5, however, the pancreatic lipase becomes irreversibly 
inactive (permanently denatured) at pH less than 4, therefore, gastric acid must be neutralised by 
bicarbonate in pancreatic juice to prevent enzyme permanent denaturation and maintain enzyme 
activity [47, 53].  
There are many cofactors that affect pancreatic activity such as colipase, bile salts, and calcium 
ions. Colipase is a small non-enzymatic protein which has molecular weight about 10 kDa. 
Colipase is secreted as a procolipase which is converted by the action of trypsin to active colipase 
[47]. Binding of colipase to pancreatic lipase prevents enzyme inhibition by bile salts and protects 
the enzyme’s surface from denaturation. Bile salts inhibit pancreatic lipase activity since the bile 
salts bind to the substrate interface, promoting surface tension and hindering the binding of lipase 
to substrate interface. Colipase remains at the substrate interaction site allowing the enzyme to 
interact with the substrate in the presence of the bile salts [45, 54]. Hydrolysis of intralipid usually 
involves two-phase kinetics: initially, the lag phase which is a slow phase followed by steady-state 
phase which is a highly hydrolytic activity phase.  
Previous in vivo and in vitro studies showed that the presence of Ca2+ ions are essential for the 
activity of pancreatic lipase [54-60]. In vitro studies on the effect of calcium ions on the pancreatic 
lipase activity have shown that the activity of pancreatic lipase increased with increasing 
concentration of Ca2+ in the reaction mixture [55, 60].  It has been supposed that the bile salts bind 
to the substrate interface via the steroid nucleus giving the substrate a negative charge. The negative 
charge increases the electrostatic repulsion between the lipases and the interface of substrate. As a 
result, the penetration of lipases to the substrate interface may be reduced by the effect of 
electrostatic repulsion caused by this negative charge [61]. Armand et al. (1992) reported that the 
lag time of the reaction, which is the time required to approach the steady state maximum velocity, 
could be decreased by the addition of calcium ions, where these divalent ions reduce the 
electrostatic repulsion between the enzyme and the substrate [55]. Whickham et al (1998) showed 
that calcium ions could reduce the surface charge of emulsion droplets in the presence of bile salts, 
however, they did not find a relationship between the surface charge and the duration of lag phase, 
ruling out any important effect that electrostatic repulsion might have on the enzyme and the 
emulsion interface. It has been stated that the concentration of calcium in the fasted state is about 
3-4 mM, however, in the fed state, the concentration of calcium increases significantly to about 15 




maximum lipase activity, subsequently, the lipolytic activity of pancreatic lipase in vivo increases 
[59]. Additionally, in vitro studies showed that the free fatty acids, which result from the hydrolytic 
action of the pancreatic lipase on triacylglycerides, accumulate at the substrate surface, preventing 
the further hydrolytic action of pancreatic lipase on the substrate. Therefore, during in vitro 
lipolysis, these free fatty acids are precipitated as soaps by the action of calcium ions forming 
insoluble Ca-soap [56, 59]. However, in vivo, these free fatty acids are removed by their absorption 
through the intestinal walls [59]. Moreover, it has been suggested that calcium ions mix with the 
bile salts forming liquid crystal. Then, free fatty acids are dissolved in this liquid crystal and 
absorbed through the epithelial cells of the small intestine. The absorption of the free fatty acids 
through epithelial cells aids in removing these free fatty acids from the substrate surface, preventing 
the inhibition of the pancreatic lipase in vivo [59].  
 Yang et al. (2000) reported that calcium binding sites are present in the tertiary structures of 
Pseudomonas lipases. The calcium ion ligands in the Pseudomonas lipase contains two molecules 
of water, two carbonyl groups of Gln 292 and Val 296, and two carboxyl groups Asp 242 and Asp 
288. The same authors investigated the effect of EDTA at different temperature on lipase with 
calcium binding sites (wild type) and without calcium binding sites (mutant type). They found that 
the wild type of lipase, which contains the calcium binding sites, at temperature 37 °C was 
relatively stable where its activity was not affected, whereas the activity of mutant enzyme was 
low, showing that calcium is essential for the lipase stability and activation process in the presence 
of chelator EDTA. They found that replacing sp242 and Asp288 which are involved in the calcium 
binding sites of lipase decreased lipase activity but did not affect the activation process of lipase 
[62]. 
Pancreatic lipase specificity towards the fatty acids at positions sn-1 and sn-2, produces 2-
monoacylglycerol and two free fatty acids. This enzyme initially attacks the fatty acid chain at sn-
1, producing 2, 3-diacyglyceride and one free fatty acid. Secondarily, it attacks the fatty acid at sn-
2, producing 2-monoacylgyceride and two fatty acid molecules. The complete hydrolysis of 
triacyglycerides by pancreatic lipase to free glycerols occurs, where 2-monoacyglyceride is 
rearranged to 1-monoacylglyceride which then undergoes enzymatic hydrolysis [63, 64].  
The catalytic activity of lipase depends on the presence of an Asp-His-Ser catalytic triad at the 




serine residue of the catalytic triad site is linked via a hydrogen bond to nitrogen on histidine, and 
the nitrogen on histidine is linked via a hydrogen bond to the carboxylate group on aspartic acid.  
The initial step in the mechanism of lipase is increasing the nucleophilicity of the serine alcohol by 
histidine which attracts the proton of the serine alcohol towards itself, producing an oxyanion 
(oxygen ion). Then, the resulting oxyanion attacks the carbonyl carbon of the substrate, producing 
the tetrahedral intermediate 1 (Figure 1.6). Both adjacent amino acids, histidine and aspartic acid, 
which are linked via hydrogen bonds to serine, stabilise the oxyanion of serine. The electrons 
present on the oxyanion are transferred to the carbon of carbonyl group, and the proton present on 
the histidine is moved to the diglyceride which is consequently liberated. The produced serine ester 
reacts with alcohol to complete the transesterification process. The hydrogen atom of alcohol 
molecules is removed by nitrogen atom of histidine, producing alkyl oxide onion. The carbon of 
the carbonyl group is attacked by hydroxide, the oxyanion of the intermediate is stabilised by 
hydrogen bonds (tetrahedral intermediate 2), and the electrons are moved back to the carbon 
carbonyl, hence, the free fatty acid is produced. Then, the oxygen atom on serine retrieves the 
hydrogen from the histidine, and subsequently, the serine becomes hydrogen-bonded to the 
histidine. During the catalytic mechanism of lipase, the function of aspartic acid is attracting the 






Figure 1.6. Mechanism of lipase-catalysed transesterification of triglycerides.Taken from Jegannathan & 
Abang, (2008) [65]. 
 
1.4 Treatment of obesity 
1.4.1   Conventional obesity treatment 
Methods such as diet, improved eating habits and physical activity can be used in obesity treatment. 
Obese individuals are advised to eat low-fat foods, and to eat a reduced-calorie diet to reduce 
energy by 500-1000 kcal per day resulting in a body weight loss of 0.5-1 kg per a week [66]. 




15% of cases [67]. Daily physical exercise such as walking for 80-90 minutes or jogging for 35 
minutes is suggested as an obesity treatment because it can promote weight loss [68]. However, 
physical activity without a calorie reduced diet minimally reduces body weight. Walking 40-60 
minutes for four days every week managed only an energy deficiency of 1,000 kcal with reduction 
in body weight by 0.15 kg. Conversely, low calorie diets showed weekly energy deficiency of 
3.500-7000 kcal with reduction in weight by 0.5-1 kg per week [66]. 
 
1.4.2 Surgical treatment for obesity 
Surgical therapy such as gastric bypass, gastric banding, sleeve gastrectomy, and gastroplasty can 
be a reasonable option for obese individuals with a BMI >35 kg/m2 [69]. Surgical treatment has 
produced considerable and well-documented results in weight loss, improving the patients' health 
and quality of life [66, 70]. However, due to the serious side effects of surgical treatments such as 
nutritional deficiency, gastrointestinal symptoms, vomiting, and shortness of breath, it is only 
recommended for morbidly obese people whose lives are in great danger because of their excess 
weight [69, 71]. 
 
1.5 New approaches to the treatment of obesity 
1.5.1 Anti-obesity drugs targeting digestive enzymes: 
Mu & Høy's 2004 study demonstrated that about 40% of all energy intake results from dietary fats, 
mainly from triacylglycerol. Therefore, the inhibition of pancreatic lipase activity has become the 
strategy most frequently used for the treatment of obesity. Different types of potential anti-obesity 
drugs from microbial and plant sources such as lipstatin and its derivative Alli/Orlistat have now 
been developed [4, 72], and it has been reported that obesity can be treated successfully by using 






1.5.2  Orlistat 
Lipstatin is a highly selective drug which is isolated from Streptomyces toxytincini. This drug 
irreversibly inhibits pancreatic lipase with IC50 of 0.14 μM. However, due to its instability, it has 
been replaced by Orlistat [4, 74]. Orlistat, which is commercially available as Xenical and Alli, 
was approved in 1998, and it is considered the main clinically available drug for the long-term 
treatment of obesity [75]. In 2010, approximately 98% of all prescriptions for obesity treatment in 
the United Kingdom were for this drug. [72]. Orlistat is a saturated form of lipstatin, which is 
prepared by hydrogenation of lipstatin [76, 77]. Gastric and pancreatic lipases are inhibited by 
Orlistat through the nucleophilic attack of hydroxyl group of serine 152 residue at the active site 
of the lipase by the carbonyl carbon on the β-lactone ring of Orlistat, resulting in formation of long-
lived acyl enzyme complex 1. The acyl enzyme complex 1 undergoes a spontaneous hydrolysis 
where the covalent bond between the –OH group on serine and the β-lactone ring of Orlistat is 
cleaved, releasing the active enzyme and producing the β-hydroxy carboxylic acid 2 (Figure 1.7) 
[78, 79]. It has been reported that Orlistat reduces the absorption of dietary fat by 30% [80].  
However, this drug does produce some side effects such as diarrhoea, faecal incontinence, oily 
spotting, flatulence, nausea, and vomiting [77, 80, 81]. However, a 2001 study by Cavaliere et al 
suggested that avoiding a fat-rich diet and eating natural fibre such as Psyllium mucilloid can 






Figure 1.7. Schematic representation for the structure of Orlistat. A represents Orlistat structure, whereas 





Due to the limitation in the success of low-fat diets, calorie-restricted foods, and very low-calorie 
diets, and because the high cost and side effects of anti-obesity drugs as well as the negative effects 
arising from surgical treatment such as gastrointestinal symptoms and nutritional deficiencies [71], 
current treatments to combat obesity have been focused on using strategies such as satiety to control 
food consumption, and thus reduce energy intake [82]. The beneficial health effects of consuming 
high-fibre diets or fibre supplements as a method for weight loss have been confirmed by several 
international studies [83]. Dietary fibre can be defined as the edible parts of plants or analogues of 
non-starch polysaccharides and lignin which are indigestible and unabsorbed in the small intestine 
and are fermentable in the large intestine to short chain fatty acids which can be absorbed and used 
as energy source [84]. Dietary fibre is classified into water-soluble fibre such as storage 
polysaccharides, gum, pectin and mucilage, and water-insoluble fibre which includes cellulose, 
hemicellulose, and lignin. Both soluble and insoluble fibres have the ability to bind water and make 
a further reduction in the energy to weight ratio in diets [84-86]. However, in human, the amount 
of energy from short chain fatty acids of fermented fibre is low (5-10%) since only 40% of fibre 
undergoes the fermentation process, thus the consumption of fibrous food considerably reduces 
energy density [87, 88]. 
 
1.5.3.1 Beneficial health effects of dietary fibres 
Most studies related to adult health have clearly shown that the consumption of dietary fibre 
possesses well-documented physiological effects such as the promotion of satiety, the reduction of 
hunger, the regulation of energy intake, and assistance in weight loss [85, 86, 88]. It was indicated 
that when energy intake is ad libitum, eating an additional 14 g/day of fibre for more than two days 
for 3.8 months decreased the energy intake and body weight by 10% and 1.9 kg, respectively [88]. 
Furthermore, obese and overweight individuals, who consumed high amounts of fibre showed 
greater decrease in energy intake by 18% and weight loss by 2.4 kg compared with normal 
individuals whose energy intake was reduced by 6% and body weight by 0.8 kg [88]. Chewing 
foods rich in fibre decreases the rate of ingestion and enhances satiation since the chewing requires 
more time and increased effort. This may also enhance the secretion of saliva and gastric acid in 




has the ability to slow the transport of macronutrients from the stomach and reduce their digestion. 
In the small intestine, soluble fibre slows insulin and glycemic responses after eating and reduces 
hunger and energy intake [86, 88]. It has been reported that the reduction in energy density occurs 
due to the fibres capacity to provide bulk and weight to the diet which causes early signals of 
satiation and gastric fullness [88]. Also, Howarth et al (2001) reported that the addition of viscous 
dietary fibres, which tend to absorb enormous amounts of water, into foods promotes the signals 
of satiety by increasing the viscosity of gastrointestinal contents. The increase in viscosity of small 
intestinal contents delays stomach emptying and small bowel movement. As a result, the process 
of fat and carbohydrate absorption is delayed, thus the period in which the reaction between the 
nutritional substances and preabsorpative mechanisms of satiety lasts for a long time [86]. In 
addition, Burton-Freeman’s study showed that healthy adult humans require consumption of 20 to 
35g of dietary fibre every day. The same author noted that many epidemiologic studies have made 
a connection between the consumption of low fibre foods and obesity development [86].  
 
1.5.3.2 The influence of dietary fibre on digestive enzymes 
Previous studies have reported that dietary fibres can inhibit the activities of digestive enzymes. 
Ikeda and Kusano (1983) studied the effect of various indigestible polysaccharides on the activities 
of different digestive enzymes in vitro. They found that xylan, agar-agar and apple pectin could 
significantly reduce trypsin activity in vitro to 23, 52.4 and 38.3%, respectively [89]. The same 
authors reported that the activity of α-chymotrypsin was sharply decreased in vitro to 46.5, 54.4, 
and 56% by the action of xylan, sodium alginate and yeast mannan, respectively. Apple pectin and 
the carboxymethyl cellulose sodium salt considerably reduced α-amylase activity in vitro to 50.7 
and 57.1%, whereas apple pectin could significantly reduce pepsin activity in vitro to 42.6%. Many 
studies reported that fibre-enriched foods considerably reduced the process of protein digestion in 
humans [89]. The activity of pancreatic lipase was inhibited in vitro by wheat germ and wheat bran. 
A subsequent decrease in the absorption rate of cholesterol by 10% and dietary triglycerides by 24% 
in the small intestine was observed in seven healthy adult men who consumed standardised coarse 
wheat bran (0.5 g/kg body weight) every day over four weeks [90]. Based on the previous findings, 
it has been proposed that the influence of dietary fibre on lipid metabolism involves inhibition of 




reduction in cholesterol and triglyceride absorption was assessed either by the decrease in the fat 
level in the plasma or the increased amount of fat present in the stool [91]. 
 
1.5.4 Bio-active algal polysaccharides 
Marine-derived nutrients and some other marine bio-actives have been used as components in 
functional foods due to their physiological influence, with medical properties and numerous 
beneficial effects on health [92]. There are two types of dietary fibre involved in marine algae: 
water-soluble fibres including agars, alginic acid, furonan, laminarin and porphyran, and water-
insoluble fibres cellulose, mannans and xylan [93]. In this literature review, marine bio-active 
compounds obtained from the macroalgae species, namely algal polysaccharide alginates, have 
been focused on due to their effects on health as soluble fibre, and their wide range of applications 
in medicine, pharmacology and industry.  Algal polysaccharides are rich sources of carbohydrate, 
but they are indigestible and unabsorbed in the gastrointestinal tract, hence it cannot be deemed as 
high energy content food [92]. Edible seaweeds contain higher levels of fibres than the higher 
plants making up 33-50% of their dry weight [93]. The total content of polysaccharides in seaweeds 
is about 76% of dry weight [94].  
Algal polysaccharides can be used as prebiotics, antibacterial agents, antiviral agent, non-toxic 
antioxidants, stabilisers, thickeners, and emulsifiers [94]. Furthermore, they can act as anti-
coagulants, reduce low density lipid (LDL)-cholesterol in rats, provide protection against obesity 
and diabetes, decrease incidence of cancer of the large intestine, and decrease the absorption of 
after-meal glucose [93]. Eom et al’s study (2013) on the effect of algal polyphenolic compounds, 
phlorotannins extracted from brown algae Eisenia bicyclis by methanol, showed that phlorotannins 
could reduce pancreatic lipase activity in vitro, and among the six tested derivatives (eckol, 
fucofuroeckol A , 7-phloroeckol , dioxindehydroeckol, phlorofucofuroeckol A, and dieckol), 7-
phloroeckol had the most potent inhibitory effect (IC50=12.7 µM), however, the anti-pancreatic 
lipase activity of 7-phloroeckol was lower than its positive control Orlistat (IC50= 0.4 µM) [95]. 
Moreover, Matsumoto et al. (2010) reported that both algal bioactives fucoxanthin, which is 
extracted from edible brown algae, and its metabolite, fucoxanthinol, could reduce the lymphatic 
absorption of triglycerides as well as the concentration of triglycerides in the blood of rats, 




of rats [96]. Matsumoto and his colleagues (2010) found that the amounts of triglycerides liberated 
into the lymph after 4 h of administrating 1 ml of soybean oil containing 2 mg of fucoxanthin and 
fucoxanthinol to the lymph duct and the portal or the jugular vein were 53.1 and 59.4µmol, 
respectively, compared to 113.5 µmol of triglycerides released from the control group in which 
only 1 ml of soybean oil was administrated [96]. Additionally, Chater et al’s study (2016) on the 
effect of three brown algal species Ascophyllum nodosum, Fucus vesiculosus, and Pelvetia 
canaliculata, used as whole seaweed homogenate, sodium carbonate extract, and supernatants and 
pellets of ethanol extract, on pancreatic lipase activity in vitro using a turbidimetric lipase activity 
assay or a synthetic model gut model mimicking the upper part of the gastrointestinal tract  in vivo, 
found that all the algal extracts reduced the activity of pancreatic lipase, indicating that different 
algal bioactive compounds, namely alginate and polyphenols, are potent pancreatic lipase 
inhibitors [97].  
Recently, considerable efforts have been made to study the role of fibrous polysaccharides from 
algae in modulation of digestive processes by using them in the food industry as food ingredients 
in an attempt to manage body weight and treat obesity [92, 93]. 
 
1.5.5 Chemical structure of alginate 
Alginate is an ionic fibrous polysaccharide found in the cell walls of brown seaweed and some 
bacteria. Alginate is present in brown seaweed mainly as calcium salt of alginic acid, and 
sometimes as sodium, potassium and magnesium salts. Structurally, alginate is a linear unbranched 
biopolymer containing D-mannuronic (M) acid and L-guluronic (G) acid linked together by 1 →4 






Figure 1.8. Chemical structures of G-block (G), M-block (M), and alternating M-G block in 
alginate.Adapted from Lee & Mooney, (2012) [100]. 
 
1.5.5.1 Alginate sources and production 
Laminaria hyperborea, Macrocystis pyrifera and Ascophyllum nodosum are the most common 
kinds of brown seaweeds rich in alginate (Figure 1.9) [98]. 
The sodium and potassium salts of alginates are water-soluble, while calcium and magnesium salts 
are water-insoluble. Therefore, the first step in alginate extraction involves the conversion of 
insoluble calcium and magnesium alginates into soluble sodium alginate by treating them with an 
alkaline reagent: sodium carbonate pH 10 [101]. Alternatively, the same authors reported that 
alginate would extract efficiently by treating it with diluted mineral acid to convert the calcium 
alginate to alginic acid, and then alkali reagent is added to produce sodium alginate. 




chloride precipitation and hydrochloric acid precipitation. However, ethanol precipitation is the 
only method used to directly produce pure sodium alginate, whereas calcium chloride precipitation 
and hydrochloric acid precipitation produce calcium alginate and alginic acid, respectively, which 
can then be converted to sodium alginate. In the hydrochloric acid method, a solution of crude 
sodium alginate at pH 10 is mixed with hydrochloric acid (HCl) to produce alginic acid, then 
sodium carbonate (Na2CO3) is added and sodium alginate is formed. Next, the newly-formed 
sodium alginate is washed with ethanol, followed by exhaustive washing with ethanol using a 
soxhlet extractor to produce purified sodium alginate, which finally is dried (Figure 1.10). However, 
several comparative studies have indicated that purified sodium alginate can be made quickly, and 
in large amounts of high quality by the ethanol method which takes fewer steps compared to the 






Figure 1.9. Brown seaweeds rich in alginate. (A) Laminaria hyperborea, (B) Macrocystis pyrifera and (C) 






Figure 1.10. A schematic representation of the extraction-purification of sodium alginate from                 




1.5.5.2 Methods of gelling alginate 
Alginate has a wide range of applications in biomedical, pharmacological and industrial fields due 
to its gelling properties. In this literature review, two methods of gelling alginate have been 
summarised.   
 
1.5.5.3 Ionic cross-linking 
Alginate gel can be simply produced by using divalent cations. When calcium ions are added to 
sodium alginate polymer, the sodium ions of guluronic acid residues in the polymer are replaced 
by calcium ions, which are bound strongly to α-L-guluronate blocks, and an egg-box shaped 
structure is formed between alginate chains resulting in the formation of “cross-linked networks 
(Figure 1.11). Gels produced by ionic cross-linking contain large amounts of calcium ions which 
may cause cell toxicity, leading to formation of giant foreign body cells [100]. 
 
 
Figure 1.11. Alginate hydrogels prepared by ionic cross-linking (egg-box model)Adapted from Lee & 








1.5.5.3.1 Alginic acid gels 
Acid gels can be formed by reducing the pH of a sodium alginate solution slowly below the pKa of 
the uronic residues, where pKa for guluronic acid and mannuronic acids are 3.65 and 3.38, 
respectively. The direct addition of acid to the alginate solution results in alginic acid precipitation 
instead of acidic gel formation. Therefore, lowering the pH value of the alginate solution should 
be carried out by adding hydrolysing lactones such as D-glucono-δ-lactone (GLD) gradually, thus 
the electrostatic repulsion between the chains of alginate polymer will be decreased leading to the 
formation of hydrogen bonds, and thus a weak acid gel is formed. The addition of mineral acid to 
pre-formed ionically cross-linked gel results in the formation of alginic acid gel [102, 103]. 
 
1.5.5.3.2 Properties and applications of alginate 
There are multiple applications for alginates in industry, medicine and pharmacy. In the food 
industry, alginates are used mainly as stabilisers, viscosifiers and gelling agents. Alginates are 
widely used as additives in jam, jellies, fruit fillings, onion rings and reconstituted meat [104]. 
Many studies have recently focused on using alginate hydrogel in the biomedical and 
pharmaceutical fields because it is biocompatible, low toxicity, fairly inexpensive and quickly 
forms gels [100]. The biomedical and pharmaceutical applications of alginates include using the 
hydrogel alginate as a dressing for moderate to severe wounds and also for dental impressions, in 
addition, the hydrogel alginate is used in formulations for protecting from gastric reflux, also in 
cell immobilisation for the production of antibiotics, steroids or ethanol from yeast cells [104] . 
 
1.5.5.4 The valuable health benefits of alginates as a digestive enzyme inhibitor 
Previous studies have shown that the addition of seaweed extracts of alginate to diets has potential 
positive health effects such as a decrease in blood glucose level in human [105], a promotion in fat 
discharge with stool [106], a decrease in energy consumption [10], and protection of the gastric 
and intestinal surface membranes from carcinogenic substances. The consumption of food 
containing sodium alginate modulates appetite since alginate gel formation in the stomach 




addition of alginate with calcium alters gelation and viscosity, and subsequently increased gastric 
distension, decreased nutrient absorption and delays postprandial insulin and glucose responses 
[83]. Furthermore, it has been demonstrated that about 52% [107]and 53.9% [108] of the digestive 
enzyme pepsin activity was inhibited by alginate, and the level of pepsin inhibition depended on 
the molecular weight of the alginate [109]. In the 2014 study by Wilcox et al. it was shown that 
alginates have an inhibitory effect on pancreatic lipase, and this can provide an explanation for the 
previous observation in the 1994 study by Sandberg et al., showing an increase in fatty acid 
discharge in the stool of ileostomy patients (Wilcox et al, 2014). The level of the inhibitory effect 
of the alginate relies on its structural content. Alginate containing a high proportion of guluronate 
(G) units inhibits pancreatic lipase more than alginate with high mannuronate (M) content [72]. 
 
1.5.5.5 Modification of alginate 
Alginate biosynthesis studies have revealed that in both algae and bacteria the alginate is 
synthesised as a polymer of mannuronate, and the variety of structural and functional features of 
various alginates is produced by the modifying enzymes mannuronan C-5 epimerases, lyases, and 
acetylases. Alginate epimerases AlgE1, AlgE4, and AlgE6 have been isolated from the bacterium 
a.vinelandii, and can be used to modify chemical composition and the sequence of M and G 
residues in alginate in vitro to produce alginate polymer with the desired ratio of M and G residues 
and the arrangement of these residues for use in medical, pharmaceutical and industrial applications. 
AlgE4 converts M-blocks into a polymer consisting of MG sequences, while AlgE6 and AlgE1 
form G-block homopolymers and bifunctional G-blocks + MG-blocks, respectively [103]. The M 
and G contents and their arrangement affects the properties of alginates such as viscosity, chain 









Chapter 2: Lipase Regulation by Alginate 
2.1 Introduction 
Obesity has become a serious public health problem in all industrial countries. In western countries, 
40% of energy from diets comes from fats, mainly triglycerides [110]. It had been reported that fats 
contain a large amount of carbon-hydrogen bonds which are rich in energy. Approximately 38 kJ 
is released from the consumption of one gram of oil or fat, and this is double the amount of energy 
released from the consumption of one gram of carbohydrates or proteins [111]. The daily average 
amounts of fats consumed by adults in the western world is 60 to 150 g, and about 90% of this fat 
intake is in the form of triglycerides, whereas the remaining 10% includes free fatty acids, 
cholesterol ester (CE), phospholipids, and plant sterols [23]. Triglyceride forms 90-95% of dietary 
fat, and their digestion occurs mainly in the small intestine by pancreatic lipase. Therefore, several 
studies have focused on reducing triglyceride digestion through inhibiting pancreatic lipase to 
reduce caloric intake and thus fight obesity [4, 112].  
Orlistat, which is a derivative of lipstatin from Streptomyces toxitricini, has managed to decrease 
about 35% of fat absorption in humans by inhibiting gastric and pancreatic lipases as well as 
carboxyl esterase, thus reducing triglycerides and cholesterol ester hydrolysis [112]. Although 
Orlistat has become a very popular anti-obesity drug especially in the United Kingdom where it 
formed 98% of prescriptions for obesity treatment in 2010, some unpleasant gastrointestinal side 
effects were associated with using Orlistat. However, it has been reported that consuming natural 
fibres, such as Psyllium mucilloid, at the same time with Orlistat may decrease these [113]. 
Currently, many studies have suggested using dietary fibres, namely alginate as an obesity 
treatment. In 2015, Chater and his colleagues reported that alginate has the ability to reduce pepsin 
activity by 53.9% in vitro [108]. Additionally, it has been indicated that consumption of beverages 
or cereal bars containing alginate was linked to many health benefits including extended satiety, 
reduction in overall caloric intake, reduced levels of glucose and insulin in the blood, reduced fat 
digestion and weight loss. However, in these studies alginates caused some side effects such nausea, 
flatulence, burping, stomach-ache, and poor acceptability due to texture (reported as slimy in the 
mouth) and the individuals preferred the ordinary products which did not contain alginate [83, 105, 




Alginate is an indigestible polysaccharide present in cell walls and intercellular spaces of brown 
seaweed (Phyophyceae). Furthermore, some bacteria such as Azotobacter and Pseudomonas have 
the ability to generate alginate as a component of their extracellular matrix. Alginate usually exists 
as a salt of alginic acid in brown seaweeds, mainly as calcium salt and sometimes as sodium, 
potassium or magnesium salts [108, 115-117]. Alginate is a linear biopolymer consisting of D-
mannuronic (M) acid and L-guluronic (G) acids linked together by (1 →4) glycosidic bonds (Figure 
1.8). Knowing the chemical structure and monomeric sequence of alginate is essential since it 
provides information about the functionality of alginate. For example, the content of guluronic acid 
residues (FG) and the average number of consecutive guluronate units in the alginate polymer 
determines the alginate gel strength. Alginate with high content of G blocks forms a rigid gel due 
to the restricted rotation around the glycosidic bond creating by diaxial linkage in G-block, whereas 
the alginate containing a high amount of M blocks forms a flexible gel since the diequatorial,  
axial/equatorial, equatorial/axial in M, MG, and MG blocks composition can freely rotate around 
the glycosidic bond [108, 118-121]. Alginate chemical composition and sequence can be 
characterised by using either 1H or 13C-nuclear magnetic resonance spectroscopy (NMR).  
Alginate has been suggested as an inhibitor of pancreatic lipase, which is the main enzyme in 
triglyceride digestion, in an attempt to fight obesity. Therefore, the activity of pancreatic lipase 
must be assessed in the presence and absence of alginate to investigate alginate’s effect on lipase 
activity. In this chapter, the activity of lipase was determined using an adapted version of Vogel & 
Zieve’s (1963) assay [122]. This method is a turbidimetric assay which measures the reduction in 
triglyceride turbidity due to their hydrolysis to monoacylglycerol and free fatty acids by the action 
of pancreatic lipase. According to Vogel and Zeive (1963), the turbidimetric assay for determining 
lipase activity is one of the most effective titrimetric assays since it is rapid, sensitive, accurate, 
and repeatable. The same study reported that this method could be used in a routine clinically 
laboratory if the lipase substrate was carefully prepared as described in the paper. 
 
2.2 Overview of triglycerides  
Triglycerides are composed of glycerol and three fatty acids linked together by ester bonds (Figure 




enzyme under acidic conditions. This enzyme releases the short chain fatty acid from position 3 of 
triglycerides, producing a fatty acid and 1,2-diglyceride. Triglycerides which possess short-or 
medium chain fatty acids, such as milk triglycerides, are hydrolysed by gastric lipase [64]. Since 
the gastric lipase is inhibited by protonation of free fatty acids, only a trace amount of dietary fat 
is digested in the stomach compared with complete hydrolysis of these fats in the small intestine 
by the action of pancreatic lipase [123]. The lingual and gastric lipases are not able to hydrolyse 
cholesterol esters and phospholipids [124]. The majority of lipid digestion occurs in the small 
intestine where emulsified triglyceride molecules are hydrolysed by pancreatic lipase into 
monoglycerides, glycerol, and fatty acids [110].  
Pancreatic lipase prefers to attack the ester bond at position sn-1 producing, 2, 3-diacylglycerol and 
free fatty acids, then the lipase attacks the ester bond at position sn-3, producing 2-
monoacylglycerol and free acid [125, 126]. The digestion of triglycerides, cholesterol ester, and 
phospholipids in the small intestine by their digestive enzymes is controlled by two hormones:  
cholecystokinin (CCK) and secretin. Cholesterol ester is hydrolysed by the action of pancreatic 
enzyme cholesterol esterase into free cholesterol and free fatty acids which are absorbed in their 
free form. Phospholipids are hydrolysed by two pancreatic enzymes: phospholipase A1 (PLA1) and 
phospholipase A2 (PLA2). PLA2 is initially secreted as an inactive form (zymogen) and then 
activated by trypsin. It releases fatty acid at C2 position of the phospholipid, producing a 
lysophospholipid.  PLA 1 releases the fatty acid at C1 position of lysophospholipid, producing a 
glycerophosphoryl base which may then be excreted in faeces or undergo further hydrolysis and 
absorption [23]. The products resulting from dietary fat hydrolysis are absorbed in the form of 







Figure 2.1. Schematic picture of a triglyceride molecule shows the glycerol backbone, fatty acid (FA) 




Figure 2.2. Schematic representation for mechanism of triacylglycerol hydrolysis by lipase. Taken from 
Kumar & Dubey, (2015) [125]. 
 
Fatty acids consist of a hydrocarbon chain, which is hydrophobic, and a terminal carboxyl group. 
Although, the chain length of fatty acids may range from 4 to 24 carbons long, fatty acids with 18 
carbons long are the most predominant fatty acids in food [128]. Depending on the number of 
carbon atoms, fatty acids can be classified into short, medium and long chain fatty acids. Short 
chain fatty acids (SCFAs) contain 2-4 carbon atoms. Medium chain fatty acids (MCFAs) are 
composed of 6-10 carbon atoms, while long chain fatty acids (LCFAs) consist of 12-26 carbon 
atoms. Furthermore, fatty acids can be divided depending on the presence or absence of double 




their structure and can pack closely to each other, hence triglycerides with saturated fatty acids are 
solid at room temperature. Unsaturated fatty acids may have one double bond (monounsaturated) 
or more (polyunsaturated). These unsaturated fatty acids lack the ability to arrange closely to each 
other, thus triglycerides with this kind of fatty acids tend to be liquid at the room temperature [128-
131]. LCFAs are the major form of fatty acids present in food [16, 26]. MCFAs are infrequently 
present in food. However, short-chain fatty acids are not present in food, but they are the main 
anionic components present in the faeces. SCFAs are produced from the breakdown of undigested 
lipids by the action of bacteria in the colon. Therefore, the synthesis and absorption of SCFAs occur 
solely in the colon [16]. Polyunsaturated linoleic acid (omega-6 fatty acid) and linolenic acids 
(omega-3 fatty acid) are not synthesised from other substances in the human body and must be 
taken in the diet and therefore are known as essential fatty acids [128]. 
Both chain length and degree of unsaturation of fatty acid affect fat absorption and digestion [132, 
133]. Triglyceride digestion starts in the stomach by the action of lingual and gastric lipases and 
continues in the small intestine by the action of pancreatic lipase. Lipases have great affinity to 
hydrolyse triglycerides containing medium-chain fatty acids (MCFAs) more rapidly than 
triglyceride containing long-chain fatty acids (LCFAs), producing two free fatty acids and 2-
monoacylglyceride for each triglyceride molecule acted on [134]. Additionally, the absorption rate 
of unsaturated fatty acids and MCFAs is quicker than the absorption rate of LCFAs [132]. MCFAs, 
which are released from the hydrolysis of medium-chain triglycerides (MCTs) in the stomach by 
the action of gastric lipase, can be absorbed in the stomach [135]. Also, due to the solubility of 
these MCFAs in the aqueous phase of small intestine,  these fatty acids can be absorbed bound to 
albumin and transported to the liver via the portal vein [136].  
Digestion of long-chain triglycerides (LCTs) requires stimulation of the pancreas to secrete the 
hormone cholecystokinin (CCK) and the pancreatic enzymes. CCK stimulates the gallbladder to 
release further bile in order to enable the emulsion process in which the triglyceride 
macromolecules are broken down to smaller fat droplets to increase their digestion by pancreatic 
lipase. Individual LCFAs released from the digestion of LCT combine to form micelles. Then, the 
micelles either cross the intestinal brush border through passive diffusion or are transported by fatty 
acid transporters to enter the enterocyte. After that, the free fatty acids are transported to the 
endoplasmic reticulum where they are converted to triglycerides and packaged with lipoprotein, 




enterocyte into the intercellular space through exocytosis, enter and transport along the lymphatic 
system and finally flow into the subclavian vein to arrive the bloodstream. LCFAs are transported 
to the mitochondria through the carnitine carrier for consequent β-oxidation [133, 137, 138].  
Unlike LCT digestion, the digestion of MCT is simple and rapid and does not require CCK for its 
digestion. Also, MCT does not require packaging or modification and can be absorbed bound to 
albumin through passive diffusion along the gastrointestinal tract into the portal vein. Additionally, 





















The aims of this chapter are to: 
 Study the inhibitory effect of different concentrations of alginate on pancreatic lipase 
activity in vitro using an improved version of the turbidity assay (Vogel & Zeive, 1963). 
 Characterise chemical structures of alginates using proton nuclear magnatic resonance (1H 
NMR) to investigate whether their content of guluronic (G) and mannuronic acids (M) 












Seven alginate samples (1LF80, 1N80, BG3600, BG3610, BG3700, BG3800 and BG3900) were 
kindly supplied by Ruitenberg, (The Netherlands), whereas alginate CC01 was provided by Coca-
Cola, the UK. Lipase, colipase, Orlistat (Tetrahydrolipstatin, Ro-18-06-47, C29H53NO5) citric acid 
(C6H8O7), potassium hydroxide (KOH), phosphoric acid (orthophosphoric acid, H3PO4), boric acid 
(H3BO3), acetone (C3H6O), hydrochloric acid (HCl), bile acids, and taurodeoxycholate sodium salt 
were purchased from Sigma Aldrich (Poole, UK).  Aluminium oxide (Al2O3) was purchased from 
Fisher Scientific (Loughborough, UK), and olive oil was purchased from a local supermarket 
(Cooperative Food, UK). 
 
2.4.2 Lipase activity assay  
Lipase activity was determined using an improved version of Vogel & Zieve (1963) [122]. In this 
method, the activity of lipase was assessed by measuring the reduction in turbidity due to the 
hydrolysis of triacylglycerol to monoacylglycerol and free fatty acids by the action of lipase. In 
this study, a natural substrate, olive oil, was used as a lipase control (did not contain Orlistat or 
alginate) whereas Orlistat and alginates were used as an inhibition control and inhibitors, 
respectively.  
 
2.4.2.1 Preparation of the olive oil substrate 
Olive oil was passed through aluminum oxide (8 cm deep in a 2 x 32 cm glass chromatography 
column) to remove free fatty acids present in the oil. Then, purified olive oil stock was prepared 
by mixing 10 g of the olive oil with 100 ml of acetone. Next, 1 ml of the 10% solution was diluted 
with 10 ml of acetone to form 1% (v/v) olive oil stock solution. This stock solution was stored at 4 





2.4.2.2 Preparation of the buffer diluent containing 0.35% of sodium taurodeoxycholate 
Buffer diluent consisted of 0.033M citric acid (C6H8O7), 0.343M potassium hydroxide (KOH), 
0.033M orthophosphoric acid (H3PO4, has a specific gravity: 1L= 1.69 Kg, MW 98, 95%), 0.033M 
boric acid (H3BO3), and 0.35% taurodeoxycholate sodium salt. The buffer diluent was titrated to 
pH 7.3 using 6M HCl. For use in the assay, 100 ml of buffer diluent was heated to 70 ˚C, and then 
4 ml of 1% stock olive oil solution was added, giving a 0.04% (vol/vol) substrate solution. Next, 
the substrate/ buffer solution was homogenised with heating at 70 ˚C for 10 min. Finally, the 
solution was allowed to cool at room temperature, and it must be used within 6 h from the 
preparation.  
 
2.4.2.3 Preparation of lipase, Orlistat, and alginate solution 
Lipase in buffer diluent at a concentration of 1 mg/ml was prepared. Then, 60 μl of colipase was 
added to the lipase/buffer diluent solution and the mixture vortexed. 0.025 mg/ml of Orlistat in 
substrate solution was prepared. For alginate preparation, 12 ml of substrate/ buffer diluent solution 
was added to 60 mg of alginate, giving a 5 mg/ml alginate solution. Then, this alginate solution 
was homogenised for 2 minutes. After that, lower concentrations of alginate (0.125. 0.25, 0.5, 1.25, 
and 2.5 mg/ml) were prepared by diluting 5 mg/ml alginate/substrate solution with the appropriate 
volumes of the substrate/ buffer solution. The dilutions were carried out in 96-well microplate 












Volume of 5 mg/ml alginate in 
substrate solution 
Volume of 5 mg/ml substrate in 
buffer diluent solution 
5 240 μl 0 μl 
2.5 120 μl 120 μl 
1.25 60   μl 180 μl 
0.5 24   μl 216 μl 
0.25 12 μl 228 μl 
0.125 6    μl 234 μl 
Table 2.1. Preparation of alginate solutions by addition of stock solution with diluent.  
 
2.4.2.4 Sample preincubation 
Two 96-well microplates (Bio Tek, USA) were used for lipase activity assays. In plate 1, 10 μl of 
lipase solution (1mg/ml) and 10 μl of the buffer diluent solution (blank) were placed separately in 
triplicate. In plate 2, 240 μl of each substrate solution alone (as lipase control), alginate/substrate 
at concentrations 5, 2.5, 1.25, 0.5, 0.25, and 0.125 mg/ml, and Orlistat/substrate solution (as 
inhibition control) were placed separately in six wells. Both plates were incubated at 37 ˚C for 10 
minutes. Then, 200 μl of the three solutions present in plate 2 was transferred to plate 1 containing 
10 μl of both lipase and blank solutions as shown in Figure 2.3. Finally, plate 1 was placed in the 
reader where the optical density was read every 5 minutes at 405 nm for 55 minutes. In the assay, 
10 μl of lipase solution (1mg/ml) was added to 200 μl of samples (substrate/buffer diluent solution, 
Orlistat/substrate solution, or alginate/substrate solution), hence, the final concentration of lipase 
in the assay would be 0.048 mg/ml based on the equation:𝐶1 × 𝑉1 = 𝐶2 × 𝑉2, where C1 is initial 
concentration of solution, V1 is the initial volume of solution, whereas C2 is final concentration of 
solution, and V2 is final volume of solution. The final concentration of 200 μl of 5, 2.5, 1.25, 0.5, 
0.25, and 0.125 mg/ml of alginate solution added to 10 μl of either lipase or blank solution would 
be 4.8, 2.4, 1.2, 0.47, 0.24, and 0.12 mg/ml, respectively. The final concentration of 200 μl of either 




0.38 mg/ml and 0.024 mg/ml, respectively. The lipase inhibition was calculated as follows: 
Percentage of pancreatic lipase inhibition= 1- ((Inhibition Control - Polymer Sample) / (Inhibition 
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2.4.3 Preparation of alginate for 1H NMR neighbour analysis 
In this study, three alginates (CC01, 1LF80, and 1N80) inhibited pancreatic lipase activity, 
therefore the composition and monomer sequence of these alginates were determined using1H 
NMR. 10 mg/ml of alginate solution was prepared by dissolving powdered alginate in DH2O under 
the vortex produced by a magnetic stirrer to allow complete dissolution of all alginate in the 
solution. Then, the alginate solution was titrated to pH 2 using 6 M HCl and incubated at 100 ᵒC 
for 2-4 hours. Next, the alginate solution was neutralised to pH 7 using 1 M KOH. After that, 
aliquots of 1ml of the alginate solution were put in Eppendorf covered with plastic parafilm with 
holes to allow release of vapour, and frozen overnight at -20ᵒC. Finally, the frozen alginate samples 
were placed in the freeze dryer which enables them to be dried under a vacuum without passing 
through the liquid phase. The dried alginate samples were analysed using 1H NMR to determine 
the chemical structure and sequence of the different alginates from the integrated intensities of the 
signals A (G, proton1), B1 (GGM, proton 5), B2 (MGM, proton 5), B3 (MG, proton 1), B4 (MM, 
proton 1) and C (GG, proton 5) (Figure 2.4 and Table 2.2).  
 
 
Figure 2.4. The Region of 1H NMR Spectrum of Alginate used for Quantitative Analysis. Adapted from 




Alginate sequence Equation 
Guluronate (G) G= 0.5 (A+ C+ 0.5(B1+ B2+ B3))  
Mannuronate (M) M= B4+ 0.5 (B1+ B2+ B3) 
Guluronate dimers (GG) GG= 0.5 (A+ C- 0.5 (B1+ B2+ B3)) 
Uronate dimer consisting of guluronate and mannu-
ronate residues (GM) 
GM= MG= 0.5 (B1+ B2+ B3) 
Mannuronate (MM) MM= B4 
Uronate trimer consisting of two guluronates and 
mannuronate residues (GGM) 
GGM= MGG= (B1) 0.5 (B1+ B2+ B3)/ (B1+B2) 
Uronate trimer consisting of guluronate and two 
mannuronates residues (MGM) 
MGM= (B2) 0.5 (B1+ B2+ B3)/ (B1+B2) 
Guluronate trimers (GGG) GGG= GG-GGM 
Fraction of guluronate (FG) FG = G/ (M+ G) 
Fraction of mannuronate (FM) FM = M/ (M+ G) 
Fraction of guluronate dimers (FGG) FGG = GG/ (M+ G) 
Fraction of mannuronate dimes (FMM) FMM = MM/ (M+ G) 
Fraction of uronate dimer consisting of guluronate 
and mannuronate residues (FGM) 
FGM = FMG = MG/ (M+ G) 
Fraction of guluronate trimers (FGGG) FGGG = GGG/ (M+ G) 
Fraction of uronate trimer consisting of two gulu-
ronates and one mannuronate residue (FGGM) 
FGGM = FMGG = GGM/ (M+ G) 
Fraction of uronate trimer consisting of one gulu-
ronate and two mannuronates residues (FGMM) 
FGMM = MGM/ (M+ G) 
An average length of blocks of consecutive G mon-
omers N (G> 1) 
N (G> 1) = (FG- FMGM)/ FGGM 
Table 2.2. Equations used for calculation of alginate content of guluronate (G), mannuronate (M), 
guluronate dimers (GG), uronate dimers consisting of guluronate and mannuronate residues (GM), 
mannuronate (MM), uronate trimer consisting of two guluronates and one mannuronate residues (GGM), 
uronate trimer consisting of one  guluronate and two mannuronates residues  (GMM), guluronate trimers 
(GGG), fraction of guluronate dimers (FG), fraction of mannuronate (FM), fraction of guluronate dimers 
(FGG), fraction of mannuronate dimers (FMM), fraction of uronate dimers consisting of guluronate and 
mannuronate residues (FGM), fraction of guluronate trimers (FGGG). Adapted from ASTM International 




2.5 Statistical analysis 
 GraphPad Prism 7 statistical software was used to evaluate pancreatic lipase activity with olive oil 
(lipase control) versus the activity of pancreatic lipase with olive oil plus either Orlistat or different 
concentrations of alginates. One-way ANOVA (ordinary) followed by a post-hoc Dunnett’s test 
was performed, and significance was taken at P<0.05. Two-way ANOVA followed by a post-hoc 
Bonferroni’s test was used to compare inhibition level caused by different alginates at different 
concentrations. The data were analysed by calculating means, standard deviation (SD), and a 
Student’s t-test (unpaired t- test) for the samples of the lipase assay. Each measurement used at 


















2.6.1 Orlistat inhibition of lipase activity  
In control conditions, absorbance plotted against time had a negative slope and Spearman’s rank 
correlation coefficient rs= - 0.99 (P<0.0001), indicating an inverse relationship between time and 
absorbance (Figure 2.5). The significant decrease in absorbance of olive oil over time demonstrates 
that the triglycerides are being hydrolysed by lipase to monoacyglycerol and free fatty acids. 
However, an inhibition control (lipase plus olive oil plus Orlistat 0.025 mg/ml) showed a negligible 
decrease in absorbance over time where the absorbance changed from 0.42 to 0.40 over 50 minutes 
(rs= - 0.98, P<0.0001). 
 
 
Figure 2.5. Change in absorbance over time in lipase activity assay. The change in absorbance at 405 nm 
over time (0-50 minutes) for lipase control (lipase plus olive oil) and an inhibition control (lipase plus 
olive oil plus 0.025 mg/ml Orlistat). Values are mean ± SD (n=6).  
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2.6.2 Alginate inhibition of lipase activity 
Initially, the inhibitory effects of seven alginate samples at concentrations 4.8 and 1.2 mg/ml on 
lipase activity were investigated. The data presented in Table 2.3 showed that all alginate samples 
at 4.8 mg/ml could significantly inhibit pancreatic lipase activity (p < 0.05) with different levels of 
inhibition. However, among these alginates, CC01, 1N80 and 1LF80 had the highest inhibitory 
effects where they reduced lipase activity by 77.5 (±8.4), 73 (±3.02), and 68.9 (±0.92) %, 
respectively. Moreover, although all alginates at 1.2 mg/ml reduced lipase activity with different 
levels of inhibition, only CC01 and 1N80 had significant inhibitory effects on pancreatic lipase 
activity with P values less than 0.05. 
 
Alginate Lipase inhibition (%) 
1.2 mg/ml 4.8 mg/ml  
Inhibition 
(%) 
P value Significance Inhibition 
(%) 
P value Significance 
CC01 37.5 (±14.0) 0.002 ** 77.5(±8.3) 0.0001 **** 
1N80 24.6 (±12.0) 0.002 ** 73 (±3.0) 0.0001 **** 
1LF80 20.1 (±18.3) 0.227 ns 68.9 (±0.92) 0.0001 **** 
BG3600 11.4 (±13.0) 0.546 ns 56.3 (±13.6) 0.0001 *** 















BG3900 17.6 (±13.8) 0.062 ns 58.9 (±4.5) 0.0001 **** 
Table 2.3. Concentration dependent inhibition of lipase by alginates.Values are mean % inhibition and the 
error bars are the standard deviation of three replicates (± SD, n=3), P values < 0.05 are represented by *, 
<0.005 are represented by **, <0.001 are represented by ***, and <0.0005 are represented by ****. Non-
significant difference (P>0.05) is represented by ns. The substrate was prepared by diluting 1% (vol/vol) 







2.6.3 Concentration dependence of lipase inhibition by alginate 
Previous data of alginate’s effects on pancreatic lipase activity showed that CC01, 1LF80 and 1N80 
at 4.8 mg/ml had the greatest inhibitory effects. Therefore, the lipase activity assays in the presence 
of these three alginates at six different concentrations were repeated to investigate whether 
concentration influences the inhibitory effect and to determine concentration of alginate at which 
50% of pancreatic lipase activity is inhibited (IC50). 
 As seen in Figure 2.6 (graph A) CC01 alginate significantly inhibited pancreatic lipase activity 
(P<0.05) by 75.6 (± 10.6) %, 37.6 (± 11.5) % and 16.1 (± 9.4) %, at 4.8, 2.4, and 1.2 mg/ml, 
respectively, however, CC01 did not show a significant reduction in lipase activity at 
concentrations less than 1.2 mg/ml.  
The activity of pancreatic lipase in the presence of 4.8 and 2.4 mg/ml of alginate 1N80 was 
significantly reduced by 62.7 (± 20) % and 22.7 (± 4.1) % with P values less than 0.05, respectively 
(Figure 2.6, graph B). 1LF80 significantly decreased lipase activity by 53.7 (± 8.5) % (P<0.05) at 
4.8 mg/ml and by 20.3 (±1.1) % at 2.4 mg/ml (Figure 2.6, graph C). Also, no significant reduction 
in lipase activity was seen in the presence of either 1N80 or 1LF80 at concentrations below 2.4 
mg/ml (P>0.05).  
Figure 2.7 shows the correlation (Pearson’s R) between inhibition level of lipase and CC01, 1N80 
and 1LF80 alginates at different concentrations (0.12-2.4 mg/ml). Pearson’s correlation coefficient 
values for CC01, 1LF80 and 1N80 were 0.99, 0.98 and 0.99 with P values of 0.0001, 0.0005, and 
0.0001, respectively, indicating a robust positive relationship between inhibition level of lipase and 
alginate concentration. Inhibition of lipase by CC01 alginate was dose dependent as increasing 
alginate concentration twofold either from 1.2 to 2.4 mg/ml or from 2.4 to 4.8 mg/ml caused a 
significant increase in lipase inhibition level by 21.6% (P<0.001) and 38 % (P<0.0001), 
respectively. Also, a significant increase by 60% (P<0.0001) in inhibition level of lipase was 
observed when CC01concentration was increased by four times from 1.2 to 4.8 mg/ml (Figure 2.6, 
graph A). Moreover, although lipase inhibition by 1N80 looks to be dose dependent from 1.2 mg/ml, 
inhibition was only significant (P< 0.05) at concentrations 2.4 and 4.8 mg/ml. A significant increase 
in inhibition of lipase by 17.8 % (P<0.03) and 40.03% (P<0.0001) was seen upon doubling 1N80 




Additionally, increasing 1N80 concentration by fourfold from 1.2 to 4.8 mg/ml a significantly 
increased inhibition of lipase by 57.8% (P<0.0001) (Figure 2.6, graph B). Further, lipase inhibition 
by 1LF80 was dose dependent from 2.4 mg/ml where there was a significant increase in lipase 
inhibition by 19.7% (P<0.009) and 33.3% when the 1LF80 concentration was increased twofold 
from 1.2 to 2.4 mg/ml or from 2.4 to 4.8 mg/ml, respectively. Also, increasing 1LF80 concentration 
four times, from 1.2 to 4.8 mg/ml, caused a significant reduction by 53% (P<0.0001) in lipase 





Figure 2.6. Concentration dependent inhibition of lipase by three alginates: (A) CC01, (B) 1N80 and (C) 
1LF80. Lipase activity (%) for olive oil alone (control), olive oil with different concentrations of alginate, 
and olive oil with Orlistat were measured at 35 minutes where the reaction at this time point was still close 
to the linear phase. Values are percentage lipase activity and the error bars are the standard deviation of six 
replicates (± SD, n=6), P values < 0.05 are represented by *, <0.005 are represented by **, <0.001 are 
represented by ***, and <0.0005 are represented by ****. The absorbance was read at 405 nm every 5 





Figure 2.7. Correlation between inhibition of lipase and alginates concentrations. A significant positive 
correlation (P<0.05) existed between lipase inhibition level and alginate concentration with Pearson’s R 
values of 0.99, 0.98 and 0.99 for CC01, 1LF8 and 1N80 alginates, respectively. Values are shown as mean 
± SD (n=6). P values, <0.001 are represented by ***, and <0.0005 are represented by ****. Calculated 
from data presented in figure 2.6. 
 
Two-way ANOVA analysis followed by a post-hoc Bonferroni’s test indicated that CC01 reduced 
pancreatic lipase activity more than 1N80 and 1LF80 at all concentrations (0.12-4.8 mg/ml), 
however, the difference in inhibition in lipase activity was significant (P<0.05) between CC01 and 
1LF80 at concentrations 1.2, 2.4, and 4.8 mg/ml, whereas the difference in inhibition level of lipase 
caused by either CC01 or 1N80 was significant only at 2.4 mg/ml (Figure 2.8).  
Although there were significant differences in inhibition levels among different concentrations 
where all the three alginates (CC01, 1N80 and 1LF80) at concentrations 4.8 and 2.4 mg/ml reduced 
lipase activity more than the other concentrations with P<0.05, CC01 was the only alginate that 
significantly inhibited pancreatic lipase activity at 1.25 mg/ml and the inhibition of lipase by 
alginate was dose dependent. Orlistat significantly reduced lipase activities in all experiments with 






Figure 2.8. Concentration dependent inhibition of lipase caused by alginates. Three alginates CC01, 1N80 
and 1LF80 at different concentrations (0.12-4.8 mg/ml)from left to right on the x-axis were used. The 
values are mean % inhibition and the error bars are the standard deviation of six replicates (± SD, n=6), P 
values < 0.05 are represented by *, <0.005 are represented by **, and <0.001 are represented by ***. In 
the assay, concentrations of lipase and substrate were 0.048 and 0.38 mg/ml, respectively. Combined data 
from figure 2.6 to compare inhibition level caused by different alginates at different concentrations. 
 
Data from IC50 measurements shows that concentration of CC01 alginate required to reduce lipase 
activity by 50% was lower than those of 1N80 and 1LF80, suggesting that CC01 is a more potent 
inhibitor than either 1N80 or 1LF80. This variation in IC50 values could be due to alginate structure 






Alginate IC50 (mg/ml) Standard deviation 
CC01 3.02 (±0.25) 
1N80 4.06 (±0.23) 
1LF80 4.65 (±0.67) 
Table 2.4. IC50 measurement for alginates CC01, 1N80 and 1LF80. Values are mean and standard deviation 
(± SD); n=6. 
2.6.4 Characterisation of the alginates by 1H NMR 
CC01, 1LF80 and 1N80 alginates inhibited lipase activity with different levels of inhibition at the 
same tested concentrations, and the difference in inhibition levels may be associated with their 
chemical structure. Therefore, 1H NMR neighbour analysis was used to analyse the alginate 
structure and determine their content of guluronate (G) and mannuronate (M) monomers.  
Data shown in Table 2.5 demonstrated that among three alginates, CC01 has the highest content of 
guluronate F(G), guluronate dimers F(GG), and guluronate trimers F(GGG) and the lowest content 
of mannuronate F(M) and mannuronate dimers F(MM). 1N80 alginate contains more F(G), F(GG), 
and F(GGG) than 1LF80, while its content of mannuronate and mannuronate dimers is higher than 
CC01, but lower than 1LF80. Alginate 1LF80 has the lowest fractions of G, GG, and GGG, and 
the highest fractions of mannuronate and mannuronate dimers. Moreover, 1H NMR data showed 
that among the three alginates, CC01 has the highest average length of blocks of consecutive G 
monomers (N (G>1) =21.5), which is about three times higher than that in 1N80, and 20 times 
higher than the lowest one in 1LF80. 
 Both 1H NMR spectrum of alginates (CC01, 1N80 and 1LF80) used for quantitative analysis, and 
the manual integrated intensities of the signals A (G, proton1), B1 (GGM, proton 5), B2 (MGM, 









































Table 2.5. Codes and molecular characteristic for CC01, 1N80 and 1LF80 alginates used in this study. F(G) 
is the fraction of guluronate, F(GG) is the fraction of guluronate dimers, F(GGG) guluronate trimers. F(M) 
and F(MM) are the fractions of mannuronate and mannuronate dimers, respectively. F(GM) is the fraction 
of uronate dimer consisting of guluronate and mannuronate residues, and F(GGM) the fraction of uronate 
trimer consisting of two guluronates and one mannuronate residues. F(GMM) the fraction of uronate trimer 
consisting of one guluronate and two mannuronates residues. N (G>1) is the average length of blocks of 
consecutive G monomers. 
 
 
Table 2.6 shows the correlation between IC50 of CC01, 1N80 and 1LF0 alginates and their contents 
and sequence of G, GG, GGG, M, MM, GM, GGM, and NG>1. Pearson’s correlation coefficients 
showed a significant negative relationship (P<0.05) between alginate IC50 and content of G, GG, 
and GGG where the more G, GG, and GGG residues, the lower the IC50, and the more potent 
inhibitor it is. Furthermore, Pearson’s correlation coefficients showed a positive relationship 
between alginate fraction of M block and IC50 where the higher amount of M blocks, the greater 
the IC50, and the weaker inhibitor it is. However, there was no significant correlation between 
alginate content of MM, GM, and GGM residues. Also, N (G>1), which is the average length of 











IC50 Pearson       
coefficient 
P value Significant 
CC01 1N80 1LF80 
F(G) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) -0.99 0.014 * 
F(GG) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) -1 0.002 ** 
F(GGG) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) -0.99 0.014 * 
F(M) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) 0.99 0.032 * 
F(MM) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) 0.78 0.434 ns 
F(GM) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) 0.99 0.054 ns 
F(GGM) 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) 0.98 0.100 ns 
NG>1 3.02(±0.25) 4.06(±0.23) 4.65(±0.67) -0.99 0.063 ns 
Table 2.6. The chemical features and mean IC50 vlaues of CC01, 1N80 and 1LF80 alginates. Pearson’s 
correlation coefficients, P value, and whether the correlation is significant (P<0.05) or not significant (ns). 
FG is the fraction of guluronate, F(GG) is the fraction of guluronate dimers, F(GGG) guluronate trimers. 
F(M) and F(MM) are the fractions of mannuronate and mannuronate dimers, respectively. F(GM) is the 
fraction of uronate dimer consisting of guluronate and mannuronate residues, and F(GGM) the fraction of 
uronate trimer consisting of two guluronates and one mannuronate residues. F(GMM) the fraction of uronate 
trimer consisting of one guluronate and two mannuronates residues. N (G>1) is the average length of blocks 
of consecutive G monomers. P values < 0.05 are represented by *, <0.005 are represented by **, whereas P 















Data from the pancreatic lipase activity assay showed a strong reduction in the turbidity of lipase 
control (olive oil plus lipase) over time in contrast to olive oil treated with Orlistat (an inhibition 
control) which showed only a slight decrease in turbidity of over time, indicating that Orlistat is a 
potent inhibitor for lipase. 
Also, the data available here indicated that all the alginates used reduced pancreatic lipase activity 
in vitro, showing that alginates could be used as pancreatic lipase inhibitors. This finding is 
supported by previous findings from Wilcox et al. (2014) in which the activity of pancreatic lipase 
with a synthetic substrate, DGGR, and natural substrate, olive oil, in the presence of alginate was 
assessed using colourimetric and turbidimeteric assays. Wilcox and his colleagues found that 
alginate reduced pancreatic lipase activity in vitro by 72.2% and 58% with DGGR and olive oil as 
substrates, respectively [72]. 
Furthermore, the data presented here showed that at the same concentration different alginates 
inhibited pancreatic lipase activity with varying degrees of inhibition. CC01, 1N80, and 1LF80 
alginates had the most potent inhibitory effects compared with other alginates. This variation in 
reduction of the level of lipase activity could be attributed to alginate source or structure. Wilcox 
et al. (2014) reported that alginate isolated from Laminaria hyperborea caused a greater reduction 
in pancreatic lipase activity in vitro than alginate isolated from Lessonia nigrescence seaweed, 
showing that the type of seaweed from which alginate is extracted might influence inhibition 
properties of alginate [72]. However, in this work, the impact of alginate source on alginate 
inhibitory effect could not be assessed since no data are available about the source of alginates used 
here. 
1HNMR analysis for CC01, 1N80 and 1LF80 alginates showed that CC01 had the highest fractions 
of guluronate, guluronate dimers, guluronate trimers (F[GGG=0.70], and the lowest fractions of 
mannuronate, suggesting that the highest inhibitory effect of CC01 on lipase activity compared 
with other alginates could be explained by its high content of G, GG, and GGG residues. Previous 
studies by Taylor et al (2005) indicated that alginate rich in G units was able to bind to the protein 
part of mucin, whereas alginate containing high amounts of M units was unable to bind with the 
protein part of mucin, showing that the G blocks were essential for alginate-protein binding 




trimers, and the highest fraction of mannuronate residues, hence, its content of M residues could 
account for its low inhibitory effect compared with CC01 and 1N80.  
The high content of G, GG, and GGG residues in CC01 could also provide a reasonable explanation 
for relative lower IC50 value compared with those of 1N80 and 1LF80 especially that Pearson’s 
coefficients indicated a significant negative correlation (P<0.05) between IC50 values and alginate 
content of G, GG, and GGG units, however, there was a significant positive correlation (P<0.05) 
between IC50 values and alginate content of M block, providing a reasonable explanation for the 
highest IC50 value of 1LF80 which has the greatest content of M residues compared with CC01 and 
1N80. This finding is consistent with Wilcox et al’s study (2014) which showed that alginate rich 
in G, GG, GGG residues inhibited pancreatic lipase activity in vitro more than alginate rich in M, 
MM residues, demonstrating a positive correlation between alginate content of G block and 
inhibition level. Hence, the activity of pancreatic lipase can be modulated to a varying level based 
on the alginate used. 
 Furthermore, the data presented here showed a significant positive correlation (P<0.05) between 
alginate concentration and inhibition level of lipase. This finding is also in agreement with Wilcox 
et al’s study (2014) which showed that increasing lipase inhibition by alginate was concentration 
dependent [72]. In the study, Wilcox and his colleagues studied the impact of alginate concentration 
on lipase activity using a modified version of a turbidimetric assay (Vogel & Zeive, 1963) and olive 
oil as a substrate, the same as used in this study. They found that increasing concentration of 
LFR5/60 alginate from 0.21 to 0.86 mg/ml and from 0.86 mg/ml to 3.43 mg/ml increased inhibition 
level of lipase by 1.7-fold and 2.3-fold, respectively. They also found the same effect where 
inhibition level of lipase increased by100.0%, 76.4%, and 85% when the concentration of SF120, 
SF/LF, and SF200 alginates was increased four-fold in concentration from 0.21 to 0.86 mg/ml, 
respectively [72]. 
Inhibitory capacity of alginate is not limited to pancreatic lipase activity since earlier in vitro studies 
found that some alginates could reduce pepsin activity by 52% [107] and by 53.9% [108]. Also, 
alginates are not the only dietary fibres which reduce pancreatic lipase activity, as in vitro data from 
a microplate assay conducted by Wilcox, (2010) showed that pectin also had the ability to diminish 
pancreatic lipase activity by 24.7 (±6.3) %, and the inhibition level of lipase by pectin was based 




of Isaksson et al [141]. Isaksson and his colleagues investigated the activity of pancreatic lipase in 
a synthetic buffer solution and human pancreatic juice following in vitro incubation with pectin of 
low methyl ester (LM pectin) and pectin with high methyl ester (HM pectin). They found that both 
LM pectin and HM pectin had the ability to reduce pancreatic lipase activity in a synthetic buffer 
solution and human duodenal juice in vitro, however, pectin inhibitory effect was greater in the 
human pancreatic juice. The same authors stated that the capacity of pectin to inhibit pancreatic 
lipase activity is related to its level of esterification. Moreover, Isaksson et al. (1983) stated that 
feeding rats with diet containing 5% pectin raised fat content in ileostomy effluent samples, 
proposing that pectin might reduce fat digestion [142].  
Several mechanisms for lipase inhibition by alginate have been proposed. Alginates have the 
affinity to bind to both the substrate and the enzyme. In 2005, Taylor and her colleagues reported 
that rheological studies on various mixtures of mucin: alginate showed an intermolecular 
interaction between mucin (glycoprotein) and alginate [139]. Mucin is an amphoteric polymer, 
whereas alginate is negatively charged polymer, therefore, some charge-charge interactions may 
occur between mucin and alginate, also, hydrogen bonding may be involved in mucin-alginate 
interaction [143]. Taylor and her colleagues reported that alginate rich in G units has the ability to 
bind to mucin at particular positions along the protein backbone of the mucin, linking several mucin 
molecules together and producing a gel. 
Kumar and Chauhan (2010) stated that pectin (pectin: lipase, 2:1) with a high degree of 
esterification (approximately 53%) reduced lipase activity by 82%, and this level of inhibition is 
rather similar to that produced by Orlistat (Orlistat: lipase, 1:1 ratio) which was 88%. Additionally, 
Kumar & Chauhan (2010) reported that pectin does not only bind to the substrate, but it can form 
a complex with the enzyme, resulting in protonation of serine and histidine residues in the active 
site [144]. However, there was limited information available about the substrate concentration and 
the units used for lipase activity in that study. In contrast, Wilcox et al. (personal communication) 
showed that when olive oil was used as a substrate to assess the activity of pancreatic lipase (3.4 
U/ml) in the presence of 3.8 mg/ml of a commercial pectin with a level of esterification equal to 
60%, the pectin reduced pancreatic lipase activity only by 11% [72]. It has been suggested that 
pectin inhibits pancreatic lipase activity through protonation of –OH groups of a serine residue in 
the active site of lipase by the carboxyl groups [144]. Since the carboxyl groups in the guluonate 




groups may interact with the pancreatic lipase, forming an alginate-lipase complex, and protonate 
the serine residues at the enzyme active site, subsequently, pancreatic lipase activity will be reduced 
(Figure 2.9) [72].  
Both α-D-(1→4) polygalacturonate chains in low-methoxy (LM) pectin and α-L-(1→4) 
polyguluronate chains in alginate show specific binding ability for calcium ions due to the 
electrostatic interaction between Ca2+ and galacturonate and guluronate blocks of pectin and 
alginate, respectively, resulting in a gel formation. Both alginate and pectin show the same 
mechanism for binding Ca2+ due to the similarity in their structures, and the resulting structure 
from the interaction between the Ca2+ and pectin or alginate can be described as “egg-box” model 
(Figure 2.10). These α-(1→4) polyuronates in pectin (polygalactouronate) and alginate 
(polyguluronate) offer tetradentate binding sites (cavities) for Ca2+. These cavities are produced 
from intermolecular interaction between chains of two uronate residues due to an electrostatic and 
ionic bonding of their carboxyl groups, producing a structure similar to the “egg box”. The calcium 
ions then will fit in the cavities through the electrostatic interaction between calcium ions and 
oxygen of carboxylate, the ring, in glyosidic bond, and the -OH group of the subsequent residue 
[145-147]. These similarities in calcium binding further demonstrate the close agreement in -
COO⁻ group orientation between alginate and pectin.   
In pectin, the carboxyl groups are present at the site where the methyl groups are added by ester 
bonds though an esterification process. Increasing the degree of esterification where the methyl 
groups substitute for carboxyl groups, will reduce the number of carboxyl groups. This provides a 
reasonable explanation for the reduction observed in lipase inhibition caused by the pectin with a 






Figure 2.9. Schematic representation of (a) galacturonate and (b) guluronate chains of pectin and alginate, 






Figure 2.10. Schematic diagrams of the egg-box model for pectin and alginate. The left diagram 
represents the egg-box model for pectin taken from Axelos and Thibault, 1999 [148], whereas the right 
diagram represents the egg-box model for alginate taken from Leick e al., (2010) [149] gel formation. 
Alginates may bind strongly to the substrate surface (oil/water interface), reducing opportunity for 
the enzyme to interact with the oil/water interface. Pancreatic lipase is water- soluble whereas 
triglyceride substrate is water-insoluble, hence, for the lipolytic reaction to occur, the lipase enzyme 
initially has to adsorb to the water/oil interface of substrate. Enzyme adsorption to the substrate 
surface enhances the activity of the lipase and increases the binding affinity of the enzyme to the 
substrate, producing the enzyme-substrate complex based on Michaelis-Menten Kinetics [91]. This 
is thought to be the mechanism by which other potent inhibitors such as chitosan, DEAE-Sephadex 
and DEAE polydextrose inhibit pancreatic lipase activity; however, chitosan, DEAE-Sephadex and 
DEAE polydextrose are positively charged polysaccharides whereas alginate is a negatively 
charged polysaccharide [91, 150]. Both DEAE-Sephadex and DEAE polydextrose contain many 
diethylaminoethyl (DEAE) groups in their structure, and can inhibit lipase activity in vitro, and the 
inhibition level relies on the substitution level of DEAE groups. When the substitution level of 
DEAE-polydextrose is high, only low concentration of DEAE polydextrose is required to reduce 
lipase activity by 50%. The same study reported that DEAE polydextrose at concentrations 1.44, 
16.9, 61 and > 1000 µg/ml with a level of substitution equal to 1.09, 0.18, 0.079 and 0.048, 





Alginate polymers caused a significant reduction in pancreatic lipase activity in vitro, suggesting 
alginates as potential lipase inhibitors which can reduce digestion of dietary triglycerides, hence, 
decreasing the amount of triglycerides absorbed by the body, and suggesting alginate may be used 
in weight management. However, the efficiency of alginates as lipase inhibitors depends on 
alginate concentration and their contents of guluronate and mannuronate blocks. Alginate 
inhibition of lipase is concentration dependent. Also, alginates that are rich in G blocks are more 
effective in inhibiting lipase activity than alginates rich in M blocks. Alginate could undergo 
enzymatic modification to easily produce the alginates with the preferred the properties. Therefore, 
alginates may be recommended in obesity treatment instead of conventional anti-obesity drugs 
such as Orlistat because the fibres present in alginates  have the ability to decrease or prevent the 
















Chapter 3:  Kinetic Studies of Lipase Activity 
3.1 Introduction  
Enzymes are biological catalysts which are produced by living cells and accelerate the rate of 
biochemical reactions in organisms, however, these molecules are not consumed throughout the 
reaction they catalyze [151, 152]. Enzymes can be isolated from living cells and applied 
commercially in speeding up rates of many essential processes such as production of sweetening 
agents, washing powders and different cleaning products [152]. However, the rates of enzyme-
catalysed reactions are affected by factors such as substrate concentration, enzyme concentration, 
temperature, and concentration of free hydrogen ions (pH). Additionally, compounds called 
inhibitors affect enzyme activity [151, 152].  
Enzyme kinetic studies are usually carried out to determine rates of enzyme-catalysed reactions, to 
understand the catalytic action of enzyme, to identify mechanisms of enzyme inhibition, and to 
determine how the variations in experimental circumstances impact reaction rates. The kinetics of 
an enzyme-substrate interaction usually depends on substrate concentration (or enzyme: substrate 
ratio) and the way by which inhibitors affect the interaction between enzyme and substrate can 
display useful information about their mode of action.  
A Michaelis-Menten plot is usually used to express the interaction between enzyme and substrate 
in term of reaction initial velocity (V0) and substrate concentration [S]. A Michaelis-Menten plot 
was used here to assess the rate of lipase-catalysed reactions in the presence and absence of 
alginates as inhibitors. On a Michaelis-Menten graph, the reaction velocity (V), which was 
measured from the alteration in absorbance over 35 minutes, was plotted on the y-axis versus 
substrate concentration on the x-axis in an attempt to determine the regulatory effect of alginates 
on lipase-catalysed reaction via comparing the kinetic parameters obtained from Michaelis-Menten 
plots of inhibited and uninhibited reactions. The non-linear data from Michaelis-Menten curves 
were then transformed into straight line Lineweaver-Burk plots in an attempt to identify the type 
of inhibition caused by alginate. 
 




3.1.1 Michaelis-Menten plot 
In enzymology, a single-enzyme, single-substrate reaction usually consists of two stages. Firstly, 
the substrate [S] binds to an enzyme [E], producing enzyme-substrate [ES] complex. Secondly, the 
[ES] complex converts to a product through a unimolecular reaction. This type of reaction usually 
follows the Michaelis-Menten equation which was obtained in 1913 by Leonor Michaelis and 
Maud Menten. It defines the initial rate of product formation for an enzyme-catalysed reaction with 
regard to two kinetic parameters Vmax (maximal velocity of the reaction) and Km (Michaelis-
Menten constant) [153]. 
The Michaelis-Menten equation describing the initial rate of reaction involving a single substrate 






Equation 3.1. Michaelis-Menten equation for an-enzyme catalysed reaction. 
     
Briggs and Haldane (1925) studied the theoretical foundation of Michaelis-Menten equation taking 
into consideration that the reaction is an irreversible unimolecular reaction (A→B) which is 
catalysed by an enzyme (E). They assumed that one molecule of substrate A (represented currently 
as S) binds reversibly with one molecule of enzyme (E), giving EA complex which is then converted 
to free enzyme (E) and product B (represented currently as P), where B may denote numerous 
molecules. They characterised this equation by the following reaction:   
 








→ 𝑩 + 𝑬 
Equation 3.2. An enzyme-catalysed reaction.  
 
 




fitted to the Michaelis-Menten equation using non-linear regression in which the initial velocity of 
reaction [V0] is plotted versus the substrate concentration [S], producing a hyperbolic curve (Figure 
3.1). Two essential kinetic parameters: maximal initial velocity (Vmax) and Michaelis-Menten 
constant (Km) can be determined from Michaelis-Menten curve in which the reaction velocity is 
measured at various substrate concentrations. Vmax can be defined as the reaction velocity when all 
the enzyme active sites become completely occupied by the substrate molecules, and it can be 
determined graphically from the point where the Michaelis-Menten curve becomes a plateau. Km 
is the concentration of substrate required to produce half maximum velocity (Vmax/2). Km measures 
the affinity of enzyme for the substrate where a small Km value indicates a strong affinity between 
the enzyme and substrate, thus, the reaction requires a relatively low concentration of substrate to 
reach its maximum velocity, and vice versa [152, 154]. The Michaelis-Menten constant equation 
can be expressed as the sum of dissociation rate of enzyme-substrate complex into product and 
enzyme (K2) and the reverse dissociation rate of enzyme-substrate complex into the substrate and 
enzyme (K3) divided by the formation rate of enzyme-substrate complex (K1). However, at the 
beginning of an enzyme-catalysed reaction, the concentration of product [P] is negligible compared 
to [S], hence, the K4 constant which represents the reverse dissociation rate of product into ES 






Equation 3.3. Michaelis-Menten constant. 
 
3.1.2 Lineweaver-Burk plot 
 Before the availability of non-linear regression, the non-linear curved data from Michaelis-Menten 
equation had to be transformed into a straight-line equation such as the Lineweaver-Burk equation 
to analyse the data using linear regression analysis. The Lineweaver-Burk equation is a 
transformation of Michalis-Menten equation (Equation 3.4), and it produces a straight line with X- 
and Y- intercepts known as Lineweaver-Burk plot (a double reciprocal plot). The x-intercept of 




equal to Km/Vmax (Figure 3.1). However, the development of computer programmes able to perform 
non-linear regression analysis enables the direct fitting of data to the Michaelis-Menten equation 
[154]. 
In the current work, the Lineweaver-Burk plots for lipase reactions in the presence and absence of 
alginates were produced in an attempt to identify type of inhibition and assess the potency of 
















Figure 3.1. General example of Michaelis-Menten plot (left) and Lineweaver-Burk plot (right). 
Lineweaver-Burk plot is produced by linear transformation of Michaelis-Menten equation. Adapted from 





3.1.3 Regulation of enzyme-catalysed reaction 
As mentioned in the introduction section of this chapter, the rates of enzyme-catalysed reactions 
can be affected by various factors, and one of these factors is the presence of an inhibitor which 
results in alteration in either Vmax or Km or both. The alteration in kinetic parameters caused by 
inhibitors can be observed by comparing Michaelis-Menten and Lineweaver-Burk plots for 
inhibited and uninhibited reactions. The way by which the presence of inhibitor alters Vmax and Km 
can offer useful information about the type and potency of the inhibitor. 
 
3.1.4 Enzyme inhibition 
Inhibitors are molecules which reduce the catalytic activity of enzymes. Enzyme inhibitors can be 
either reversible or irreversible. Irreversible inhibitors bind covalently to the enzyme, causing 
permeant loss of enzyme catalytic action. Conversely, reversible inhibitors bind to enzyme non-
covalently, resulting in a temporary loss of enzyme catalytic activity. However, the enzyme has the 
ability to return to its full activity once the inhibitors are eliminated via separation techniques such 
as dialysis, gel filtration, and chromatography [152, 155]. Reversible inhibition can be competitive, 
non-competitive, uncompetitive, or mixed, and they can be distinguished by the kinetics of 
inhibition.    
 
3.1.4.1 Competitive inhibition 
In this model of inhibition, the inhibitor [I] has chemical structure similar to the substrate, therefore, 
it competes with the substrate for the active site of enzyme. The competitive inhibitor binds 
reversibly to the active site of the enzyme, preventing the formation of enzyme-substrate complex. 
The competitive inhibitor binds only to the free enzyme and does not have any affinity to ES 
complex. However, the inhibitory effect of the competitive inhibitor is temporary where this effect 
can be removed by increasing substrate concentration. This type of inhibition apparently increases 





Figure 3.2. Michaelis-Menten (A) and Lineweaver-Burk (B) plots for a reversible competitive inhibitor.I1, 
I2 and I3 are inhibitors. The black line in each plot indicates the kinetic behaviour in the absence of an 
inhibitor, and the grey lines in each plot indicate the change in kinetic behaviour for increasing 
concentration of inhibitor. In each plot, the inhibitor concentration increases in the direction of the grey 
arrow. The competitive inhibition is distinguished by a rise in the Vmax of the reaction with no change in 
Km. The Lineweaver-Burk plots are of increasing slope (showing increasing Km values) with increasing 
concentrations of inhibitor, and the lines of uninhibited and inhibited reactions cross at the ordinate axis at 
the same point. A modified version taken from Kenakin, (20120 [154] 
 
3.1.4.2 Non-competitive inhibition 
This type of inhibitor binds equally to enzyme at a site different from the active site or the ES 
complex, reducing catalytic action of the enzyme. Unlike a competitive inhibitor, the effect of non-
competitive inhibitor cannot be stopped by increasing substrate concentration. This type of 
inhibitor is structurally distinct from the substrate. In the presence of non-competitive inhibition, 
Vmax of the reaction is reduced due to diminution in concentration of active enzyme in the solution 
which in turn hinders formation of product. However, since the substrate cannot bind when the 
inhibitor is bound, also, the ES complex cannot breakdown to E and P when the inhibitor is bound, 
so both rates of formation and dissociation of [ES] complex are reduced equally, therefore, the Km 






Figure 3.3. Michaelis-Menten (A) and Lineweaver-Burk (B) plots for reversible non-competitive 
inhibition.The non-competitive inhibition is distinguished by a diminution in the Vmax of the reaction with 
no change in the Km for its substrate. On Lineweaver-Burk plot, both inhibited and uninhibited lines of 
best-fit cross the x-axis at the same point. I1, I2 and I3 are inhibitors. The black line in each plot indicates 
the kinetic behaviour in the absence of an inhibitor, and the grey lines in each plot indicate the change in 
kinetic behaviour for increasing concentration of inhibitor. In each plot, the inhibitor concentration 
increases in the direction of the grey arrow. A modified version adapted from Kenakin, (2012) [154]. 
 
3.1.4.3 Uncompetitive inhibition 
In this type of inhibition, the inhibitor [I] binds selectively to the [ES] complex and not to the free 
enzyme since the substrate binding modifies the enzyme structure to produce a binding site for the 
inhibitor. Therefore, this type of inhibition only occurs when the ES complex is formed by the 
presence of substrate bound to the enzyme. Uncompetitive inhibition reduces Vmax due to hindrance 
of the product formation, also, the Km is reduced in the presence of uncompetitive inhibitor due to 
binding of inhibitor to [ES] complex which in turn diminishes the dissociation rate of [ES] to the 






Figure 3.4. Michaelis-Menten (A) and Lineweaver-Burk (B) plots for reversible uncompetitive inhibition. 
Uncompetitive inhibition is characterised by a reduction in the apparent Km and Vmax values. The 
Lineweaver-Burk plots are parallel and do not cross.I1, I2 and I3 are inhibitors. The black line in each plot 
indicates the behaviour of kinetic reaction in the absence of inhibitor, and the grey lines in each plot 
indicate the change in kinetic behaviour for increasing concentration of inhibitor. In each plot, the 
inhibitor concentration increases in the direction of the grey arrow. A modified version taken from 
Kenakin, (2012) [154]. 
 
3.1.4.4 Mixed inhibition 
In this type of inhibition, the inhibitor has the affinity to bind to both the free enzyme [E] and the 
enzyme-substrate [ES] complex, however, the binding affinity of inhibitor for the [E] and [ES] - 
complex are not equal. The inhibitor can bind to the free enzyme at a site different from the active 
site, allowing the enzyme-substrate binding. Mixed inhibition apparently reduces the Vmax and 
apparently increases the Km value (Figure 3.5). However, when the mixed inhibitor has an equal 
binding affinity for both the [E] and [ES] complex, the Km will not be altered, and the inhibitor in 







Figure 3.5. Michaelis-Menten (A) and Lineweaver-Burk (B) plots for reversible mixed inhibition. The 
mixed inhibition is characterised by an apparent reduction in the Vmax value and an apparent increase in Km 
value. The Lineweaver-Burk plots where the best-fit lines of inhibited and uninhibited reactions do not 
cross any of the axis at the same point.The inhibitor has unequal affinity for E and ES. I1, I2 and I3 are 
inhibitors. The black line in each plot indicates the behaviour of kinetic reaction in the absence of 
inhibitor, and the grey lines in each plot indicate the change in kinetic behaviour for increasing 
concentration of inhibitor. In each plot, the inhibitor concentration increases in the direction of the grey 
arrow a modified version taken from Kenakin, (2012) [154]. 
3.1.4.5 Irreversible inhibition 
In this type of inhibition, the inhibitor binds permanently to the enzyme, altering the structural 
conformation of enzyme to create a highly stabilised [EI] complex. The inhibitor usually binds 
covalently to an amino acid residue at the enzyme active site or a site close to the active site, causing 
a permeant inactivation of the enzyme. For example, diiso-propylphosphofluoridate (DIPF), which 
is a constituent of nerve gases, causes irreversible inhibition of the enzyme acetylcholinesterase 
via the formation of a covalent bond with a serine residue in the active site of the enzyme, stopping 
transmission of nerve impulses. Also, glycopeptide transpeptidase, which creates cross-links in the 
cell wall of bacteria, can be irreversibly inhibited by the antibiotic penicillin which binds covalently 






3.1.5 Quantification of alginate’s regulatory effect  
The mechanism by which the enzyme is inhibited can be essential to know because it may assist in 
identifying the association between the inhibition level required to yield a significant effect. For 
example, the effect of a competitive inhibitor can be decreased by high concentrations of substrate, 
whereas the efficiency of uncompetitive inhibition can be promoted by high concentrations of 
substrate because the maximum amount of ES complex will be present. Lineweaver-Burk plots can 
be used to define the influence of an inhibitor of the enzyme and provide information about the 
mechanism of inhibition [154]. The inhibition dissociation constant (KI) can be defined as the 
concentration of inhibitor needed to yield half maximum inhibition and is usually used to identify 
the type of inhibition. The inhibition dissociation constant is a measure of the potency of inhibitor 
through measuring the binding affinity of the inhibitor to the enzyme. The smaller the inhibition 
constant, the stronger the inhibitor, and vice versa [157]. The inhibitor may bind either to the free 
enzyme (E) or enzyme-substrate complex (ES), or both depending on the type of inhibition. The 
inhibition dissociation constants KI and KÍ represent the binding of inhibitor to E and ES-complex, 
respectively [158] (Equation 3.5). 
 
𝐸 + 𝑆 ⇄ 𝐸𝑆 ⇄ 𝐸 + 𝑃     
+               +                       
𝐼                 𝐼                       
                𝐾𝐼 ↓↑              ⇵ 𝐾Í                                      
     𝐸𝐼             𝐸𝑆𝐼                         
 
Equation 3.5. General equation for the inhibitor binding to two forms of the enzyme with KI and KÍ 
representing the binding of inhibitor to E and ES-complex, respectively. 
 
The Vmax and Km for an uninhibited reaction, and the apparent Maximum Velocity (Vmax app) and 
Michaelis Constant (Km app) for inhibited reactions are obtained from the y- and x- intercepts of 
their Lineweaver-Burk plots where the y-intercept is equivalent to inverse of Vmax while x-intercept 
is equal to inverse of a negative Km [154, 158]. The KI and KÍ can be determined from the 
concentration of inhibitor (I), the Vmax app and Km app constants of the inhibited reaction, as well as 
the Vmax and Km of uninhibited reaction using the appropriate form of equation depending on the 






Rate of Equation 𝐾𝑚 𝑎𝑝𝑝  𝑉𝑚𝑎𝑥 𝑎𝑝𝑝  
None 
 













𝑣 = 𝑉𝑚𝑎𝑥[𝑆]/((1 + [𝐼]/𝐾𝐼)𝐾𝑚 + (1 + [𝐼]/ 𝐾Í [𝑆])) 
 
𝑣 = (𝑉𝑚𝑎𝑥[𝑆]/ (1 + [𝐼] 𝐾𝐼⁄ ))/𝐾𝑚 + [𝑆]) 
 
𝑣 = 𝑉𝑚𝑎𝑥[𝑆](𝐾𝑚 + [𝑆](1 + [𝐼]  𝐾Í ⁄ )) 




𝐾𝑚 /(1 + [𝐼]  𝐾Í ⁄ ) 
𝑉𝑚𝑎𝑥/(1 + [𝐼] 𝐾Í ⁄ ) 
 
𝑉𝑚𝑎𝑥/(1 + [𝐼] 𝐾𝐼⁄ ) 
 
𝑉𝑚𝑎𝑥/(1 + [𝐼] 𝐾Í ⁄ ) 
Table 3.1. General equations used for determining the Michaelis-Menten rate equation, the apparent Maximum Velocity (Vmax app) and the apparent Michaelis 









Data presented in Chapter 2 of this thesis showed that all tested alginates succeeded in reducing 
pancreatic lipase activity in vitro, however, CC01, 1N80 and 1LF80 possessed the most potent 
inhibition effects, suggesting that these three alginates could be used as potent inhibitors of 
pancreatic lipase in vivo. In the current chapter, the kinetics of both lipase/substrate interactions in 
the absence and presence of CC01, 1N80 and 1LF80 alginates as inhibitors were studied, and both 
Micheales-Menten and Lineweaver-Burk analysis were used to evaluate the strength of regulatory 


















3.3  Method 
3.3.1  Materials and equipment  
All chemicals and equipment used for the lipase kinetic assay were identical to those used in the 
turbidity assay of lipase activity in Chapter 2.  
 
3.3.2 Kinetic assay of lipase activity  
 Olive oil was passed through a glass chromatography column (2x 32 cm) containing 8 cm of 
aluminium oxide to remove the free fatty acids. Unlike lipase activity assay (section 2.4.2.1, p. 48), 
10 g of this purified olive oil was made up to 50 ml using acetone, producing a 20% (w/v) solution 
of purified olive oil in acetone which was stored as a stock solution at 4 ºC for use in all 
experiments. A higher concentration of substrate was used here to ensure that the saturation 
concentration is reached where all the active sites of lipase become occupied and any competitive 
inhibitor will be out competed.                                                                                                                  
Buffer diluent containing 0.35% (w/v) sodium taurodeoxycholate was prepared and titrated to pH 
7.3 as previously described in section 2.4.2.2 of Chapter 2. For lipase kinetic assay, 40.5 ml of the 
buffer diluent was heated to 70 ºC, then 4.5 ml of 20% purified olive oil solution was added to the 
heated diluent buffer, giving a 2% olive oil solution. The 2% olive oil solution (as a substrate 
solution) was homoginsed for 10 minutes with continuous heating at 70 ºC. After that, it was diluted 
further with an appropriate volume (μl) of the buffer diluent to prepare different concentrations of 
substrate (0.063, 0.125, 0.25. 0.5 and 1 % (v/v)). 1 mg/ml of lipase in buffer diluent was prepared. 
Then, 60 μl of colipase was added to the lipase solution, and the mixture vortexed. Orlistat in 
substrate solution at concentration 0.025 mg/ml was prepared. 5 mg/ml solution of alginate in 
substrate was prepared.  
For sample preincubation, two 96-well microplates (Bio Tek, USA) were used. For the kinetic 
assay of lipase control (in the absence of alginate), 10 μl of lipase solution (1mg/ml) and buffer 
diluent solution were placed separately in triplicate in plate 1. In plate 2, 240 μl of substrate (olive 
oil) solution at different concentrations (0.063, 0.125, 0.25. 0.5, 1 and 2 % (v/v)) was placed 




For kinetic assay of lipase in the presence of alginate, 10 μl of lipase solution (1 mg/ml) and buffer 
diluent solution were placed separately in triplicate in plate 1. In plate 2, 240 μl of a mixture 
consisting of 5 mg/ml alginate in different concentrations of substrate solutions (used as an 
inhibition control) was placed in six wells. Also, 240μl Orlistat solution (used as a positive 
inhibition control) was placed separately in six wells of plate 2. Both plates 1 and 2 were incubated 
at 37 ˚C for 10 minutes. Then, 200 μl of the samples present in Plate 2 was transferred to Plate 1 
containing 10 μl of both lipase and blank solutions. Finally, Plate 1 was placed in the reader where 
the optical density was read every 5 minutes at 405 nm for 55 minutes.  In the assay, 200 μl of the 
substrate solutions at 2, 1, 0.5, 0.25, 0.125, 0.063% (vol/vol) were added to 10 µl of lipase solution, 
giving final substrate concentrations of 19.05, 9.52, 4.76, 2.38, 1.19, and 0.59 mg/ml in the reaction 
mixture, respectively. Also, 10 μl of lipase solution (1 mg/ml), and 200 μl of alginate solution (5 
mg/ml) were used in the assay, hence, the final concentrations of lipase and alginate in the reaction 
mixture were 0.048 and 4.8 mg/ml, respectively. Measurements of kinetics of lipase/substrate in 
the presence and absence of alginate were carried out four times for the control and each 
biopolymer (CC01, 1N80, and 1LF80). 
 
3.4 Statistical analysis 
 Kinetic parameters (Km and Vmax) were calculated using GraphPad Prism 7 statistical software 
using substrate-velocity data and non-liner regression to produce Michaelis-Menten plot. 
Lineweaver-Burk plot was created using linear regression from GraphPad Prism 7 statistical 
software to identify type of inhibition and display inhibition kinetics. Each sample was examined 










Figure 3.6 shows Michaelis-Menten curves for lipase control reactions in the absence and presence 
of CC01 alginate at 4.8 mg/ml. For the lipase control reaction, the reaction velocity increased as 
the substrate concentration increased from 0 to 9.5 mg/ml. However, at substrate concentrations 
greater than 9.5 mg/ml, the reaction-rate curve started to level off, and the reaction reached its 
maximum velocity at Vmax = 0.328 (Δ absorbance/35 min), indicating that all the enzyme active 
sites became completely occupied by substrate molecules. Subsequently, the reaction velocity 
became independent of the substrate concentration, and any further increase in the substrate 
concentration did not change the reaction velocity. However, when CC01 alginate was added to the 
reaction mixture at concentration equal to 4.8 mg/ml, the reaction velocity increased with the 
increase in substrate concentration, however, the increase in velocity was lower than that of the 
lipase control at all substrate concentrations, and the biopolymer allowed the reaction to reach a 
plateau at a lower point where the Vmax was equal to 0.08 (Δ absorbance/35 min) compared with 





Figure 3.6. Michaelis-Menten plot for lipase control (■) and lipase with CC01 alginate (□) solutions.The 
lipase control solution consists of 0.048 mg/ml lipase and substrate at different concentrations (19.05-0.59 
mg/ml), whereas the lipase treated with CC01consists of 0.048 mg/ml lipase with different concentrations 
of substrate (19.05-0.59 mg/ml) and 4.8 mg/ml of CC01 alginate.Velocity is expressed as the change in 
absorbance over 35 minutes where the reaction at this time point was still close to the linear phase. Values 
are mean ± SD., n=4. 
The non-linear data from the Michaelis-Menten plot for lipase reactions both in the absence and 
presence of 4.8 mg/ml of alginate were transformed into linear Lineweaver-Burk plots using 
GraphPad Prism 7 to display inhibition kinetics and identify the type of inhibition (Figure 3.7).  
As shown in Figure 3.7 the y-intercept of Lineweaver-Burk plot for lipase reaction in the presence 
of CC01 (8.93 Δ absorbance/35 min) was higher than that in the absence of CC01 (2.71 Δ 
absorbance/35 min), showing that the CC01 reduced Vmax of lipase reaction.  
However, both best-fit lines for lipase in the presence and absence of CC01 crossed the x-axis at 
different points where the x-intercept for lipase in the presence of CC01 (-0.180 mg/ml) was lower 
than that of lipase in the absence of the biopolymer (-0.138 mg/ml), subsequently, the Km of lipase 
in the presence of CC01 biopolymer became lower than that in the absence of the biopolymer 







Figure 3.7. Lineweaver-Burk plot for lipase control (■) and lipase with CC01 alginate (□) solutions.The 
lipase control solution consists of 0.048 mg/ml lipase with different concentrations of substrate (19.05-
0.59 mg/ml), whereas the lipase treated with alginate consists of 4.8 mg/ml of CC01 and 0.048 mg/ml 
lipase with different concentrations of substrate (19.05-0.59 mg/ml). Velocity is expressed as the change in 
absorbance over 35 minutes where the reaction at this time point was still close to the linear phase. Values 
are mean ± SD., n=4. The absorbance was read at 405 nm every 5 min for 55 minutes. The insert shows a 
magnified view of the x- and y-intercepts of the Lineweaver-Burk plot. 
Figure 3.8 demonstrates a typical non-linear Michaelis-Menten curve for the lipase enzyme 
reaction in the absence (lipase control) and presence of 4.8 mg/ml 1N80 alginate. The lipase control 
is the same data as shown in Figure 3.6.  
When 1N80 alginate was added to the reaction, the velocity decreased at all substrate 
concentrations compared with velocity of the control reaction, and the presence of the biopolymer 




lower than the Vmax of lipase control reaction, demonstrating that the 1N80 reduced the velocity of 
lipase reaction. 
 
Figure 3.8. Michaelis-Menten plot for lipase control (■) and lipase with 1N80 alginate (□) solutions.The 
lipase control solution consists of 0.048 mg/ml lipase with different concentrations of substrate (19.05-
0.59 mg/ml), whereas the lipase with alginate consists of 4.8 mg/ml of 1N80 and 0.048 mg/ml lipase with 
substrate at different concentrations (19.05-0.59 mg/ml). Velocity is expressed as the change in absorbance 
over 35 minutes where the reaction at this time point was still close to the linear phase. Values are mean ± 
SD., n=4. The absorbance was read at 405 nm every 5 min for 55 minutes.  
 
The Lineweaver-Burk plot for the lipase reaction in the presence and absence of 4.8 mg/ml 1N80 
alginate is shown in Figure 3.9. It is obvious from the figure that the y-intercept of Lineweaver-
Burk plot of lipase in the presence of 1N80 (6.27 Δ absorbance/35 min) was higher than that in the 
absence of 1N80 (2.71 Δ absorbance/35 min), hence, the apparent Vmax of lipase in the presence of 
1N80 decreased compared with that in the absence of the biopolymer. However, the best-fit lines 
for lipase reaction in the presence and absence of the biopolymer crossed the x-axis at different 
points where the x-intercept for the reaction in the presence of 1N80 was lower than that in the 




of uninhibited reaction (Table 3.3). Therefore, the changes in both the apparent Km and Vmax show 
that adding 1N80 to the reaction mixture caused a mixed inhibition.   
 
Figure 3.9. Lineweaver-Burk plot for lipase control (■) and lipase with 1N80 alginate (□) solutions.The 
lipase control solution consists of 0.048 mg/ml lipase with different concentrations of substrate (19.05-
0.59 mg/ml), whereas the lipase treated with alginate consists of 4.8 mg/ml of 1N80 and 0.048 mg/ml 
lipase and substrate at different concentrations (19.05-0.59 mg/ml). Velocity is expressed as the change in 
absorbance over 35 minutes where the reaction at this time point was still close to the linear phase. Values 
are mean ± SD., n=4. The absorbance was read at 405 nm every 5 min for 55 minutes. The insert shows a 
magnified view of the x- and y-intercepts of the Lineweaver-Burk plot. 
 
A non-linear Michaelis-Menten curve for lipase/substrate in the presence and absence of 4.8 mg/ml 
1LF80 alginate is shown in Figure 3.10. For the lipase reaction in the presence of 1LF80, the 
reaction velocity increased with the increase in substrate concentration, but this increase in velocity 
at all substrate concentrations was lower than that of lipase control reaction in the absence of 1LF80. 




35 min) which was lower than that of lipase control reaction, indicating that adding the 1LF80 to 
the reaction mixture reduced the reaction velocity.    
 
Figure 3.10. Michaelis-Menten plot for lipase control (■) and lipase with 1LF80 alginate (□) solutions. 
The lipase control solution consists of 0.048 mg/ml lipase with different concentrations of substrate 
(19.05-0.59 mg/ml), whereas the lipase treated with alginate consists of 4.8 mg/ml of 1LF80 and 0.048 
mg/ml lipase with substrate at different concentrations (19.05-0.59 mg/ml). Velocity is expressed as the 
change in absorbance over 35 minutes where the reaction at this time point was still close to the linear 
phase. Values are mean and ± SD., n=4. The absorbance was read at 405 nm every 5 min for 55 minutes. 
It is clear from the Lineweaver-Burk plot (Figure 3.11) that both best-fit lines of lipase reactions in 
the presence and absence of 1LF80 crossed at a point close to the origin. However, in the presence 
of 4.8 mg/ml 1LF80, the best-fit values for the y-intercept was a negative value (-0.565 Δ 
absorbance/35 min) and the x-intercept was positive (0.009 mg/ml), giving unexpected negative 
values for Vmax and Km (Table 3.3).  Consequently, the type of inhibition caused by 1LF80 
biopolymer could not be determined directly from the Vmax and Km of Lineweaver-Burk plot. 
Therefore, type of inhibition caused by this biopolymer was assessed from the Vmax and Km 
calculated previously from the Michaelis-Menten curve of the biopolymer (Figure 3.10, Table 3.2).  




reduction in both Vmax and Km of the lipase reaction following addition of 1LF80, indicating that 





Figure 3.11. Lineweaver-Burk plot for lipase control (■) and lipase with 1LF80 alginate (□) solutions. 
The lipase control consists of 0.048 mg/ml lipase with different concentrations of substrate (19.05-0.59 
mg/ml), whereas the lipase treated with alginate consists of 4.8 mg/ml of 1LF80 and 0.048 mg/ml lipase 
with substrate at different concentrations (19.05-0.59 mg/ml). Velocity is expressed as the change in 
absorbance over 35 minutes where the reaction at this time point was still close to the linear phase. Values 
are mean ± SD., n=4. The absorbance was read at 405 nm every 5 min for 55 minutes. The insert shows a 
magnified view of the x- and y-intercepts of the Lineweaver-Burk plot. 
The Maximum velocity (Vmax) and Michaelis constant (Km) calculated from the Michaelis-Menten 
plots for all three alginates are shown in Table 3.2. The apparent Vmax and Km values for each 
biopolymer obtained from the Michaelis-Menten plot were compared to the Vmax and Km values of 
lipase control where no alginate was added to the reaction mixture.  
Adding CC01, 1N80, or 1LF08 alginate to the reaction mixture reduced lipase activity and allowed 
the reaction to approach the apparent Vmax at lower point compared with the Vmax of control (Table 
3.2). Moreover, there was a subsequent reduction in the apparent Km value following the addition 




increased the enzyme binding affinity for substrate to form ES-complex. The Km constant is derived 
from rate of breakdown of ES complex divided by the rate of formation of ES complex, so 
alteration of this will change Km. 
In contrast, the presence of 1LF80 in the reaction mixture increased the apparent Km; the larger Km 
suggests less ES complex will be formed, and there is a high possibility for the substrate to 
dissociate from the active site of the enzyme to free enzyme and free substrate. 
 
Sample Apparent Kinetic Constants 95% Confidence Intervals 
Vmax (Δ OD/ 35 min) Km (mg/ml) Vmax (Δ OD/ 35 min) Km (mg/ml) 
Lipase control 0.328 5.674 0.242 to 0.433 3.163 to 10.61 
CC01 0.084 3.334 0.059 to 0.131 1.129 to 10.36 
1N80 0.145 4.865 0.095 to 0.289 1.427 to 21.08 
1LF80 0.178 7.67 0.109 to 0.468 2.231 to 41.45 
Table 3.2. Michaelis Menten kinetic parameters for lipase control and lipase inhibited by 4.8 mg/ml of 
alginates.  
 
The type of inhibition caused by alginate based on the Vmax and Km constants calculated from 
Lineweaver-Burk plots are shown in Table 3.3. Obviously, there was an apparent reduction in the 
Vmax and Km values for CC01 or 1N80 compared with the Vmax and Km values of lipase control, 
also, the best-fit lines of these two biopolymers (Figure 3.7 and Figure 3.9) from Lineweaver-Burk 
plot crossed the x-axis at different points, showing that adding either CC01 or 1N80 caused a mixed 
inhibition. 
The type of inhibition caused by 1LF80 could not be defined directly from the Lineweaver-Burk 
plot due to negative values for Vmax and Km. Therefore, the type of inhibition caused by this 
biopolymer was assessed from the Vmax and Km values of Michaelis-Menten plot based on the fact 
that the kinetic constants Vmax and Km for the alginates CC01 and 1LF80 obtained from Michaelis-
Menten and Lineweaver-Burk plots showed similar values. The Michaelis-Menten kinetic data for 




the presence of biopolymer compared with those values for lipase control which was free of 1LF80. 
In addition, the best-fit lines from Lineweaver-Burk plots (Figure 3.11) crossed close to the origin 




Lineweaver-Burk Plot     
Intercepts 











Vmax             




Lipase control 2.711 - 0.138 0.369 7.194 No inhibitor was added 
CC01 8.930 - 0.180 0.112 5.524 Mixed inhibition 
1N80 6.272 - 0.169 0.159 5.917 Mixed inhibition 
1LF80 -0.565 0.009 - 1.770 - 111.11 Unknown from the Lineweaver-
Burk plot.  
Table 3.3. Lineweaver-Burk Kinetic parameters for lipase control and lipase inhibited by 4.8 mg/ml of 
alginates.  
 
The obtained kinetic information from Michaelis-Menten and Lineweaver-Burk plots showed that 
CC01, 1N80, and 1LF80 alginates were acting as mixed inhibitors where each biopolymer has the 
ability to bind to the free E (with dissociation constant KI) and ES complex (with dissociation 
constant KÍ). However, the enzyme binding affinity for the free E and ES complex is unequal 
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Equation 3.6. Enzyme-catalysed reaction in the presence of a mixed inhibitor. 
 
The inhibition constant (KI or K) is usually calculated to evaluate the potency of an inhibitor where 
the higher the inhibition constant value, the weaker the inhibitor and higher concentration is 
required to yield 50% of maximum inhibition. The CC01, 1N80 and 1LF80 biopolymers were 
classified as mixed inhibitors, and this type of inhibition usually shows the characteristics of two 
types of inhibition (uncompetitive and non-competitive inhibition), therefore, the KI and KÍ 
constants for each biopolymer were calculated to determine the predominant characteristic of 
inhibition by comparing binding affinity to the free E and ES complex through the values of their 
inhibition constants.  The KI and KÍ are usually calculated from the Vmax and Km of Lineweaver-
Burk plot. However, the Vmax and Km obtained from the Lineweaver-Burk plot gave invalid 
negative values for 1LF80, so the KI and KÍ were calculated from the Vmax and Km of the Michaelis-
Menten plot.  Both KI and KÍ were calculated from the Vmax and Km values of lipase control and the 
apparent Vmax and Km values of the alginate using the mixed inhibition equation presented in Table 
3.1.  
The kinetic inhibition constants KI and KÍ calculated from Michaelis-Menten or Lineweaver-Burk 
plots for the different alginates were similar (Table 3.4). The mixed inhibition caused by CC01 and 
1N80 showed more uncompetitive-like characteristics by their greater binding affinity to the ES 
complex than the free enzyme. The greater binding affinity of inhibitor toward the ES complex was 
shown by the smaller Kib compared to the Kia.   
However, the KI of 1LF80 was less than the KÍ, indicating that the inhibitor had a higher binding 






Sample KI (mg/ml) KÍ (mg/ml) Type of lipase inhibition  
CC01 3.71 [3.14] 1.65 [2.09] Mixed inhibition which showed more                             
uncompetitive-like characteristics  
1N80 5.11 [5.28] 3.80 [3.63] Mixed inhibition which showed more                               
uncompetitive-like characteristics  
1LF80 3.22 [unknown] 5.59 [unknown] Mixed inhibition which showed a higher     
affinity for the free enzyme. 
Table 3.4. Kinetic inhibition constants (KI and KÍ) calculated from the Vmax and Km of both Michaelis-
Menten and Lineweaver-Burk plots. The values in brackets represent KI and KÍ values calculated from 
Lineweaver-Burk plot. The KI and KÍ represent the binding affinity of inhibitor for the free enzyme and 
enzyme-substrate complex, respectively. 
The correlation between the apparent Vmax or Km of biopolymers obtained from the Michaelis-
Menten plots and their fraction of fraction of guluronate residues (F[G]) was investigated. There 
was a significant negative correlation (P<0.005) between the Vmax and F(G) where the maximal 
reaction velocity is lower in the presence of alginates with increased fraction of guluronate residues 
(Figure 3.12). Data from 1HNMR analysis of alginates in Chapter 2 of this thesis (Table 2.5 in 
results section) showed that CC01 had the highest content of G blocks and this could explain its 
capability to reduce the Vmax of reaction to level much greater than the 1N80 and 1LF80. There 
was a negative correlation between Km and F(G) alginate with high fraction of guluronate residue, 
however, this correlation was not significant (P>0.05) (Figure 3.13).  













As the concentration of inhibitor [I] is constant, then for the Km app to decrease, the KI must be larger 
than the KÍ as with CC01 and 1N80 alginates. However, if the KÍ is greater than the KI, then the Km 








Figure 3.12. Correlation between apparent Vmax of alginates and their fraction of guluronate residues 
(F[G]). Vmax was calculated from Michaelis-Menten plots. A negative correlation between Vmax and F[G] 















Figure 3.13. Correlation between apparent Km of alginates and their fraction of guluronate residues 
(F[G]). Km was calculated from Michaelis-Menten plots. A negative correlation between Km and F[G] was 














The investigations of enzyme kinetics aimed to define the regulatory effect of alginate on enzyme-
substrate affinity (Km) and the maximum velocity (Vmax) of reaction by comparing their kinetic 
parameters with those of the lipase control.  
Kinetic data showed that adding CC01, 1N80, or 1LF80 alginates into the reaction mixture 
decreased the velocity of reaction at all substrate concentrations compared to the reaction velocity 
in the absence of alginate at the same substrate concentrations. Also, the presence of alginate 
allowed the reaction to reach the Vmax at a lower point compared to the Vmax of lipase control, 
indicating that the algal bioactive could inhibit lipase activity. This result is in agreement with the 
Wilcox et al. study (2014) which reported that alginate can reduce pancreatic lipase activity in vitro. 
The inhibitory effect of alginate on pancreatic lipase is not limited only to alginate bioactives, other   
studies have shown that other algal bioactive compounds such as fucoxanthins and its metabolite 
fucoxanthinols [96], phlorotannins [95], alginates, polyphenols and fucoidans [97] can reduce the 
activity of pancreatic lipase in vitro.  
There was a significant negative correlation between the apparent Vmax and alginate’s frequency of 
gluconate residues where CC01 reduced the maximum velocity of lipase more than 1N80 and 
1LF80 biopolymers. 1H NMR data presented in Chapter 2 of this thesis showed that CC01 has the 
highest content of G, GG, and GGG residues compared with 1N80 and 1LF80. In addition, the data 
from the lipase activity assay in Chapter 2 of this thesis showed that CC01 had the ability to reduce 
pancreatic lipase activity to a much greater extent than the other two biopolymers. This finding is 
consistent with the Wilcox et al. study (2014) which showed that alginate rich in G, GG, and GGG 
residue inhibited pancreatic lipase activity in vitro more than alginate rich in M and MM residues, 
demonstrating a positive correlation between alginate content of G block and inhibition level. 
Therefore, the highest inhibitory effect of CC01 on lipase velocity could be due to its greatest 
content of G blocks.  
Alginates rich in G blocks produce strong and stiff gels compared to alginate rich in M blocks 
which produce softer and more flexible gels [159, 160].  It has been stated that alginate has the 
ability to bind to the enzyme itself and this binding is limited on alginate rich in G block. Alginate 
with high content of G residue exhibits binding affinity to the protein part of mucin, however, 




hydroxyl groups of G block in alginate can protonate serine and histidine residues at the active site 
of pancreatic lipase, reducing proton shuttle mechanism which is an essential mechanism for 
activation of pancreatic lipase; this is supposed to be the mechanism by which pectin inhibits the 
pancreatic lipase [72, 144]. This could explain the highest level of lipase inhibition achieved by 
CC01 alginate. 
According to the Vmax and Km constants obtained from Lineweaver-Burk plots of CC01 and 1N80 
biopolymers, both biopolymers were classified as mixed inhibitors since their presence in the 
reaction mixture caused an apparent reduction in the Vmax and Km values compared to the Vmax and 
Km of lipase control. However, the type of inhibition produced by the 1LF80 alginate could not be 
identified from the Lineweaver-Burk plot since both Vmax and Km constants calculated from the 
Lineweaver-Burk plot showed negative values which cannot be interpreted. These unexpected 
negative values may appear due to the effect of experimental error in this type of plots where the 
lowest concentrations of substrate usually have the largest experimental error. Therefore, the type 
of inhibition caused by the 1LF80 was determined using the Vmax and Km constants calculated from 
Michaelis-Menten plot and according to theses calculated constants, 1LF80 was classified as a 
mixed inhibitor. The KI and KÍ of mixed inhibition were determined here in an attempt to determine 
the predominant form of inhibition through evaluation of inhibitor binding affinity to the free 
enzyme and the ES-complex.  
Both KI and KÍ data showed that there was no difference between the inhibition constants of CC01 
or 1N80 obtained either from the Michaelis-Menten or Lineweaver-Burk plots. Additionally, the 
data showed that all the three biopolymers had the ability to bind the free enzyme and the ES-
complex unequally. However, CC01 and 1N80 alginates showed more uncompetitive-like 
characteristics by their greater binding affinity to the ES-complex than the free enzyme where the 
KÍ (the inhibitor binding affinity to the ES-complex) values were less than the KI (the inhibitor 
binding affinity to the free enzyme). Therefore, these lower KÍ values of CC01 and 1N80 suggested 
that the two biopolymers bound tightly to the enzyme-substrate complex, and their probability to 
dissociate is low.   
In contrast, the KI and KÍ data for 1LF80 showed that the biopolymer had the ability to bind the 
free enzyme as well as the ES-complex with a greater binding affinity for the free enzyme than the 




formation, showing that 1LF80 caused a mixed inhibition.  
 In mixed inhibition shown here, there are many possible mechanisms by which the inhibitor 
(biopolymer) can bind to the free enzyme (E) and the enzyme-substrate (ES) complex. The inhibitor 
can bind the free enzyme at a site different from the active site (allosteric site) forming enzyme-
inhibitor (EI) complex preventing the substrate binding to the enzyme active site (Figure 3.14A). 
The inhibitor binding to a site different to the active site induces some conformational changes in 
the enzyme shape which in turn reduces the effectiveness of active site. Binding of the inhibitor to 
the free enzyme reduces the turnover number (Kcat) and Vmax. The turnover number can be defined 
as the number of substrate molecules that can be converted to the product molecules by a single 
enzyme over a period of time.   
The inhibitor can also bind to the ES-complex where the substrate first binds to the active site of 
enzyme, forming the ES complex, and inducing some alterations in the structure of enzyme and 
that could either expose the inhibitor binding site which already exists, hence the inhibitor can bind 
to this site (Figure 3.14B), or creates a new binding site which did not exist previously (Figure 
3.14C). This is the only mechanism by which an uncompetitive inhibitor works.  
In uncompetitive inhibition, the inhibitor binds only to the ES-complex since the binding of 
substrate to enzyme creates a new binding site for inhibitor, allowing the inhibitor to bind, and form 
the ESI complex. However, binding the inhibitor to ES complex reduces concentration of an active 
ES complex in the reaction mixture and increases the concentration of inactive ESI complex. In 
uncompetitive inhibition, the Vmax is decreased due to the binding of inhibitor to the ES complex 
which causes a reduction in the concentration of an activated ES complex available in the mixture, 
also, the reduction in ES complex decreases the Km. Both CC01 and 1LF80 are mixed inhibitors, 
however, they showed more uncompetitive inhibition like characteristic by greater binding affinity 
to the ES complex, as well as the reduction in their Vmax and Km values. 
Many mechanisms have been suggested for pancreatic lipase inhibition by alginate, however, the 
exact mechanism by which the alginate inhibits the activity of pancreatic lipase is still unknown. 
It has been assumed that alginate can bind to both the free enzyme and the substrate. Alginate can 
interact with glycoproteins, such as mucin, and this binding has been detected using rheological 




has the ability to bind to mucin at particular positions within the protein core, linking many mucin 
molecules together and producing a gel. However, alginate with high content of M units did not 
interact and link mucin molecules together, indicating that the G blocks are very important for 
mucin-alginate binding [139]. 
Alginate also may bind to the lipid/water interface of substrate, decreasing the access of the enzyme 
to substrate interface. This is assumed to be the mechanism by which other effective inhibitors such 
as chitosan, DEAE sephadex and DEAE polydextrose inhibit pancreatic lipase activity. However, 
these inhibitors are cationic molecules while alginate is anionic [91, 150]. 
Pectin inhibits lipase by binding to the free enzyme, causing serine and histidine residues present 
in the active site to become protonated, resulting in reduced enzyme activity [144]. It is supposed 
that the carboxyl groups of pectin are responsible for protonation of serine and histidine in the 
lipase active site [141]. The same authors reported that increasing esterification of pectin reduced 
its inhibitory effect on pancreatic lipase activity since pectin esterification involves replacing the 
carboxyl groups with methyl groups which in turn reduces the number of carboxyl groups 
responsible for protonation of serine and histidine in the active site of enzyme [141]. It was assumed 
that alginate may also inhibit pancreatic lipase activity in the same way where the carboxyl groups 
in G block of alginate are in identical sites to that of carboxyl groups of pectin which explains how 







Figure 3.14. Schematic diagram showing mechanisms of mixed inhibition.(A) The inhibitor can bind to 
the free enzyme at a site different from the active site, forming enzyme-inhibitor complex (EI) and 
inducing some changes in enzyme structure. Consequently, the effectiveness of active site is reduced. (B) 
The enzyme has two sites: substrate binding site and an inhibitor binding site. The substrate can bind at 
the active site of enzyme, forming ES complex, causing some conformational changes in the structure of 
enzyme, and exposing the inhibitor binding site; hence, the inhibitor can bind to this site producing ESI 
complex. (C) The substrate binds to an enzyme active site, forming an enzyme-substrate (ES) complex, 
inducing some conformational changes in the enzyme shape. Subsequently, a new binding site is created, 











The kinetic information obtained here showed that CC01, 1N80, and 1LF80 reduced reaction 
velocity, allowing the reaction to reach a Vmax at lower substrate concentration. Alginate content of 
G blocks positively correlated with the inhibitory effect on lipase activity. Additionally, all three 
biopolymers used here acted as mixed inhibitors where they had the ability to bind the free enzyme 
and ES-complex with different binding affinities. Moreover, both CC01 and 1N80 biopolymers 
showed more uncompetitive-like characteristics by their greater binding affinity to the ES complex. 
However, the 1LF80 biopolymer showed a trend of inhibition with greater binding affinity to the 






Chapter 4: Fat Digestion within the Synthetic Model Gut System 
4.1 Overview of the synthetic model gut 
The digestion and absorption of dietary lipids are associated with health and the development of 
metabolic diseases such as obesity. Several previous studies have confirmed that alginates can 
inhibit pancreatic lipase activity in vitro by 72.2 (±4.1) %, thus reducing the energy derived from 
high calorie foods and potentially preventing the development of obesity [72, 161]. Furthermore, 
experimental data from previous investigations of the inhibitory effects of alginate on pancreatic 
lipase activity (Chapter 2), using a modified version of Vogel and Zieve (1963), showed that all the 
tested alginate samples inhibited the activity of pancreatic lipase with different levels of inhibition 
[122]. Alginates CC01, 1N80 and 1LF-80 possessed the highest inhibitory effects where they 
significantly inhibited lipase activity by 75.6 (± 10.6), 62.7 (± 20), and 53.7 (± 8.5) %, respectively. 
Therefore, further investigation was carried out to study the inhibitory effects of these alginates on 
lipase activity in vitro using a synthetic model gut system developed at Newcastle University. The 
model gut system aims to imitate in vivo digestive processes from mouth to terminal small intestine 
in a physiologically relevant manner, and thus the enzymatic and chemical digestive processes of 
these macromolecules can be studied.  
The developed model gut system consists of three synthetic gastrointestinal fluids (saliva, gastric 
juice and pancreatic juice) and porcine bile. The synthetic gastrointestinal fluids are not buffered, 
and are prepared at different pH to mimic the pH and ionic content of the relevant section of the 
gastrointestinal tract in vivo [162]. In the present study, three fat substrates (glyceryl trioctanoate, 
olive oil and sunflower oil) were used alone as controls for fat digestion, whereas the model gut 
(MG) solution without substrate, which consists of synthetic saliva in deionised water (DH2O), was 
used as a background control. The values measured for the background control were subtracted 
from those for the digestion of the fat substrate to account for any interference from digestive fluids. 
The effect of three alginate samples CC01, 1N80, and 1LF80, which were supplied by the Coca-
Cola and Ruitenberg companies, on the activity of pancreatic lipase have been studied because the 
two companies are interested in producing products containing alginates in an attempt to reduce 
caloric intake. In this chapter, the effects of these alginates, which could inhibit lipase activity in 
the turbidity assay as shown previously in Chapter 2 of this study, were analysed in the synthetic 





The data from the turbidity assay which were presented in Chapter 2 show that CC01, 1N80 and 
1LF80 alginates reduce pancreatic lipase activity at different rates depending on their source and 
content of G- and M-blocks. Therefore, the aims of this chapter were: 
 To study the overall effects of different amounts of the alginates (CC01, 1N80 and 1LF80) 
on fat digestion in vitro using a synthetic model gut system to determine whether the 
alginates can inhibit pancreatic lipase activity and slow the subsequent digestion of fat. The 
model gut system allows samples to be collected at different time points, thus enabling 
measurement of the amount of glycerol liberated to assess whether the fat substrates 
undergo digestion and to evaluate whether there is any significant difference between the 
amount of glycerol liberated from the digestion of fat substrate alone (as a control) and 
those released from the digestion of fat substrate treated with alginate 
 As many studies have suggested that fats are digested at different rates depending on fatty 
acid chain length, the digestion rates of three fat substrates with different level of fatty acid 
chain length: glyceryl trioctanoate (medium-chain triglycerides), olive oil (a mixture of 
long-medium chain triglycerides), and sunflower oil (long-chain triglycerides) were 
assessed here using the model gut to determine which fat substrates have the highest 
digestion rate, and whether there is a link between fatty acid chain length and digestion rate. 
 To investigate the impact of pH on the capacity of alginate to inhibit pancreatic lipase where 
the pH of alginate solutions within the synthetic model gut was measured at different time 
points of the gastric and small intestinal phases. 
 To assess the regulatory effect of different amounts of CC01 alginate on olive oil digestion 
in vitro using a buffered salivary diluent containing 372mM NaHCO3 instead of 62mM 








All chemicals and enzymes used in the synthetic model gut experiments were purchased from 
Sigma-Aldrich. Pig bile was obtained fresh from a local slaughterhouse. Olive oil and sunflower 
oil were purchased from a local supermarket (Cooperative Food, UK). The alginate sample CC01 
was provided by Coca-Cola, whereas 1LF80 and 1N80 alginates were supplied by Ruitenberg, 
based in the Netherlands.  
4.3.2 Preparation of synthetic gastrointestinal fluids 
The fluids of the synthetic model gut were prepared prior to use as stock solutions, and the enzymes 
were added immediately before passing the sample in the model gut.  
 Synthetic Salivary diluent (pH 7.4): Salivary diluent was composed of 62mM NaHCO3, 
6mM K2HPO4, 15mM NaCl, 6.4mM KCl and 3mM CaCl2.2H2O. For experiments, 1μl/ml 
α-amylase salivary diluent was prepared. Then, DH2O was added to the salivary diluent 
containing α-amylase in 1:1 ratio to prepare the synthetic saliva.  
 Synthetic Gastric diluent (pH 1-2): Gastric diluent consisted of 49.6mM NaCl, 9.4mM KCl, 
2mM KH2PO4 and 5mM Urea in DH2O. The gastric enzymes included 400 U/L gastric like 
lipase from bacteria – (Amano Enzyme Inc AP12), which is active at pH 2, and porcine 
pepsin (0.5 mg/ml). 
 Synthetic Pancreatic Diluent (pH 8.0): Pancreatic Diluent was composed of 110mM 
NaHCO3, 2.5mM K2HPO4, 54.9mM NaCl, 1mM CaCl2.2H2O and 1.67mM Urea dissolved 
in DH2O. For the pancreatic enzyme preparation, pancreatin was added fresh into the 
pancreatic diluent (70 mg/ml). However, because triglycerides of glyceryl trioctanoate 
produce fatty acids with low pKa (i.e. octanoic acids which have pKa 4.9), the pancreatic 
diluent used with this substrate (glyceryl trioctanoate) was made with a higher amount of 
NaHCO3, 322.8 mM, to avoid the low pH which can result from liberation of these fatty 
acids (Table 4.1).  
 Fresh porcine bile (pooled): Bile was collected from 10 – 20 porcine gall bladders. The bile 




Triglyceride Fatty Acid Fatty Acid pKa 
Glyceryl Trioctanoate Octanoic Acid (Caprylic Acid) 4.9 
Olive Oil Oleic Acid 9.85 
Sunflower Oil Linoleic Acid 9.24 
Table 4.1. Characteristics of triglyceride substrates processed in the synthetic model gut system.  
 
4.3.2.1 Synthetic model gut sample preparation 
 Fat substrate alone as a control: Three different triglycerides (glyceryl trioctanoate, olive 
oil, and sunflower oil) with different fatty acid chain lengths were tested in a synthetic 
model gut. Each fat substrate sample was prepared by adding 5 ml of DH2O into 5 ml of 
synthetic saliva and 5 ml of the substrate (glyceryl trioctanoate, olive oil or sunflower oil), 
giving a total volume of 15 ml. 
 Fat substrate solution: Contained 5 ml fat substrate, 5 ml saliva, and 5 ml DH2O. 
 Model gut solution (MG) as a background control: Prepared by adding 5 ml of synthetic 
saliva into 10 ml of DH2O. MG solution absorbance was subtracted from substrate 
absorbance to correct any interference in the model gut system. 
 Alginate with fat substrate: Prepared by adding 250, 500 or 1000 mg of alginate (CC01, 
1N80 or 1LF80) into a beaker containing 5 ml fat substrate, 5 ml DH2O, and 5 ml synthetic 
saliva.  
 Alginate in MG solution: Prepared by adding the alginates into a mixture consisting of 10 
ml DH2O and 5 ml of synthetic saliva. This was used as a background for alginate. The 
absorbance of alginate in the MG was subtracted from alginate/fat substrate absorbance to 





4.3.3 Synthetic Model Gut System Procedure 
The synthetic model gut system consists of two water baths (Figure 4.1). Artificial gastrointestinal 
fluids (gastric and pancreatic juices) as well as porcine bile were pre-incubated in water bath 1 at 
37 ᵒC.  Four beakers (each 600 ml volume) containing fat substrate alone, MG solution, fat substrate 
with alginate, or alginate in MG solution were placed in water bath 2 at 37 ᵒC. A Watson Marlow 
Peristaltic pump was adjusted to a rate of 0.5 ml/min to pump artificial gastric and pancreatic juices 
into the beakers containing samples. Four lab-egg overhead compact stirrers were used for mixing 
the samples and artificial fluids.    
 
 
Figure 4.1. Schematic diagram for model gut system set up. Water bath 1 contains the gastrointestinal 
fluids. Water bath 2 contains the sample solutions. A represents fat substrate alone, B represents model gut 
(MG) solution alone, C represents fat substrate with alginate, and D represents alginate in MG solution. 
The samples digestion process within the synthetic model gut system involved three stages: 
salivary phase (mouth), gastric phase (stomach) and small intestinal phase (small intestine). For 
the salivary phase preparation, 5μl of α-amylase was added fresh to 5ml of salivary diluent and 5 
ml of DH2O. For the gastric phase preparation, 150 mg and 12 mg of pepsin and gastric lipase, 




21 g pancreatin was added fresh into 300 ml of pancreatic diluent, then the mixture was mixed 
using a magnetic stirrer. After that, the pancreatic juice was filtered using glass wool to remove 
insoluble proteins and lipids present in the pancreatin.  
The salivary phase lasted for 10 minutes. The gastric phase started after adding 50 ml of gastric 
juice into the glass beakers containing samples, and the remaining synthetic gastric juice was 
pumped in at a rate of 0.5 ml/min for one hour. At 60 minutes, the gastric phase ended, and the 
pancreatic phase started when 25 ml of fresh porcine bile was added into the beakers. Finally, 
synthetic pancreatic juice was pumped in at a rate of 0.5 ml/min for two hours. 
 
4.3.3.1 Model gut sample collection 
500 µl samples were taken separately at time points T0, T15, T30, T60, T60T, T75, T90, T120, T150, and 
T180 minutes. T60 represents the last sample taken from the gastric phase, whereas T60T represents 
the first sample taken from the small intestinal phase. The samples were added immediately into 
500 µl of 10% (w/v) trichloroacetic acid in DH2O to stop enzymatic reactions and precipitate out 
the undigested substrate. Samples were stored at 4 ᵒC overnight. After that, the samples were 
centrifuged at 10,000 rpm (9,300 g) for 10 minutes, and 5 µl of each supernatant was placed in 
duplicate in a 96-well microplate (Bio Tek, USA) for quantification of glycerol release. Then, the 
colourimetric glycerol assay was carried out by adding 80 µl of free glycerol reagent (Sigma-
Aldrich) into the supernatants. After that, the plate was shaken and left at room temperature for 20 
minutes to allow colour development. Finally, the absorbance was read at 550 nm and the amount 
of glycerol released from digestion of triglycerides was calculated as described below. 
 
4.3.4 Quantification of glycerol 
The colourimetric glycerol assay was used to quantify the glycerol released from fat (triglyceride) 
digestion.  Free Glycerol Reagent (Sigma-Aldrich) uses coupled enzymatic reactions to produce a 
quinoneimine dye which absorbs at 550 nm. There was a positive correlation between the 
concentration of free glycerol in the sample and the absorbance. The amount of glycerol in the 




temperature, DH2O was added to the free glycerol reagent in the ratio 4:1, respectively. Then, 2 
mM glycerol in DH2O was prepared as a glycerol standard and diluted to lower concentrations (1, 
0.5, 0.25, 0.125. 0.062, and 0.031 mM). Next, 5 µl of each glycerol standard solution was placed 
in duplicate in the same 96-well microplate (Bio Tek, USA) as the sample supernatants. After that, 
80 µl of the free glycerol reagent was added to each sample and standard, mixed and left for 20 
minutes at room temperature until a pink colour developed. Finally, the plate was read at 550 nm 
and the concentration of glycerol in each sample determined from the standard curve.  To correct 
any interference, the absorbance of the MG solution alone was subtracted from the absorbance of 
the control (fat substrate alone), whereas the absorbance of alginate in the MG solution was 
subtracted from the absorbance of fat substrate with alginate. The total amount of released glycerol 
at each time point was determined by multiplying by the total volume present in the model gut 
system at that time point. The glycerol released from digestion of each substrate was calculated as 
a mean of the total number of replicates.  
 
4.3.5 pH measurements 
All pH measurements were carried out at room temperature using a Martini Mi150 pH meter. The 
pH meter was calibrated using buffer solutions of pH 4 and 7. Then, the pH of fat substrate alone 
and in combination with alginate were measured at different time points of the gastric and small 
intestinal phases of the synthetic model gut.  
 
4.4 Statistical analysis 
Statistical calculations to evaluate the effectiveness of different amounts of three alginate samples 
(CC01, 1N80, and1LF80) in reducing fat digestion were carried out using Two-way Repeated 
ANOVA followed by a Post-Hoc Bonferroni test at a significance level (α) below 0.05 to compare 
between the amount of glycerol released from the digestion of fat substrates alone and the glycerol 
amount released from fat substrates in combination with alginates. Data have been displayed as 






4.5.1 Glycerol standard curve  
Figure 4.2 illustrates the standard curve for glycerol in DH2O using the free glycerol reagent. The 
data shows that there was an increase in the absorbance (0-0.21 OD) at 550 nm which was directly 
proportional to the increase in glycerol concentration (0.031-2 mM) with good linearity (R2=0.99). 
 
 
Figure 4.2. Standard curve of absorbance at 550nm against glycerol concentration in DH2O. Values are 
mean, and the error bars are the standard deviation of six replicates (± SD, n=6). 
4.5.2 Digestion of fat substrates within the synthetic model gut system  
Figure 4.3 shows the gastrointestinal digestion of 5 ml glyceryl trioctanoate, olive oil and sunflower 
oil individually within the synthetic model gut system. 
During the gastric phase (0-60 minutes), small amounts of glyceryl trioctanoate and olive oil were 
digested, where only 2.4 (±2.2) and 1(±0.9) mg of glycerol were released from glyceryl trioctanoate 
and olive oil digestion, respectively, at the end of the gastric phase. However, no glycerol was 
released from sunflower oil digestion during the gastric phase.  



























After 60 minutes, the small intestinal phase started when porcine bile was added, and the synthetic 
pancreatic juice was pumped into the samples. During the first 15 minutes of the intestinal phase, 
there was a significant increase in the digestion rate of glyceryl trioctanoate and 25.1 (±7.2), 51.3 
(±6.8), 55.9 (5.3), and 61.3 (±7.7) mg of glycerol were released from glyceryl trioctanoate digestion 
at 90, 120, 150, and 180 minutes, respectively.  
Also, the digestion rates of olive oil and sunflower oil began to increase after 15 minutes of the 
small intestinal phase reaching 5.4 (±3.9), 12.3 (±3.8), 22.1 (±7.7), and 35.4 (±8) mg glycerol from 
olive oil digestion and 2.8 (±0.33), 8.5 (±0.68), 16 (±0.02) and 24.9 ((±4.5) mg from sunflower oil 
digestion at 90, 120, 150, and 180 minutes, respectively.  
There was a significant increase in the amount of glycerol released at the end of the small intestinal 
phase (at 180-minute) compared to the end of the gastric phase (at 60-minute), demonstrating that 
the majority of sunflower oil digestion occurred in the small intestinal phase.  
Although the amount of glycerol released from glyceryl trioctanoate digestion was higher than that 
released from olive oil or sunflower oil digestion at all time points of the model gut procedure 
(Figure 4.3), a Post-Hoc Bonferroni test showed a significant difference (P<0.05) at 75, 90, 120, 
150, and 180 minutes between the amounts of glycerol released from the digestion of glyceryl 
triocatonate and that released from olive oil or sunflower oil digestion at 75, 90, 120, 150, and 180 
minutes of the model gut procedure. Also, although the amount of glycerol released from olive oil 
was higher than that released from sunflower oil digestion, this difference was statically significant 






Figure 4.3. Release of glycerol over time from digestion of glyceryl trioctanoate, olive oil and sunflower 
oil within the synthetic model gut system. A significant difference (P<0.05) between the glycerol released 
from digestion of glyceryl trioctanoate and that released from olive oil and sunflower oil digestion, 
whereas • indicates a significant difference (P<0.05) between the glycerol released from digestion of olive 
oil and that released from sunflower oil digestion. 
 
4.5.3 Evaluation of the variability of control fat substrates digestion in the model gut system 
Table 4.2, Table 4.3 and Table 4.4 show the mean amounts of glycerol released from the simulated 
digestion within the synthetic model gut system for different repeats of 5 ml of glyceryl trioctanoate 
alone, olive oil alone or sunflower oil alone.  
As can be shown from the Table 4.2, there was a variation between the amounts of mean glycerol 
released from the digestion of the several glyceryl trioctanoate controls at all time points of the 
gastric phase. The amounts of glycerol released from the digestion of different controls ranged 
between 0.16-4.97 mg at the end of the gastric phase (at 60-minute). During the small intestinal 
phase, there was also a variation between the amounts of glycerol released from the digestion of 
glyceryl trioctanoate controls at all time points. At 180 minutes the range of mean glycerol released 




66.15mg, this represents a 1 to 1.35 ratio between the lower and higher mean value.  
The data presented in Table 4.3 shows that there was a variation between the amounts of mean 
glycerol released from the digestion of different olive oil controls during the gastric phase. During 
the small intestinal phase, there was also a difference between the amounts of glycerol released 
from the digestion of different olive oil controls at all time points, and the amounts of glycerol 
released for the different controls ranged between 24.95 and 46.90mg at the end of the small 
intestinal phase (at-180 minute), indicating a relatively high variation with a ratio of 1 to 1.88 
between the lower and higher value.     
The data in Table 4.4 demonstrate that there was a variation between the amounts of glycerol 
released from the sunflower oil controls during the gastric phase, and the amount of glycerol 
released ranged between 0.02-1.31mg. Also, varying amounts of glycerol were liberated from the 
digestion of different sunflower oil controls during the small intestinal phase, at the end of the small 
intestinal phase there was a range of 17.45-27.99 mg again indicating a relatively high variation 
with a ratio of 1 to 1.60 between the lower and higher value.  
The variation between the amounts of glycerol released from the digestion of different samples of 
the same fat substrate (glyceryl trioctanoate, olive oil or sunflower oil) might be because of the use 
of different porcine bile samples in this set of experiments. The bile is composed of different 
substances such as bile salts, mucus, phospholipids, cholesterol, and bilirubin, and different bile 
samples contain different contents of these substances which may affect the digestion rate of fat 
substrate. Also, the variation between the amounts of glycerol released by the digestion of the same 
fat substrate may occur due to the difference in the synthetic gastrointestinal fluids (saliva, gastric 
and pancreatic juices). New synthetic gastrointestinal fluids were prepared for each set of 
experiments. Therefore, each experiment performed here has its internal control, which was carried 







































Glycerol range (mg) 
0 0.290 0.873 0.646 1.695 0.212 0.341 0.794 0.525 0.449 0.217 0.171 0.194 (0.17-1.69) 
15 4.662 1.758 3.520 1.769 0.180 0.678 4.011 5.000 4.447 0.369 0.537 0.792 (0.18-5) 
30 5.609 1.919 0.531 2.248 0.086 0.229 2.782 2.677 2.499 0.120 0.262 0.063 (0.06-5.6) 
60 4.006 4.973 3.725 3.675 0.248 0.163 2.992 4.190 3.182 0.063 0.568 0.453 (0.16-4.97) 
60 3.686 4.723 5.885 2.409 1.419 0.488 6.177 6.550 8.352 1.316 0.469 1.484 (0.46-8.35) 
75 7.957 10.922 5.571 6.608 4.782 0.890 18.207 11.345 14.823 4.845 1.402 2.657 (0.89-18.20) 
90 25.499 31.712 19.789 17.705 23.992 9.066 35.854 22.840 34.205 7.551 6.141 9.305 (6.14-35.85) 
120 37.995 54.279 41.713 25.532 31.849 25.450 53.469 35.021 46.901 28.694 21.591 26.140 (21.59-54.27) 
150 39.073 63.450 58.917 32.699 44.096 38.183 46.619 36.225 45.977 45.902 38.364 42.383 (32.69-63.45) 
180 48.826 63.856 64.792 53.544 54.005 56.314 58.234 60.326 57.721 66.153 55.358 61.203 (48.82-66.15) 
Table 4.2. Glycerol release during the digestion of different glyceryl trioctanoate controls within the model gut system. Each glyceryl trioctanoate control 
sample consists of 5ml glyceryl trioctanoate, 5ml of synthetic saliva and 5ml of DH2O. The glycerol released from glyceryl trioctanoate digestion is 
measured at different time points of during the gastric (0-60 minute) and small intestinal (60T-180 minute) phases of the model gut. Data for each control 




































0 0.75 0.05 0.25 0.05 0.41 0.07 0.12 0.13 0.42 0.47 0.25 0.75 (0.04-0.75) 
15 0.83 0.07 0.05 0.91 0.92 0.46 0.19 0.02 0.18 0.28 0.66 0.30 (0.02-0.92) 
30 1.11 0.05 0.36 0.99 1.23 1.28 0.09 0.53 0.07 0.49 0.47 1.17 (0.05-1.23) 
60 0.72 0.01 0.11 2.33 2.21 1.79 0.45 0.41 0.40 0.67 0.73 1.37 (0.01-2.33) 
60 2.59 0.59 0.41 5.75 5.78 7.50 0.60 1.58 1.38 0.17 1.20 0.85 (0.17-7.50) 
75 1.78 0.04 0.77 6.45 7.99 5.88 0.51 1.32 0.07 1.96 2.98 1.38 (0.04-7.99) 
90 2.69 3.98 2.58 11.70 10.95 8.43 2.46 3.35 2.28 2.30 10.29 7.14 (2.28-11.70) 
120 13.66 12.54 7.73 18.20 17.34 14.02 8.81 11.93 6.63 9.05 24.10 10.48 (6.63-24.10) 
150 30.23 18.59 18.59 31.02 30.98 26.60 13.43 17.87 11.53 15.77 28.21 14.15 (11.53-31.02) 
180 36.59 38.39 28.50 46.90 46.32 36.36 24.95 35.34 25.64 29.05 42.18 26.24 (24.95-46.90) 
Table 4.3. Glycerol release during the digestion of different olive oil as controls within the synthetic model gut system. Each olive oil control sample 
consists of 5ml olive oil, 5ml synthetic saliva and 5ml DH2O. The glycerol released from olive oil digestion is measured at different time points of the 












Mean glycerol released from sunflower oil digestion (mg) 
Control 1 Control 2 Control 3 Control 4 Control 5 Control 6 Control 7 Control 8 Control 9 Glycerol range(mg) 
0 0.03 0.13 0.01 0.26 0.01 0.16 0.35 0.09 0.01 (0.01-0.35) 
15 0.05 0.16 0.05 0.04 0.05 0.33 0.49 0.17 0.06 (0.04-0.49) 
30 0.19 0.25 0.10 0.07 0.10 0.26 0.49 0.04 0.03 (0.03-0.49) 
60 1.31 0.17 0.12 0.02 0.07 0.11 0.65 0.12 0.06 (0.02-1.31) 
60 1.15 1.34 1.33 0.53 1.55 0.54 2.18 0.36 0.21 (0.21-2.18) 
75 1.99 1.68 1.95 1.10 0.54 1.61 2.30 0.74 0.27 (0.27-2.30) 
90 2.01 1.91 4.22 2.54 1.56 3.57 5.57 3.22 0.63 (0.63-5.57) 
120 4.57 5.85 6.67 9.84 5.24 9.30 12.79 8.44 6.70 (4.57-12.79) 
150 9.31 10.54 12.05 16.71 15.37 15.87 20.79 18.06 9.01 (9.01-20.79) 
180 26.06 17.45 19.60 20.90 25.28 27.99 23.05 24.74 18.00 (17.45-27.99) 
Table 4.4. Glycerol release during the digestion of different sunflower oil controls within the synthetic model gut system. Each sunflower oil control sample 
consists of 5ml sunflower oil, 5ml synthetic saliva and 5ml DH2O. The glycerol released from sunflower oil digestion is measured at different time points 











4.5.4 Digestion of fat substrates in combination with 500 mg alginate added at the salivary phase 
4.5.4.1 Glyceryl trioctanoate 
Figure 4.4 shows the digestion of 5 ml glyceryl trioctanoate alone and in combination with 500mg 
of alginates CC01, 1N80, and 1LF80 added at the salivary phase of the synthetic model gut, 
respectively.  
As shown in Figure 4.4 (graph A), during the gastric phase, only 3.5 (±0.5) mg and 2.3 (±0.7) mg 
glycerol were released from digestion of glyceryl trioctanoate alone and with 500 mg of CC01, 
respectively. However, during the first 15 minutes of the small intestinal phase, there was a gradual 
increase in the amounts of glycerol released from the digestion of glyceryl trioctanoate alone and 
in combination with CC01. After 75 minutes, there was significant difference (P<0.05) between 
the amount of glycerol released from digestion of glyceryl trioctanoate alone and that released from 
digestion of glyceryl trioctanoate treated with 500 mg CC01, where 30.9 (±7.1), 45.1 (±9.4), 43 
(±5.8), and 58.8 (±1.4) mg glycerol was liberated from digestion of glyceryl trioctanoate alone 
compared with 17.2 (±4.2), 29.8 (±4.3), 23.4 (±8.9), and 31,8 (±3.2) mg glycerol produced from 
glyceryl trioctanoate in combination with CC01 at 90, 120, 150, and 180 minutes, respectively 
( Figure 4.4, graph A) 
In addition, during the gastric phase, the amount of glycerol produced from the digestion of 
glyceryl trioctanoate alone was 1.4 (±2) mg compared to 0.3 (±0.78) mg glycerol released from the 
digestion of glyceryl trioctanotate with 500 mg 1N80 (Figure 4.4, graph B). During the first hour 
of the small intestinal phase (60T-120 minutes), the digestion rates of both glyceryl trioctanoate 
alone and glyceryl trioctanoate treated with 500 mg 1N80 increased gradually. However, there were 
significant differences (P<0.05) between their rates of digestion at 150 and 180 minutes, where the 
amounts of glycerol released from digestion of glyceryl trioctanoate treated with 1N80 were 22.3 
(±2.3) mg and 39.8 (±6.6) mg compared to 38 (±5.6) mg, and 54.6 (±1.5) mg of glycerol liberated 
from the digestion of glyceryl trioctanoate alone at 150 and180 minutes, respectively, indicating a 
significant effect of treatment.  
Although both CC01 and 1N80 alginates could reduce glyceryl trioctanoate digestion, the amount 




than that released from the digestion of glyceryl trioctanoate with 1N80, showing that 
CC01alginate can reduce the digestion rate of glyceryl trioctanoate more than 1N80 alginate.  
However, no significant difference (P>0.05) was seen between digestion of glyceryl trioctanoate 
alone and glyceryl trioctanoate treated with 500 mg of 1LF80 alginate, indicating that 1LF80 did 


















Figure 4.4. Glycerol liberation during the digestion of glyceryl trioctanoate alone or in combination with 
500 mg of alginates in the synthetic model gut. Three alginates: (A) CC01, (B) 1N80, and (C) 1LF80 were 
added separately into samples of 5ml of glyceryl trioctanoate at the salivary phase of the model gut. Data 
are shown as mean ± SD, (n=3). P values <0.005 are represented by ** and <0.0005 are represented by 









4.5.4.2 Olive oil 
Graphs A, B, and C of Figure 4.5 demonstrate in vitro digestion of 5ml of olive oil alone and olive 
oil treated with 500 mg of alginates CC01, 1N80, and 1LF80, respectively. During the gastric phase, 
negligible amounts (≤ 2.5 mg) of glycerol were released from the digestion of olive oil alone or in 
combination with any alginate. However, Bonferroni’s test showed that the amounts of glycerol 
released from the digestion of either olive oil alone or olive oil treated with alginate increased 
significantly (P<0.05) during the small intestinal phase compared to those liberated from their 
digestion in the gastric phase. 
At the end of the small intestinal phase, the amount of glycerol released from the digestion of olive 
oil treated with CC01 was 41.4 (±4.6) mg, compared with 36.2 (±2) mg glycerol released from the 
digestion of olive oil alone, but this difference was not significant (P<0.05) (Figure 4.5, graph A).  
At the end of the small intestinal phase, 27 (±2.4) mg of glycerol was released from the digestion 
of olive oil in combination with 500 mg 1N80, compared to 27.1 (±2.4) mg of glycerol released 
from the digestion of olive oil treated with 500 mg 1N80 compared to 26.4 (±5.8) mg of glycerol 
released from the digestion of olive oil alone, and the P value was greater than 0.05, indicating a 
non-significant effect of 1N80 on the olive oil digestion (Figure 4.5, graph B).  
Olive oil in combination with 500 mg of 1LF80 released 25.4 (±5.4) mg glycerol, compared with 
23 (±8.3) mg glycerol released from the digestion of olive oil alone at the small intestinal phase 
suggesting a non-significant effect of the alginate on olive oil digestion (Figure 4.5, graph C).  
Some gel and precipitate were formed during the simulated gastric phase in the alginate samples. 
This gel was still present in the beaker of the olive oil treated with alginate for all the samples 
during the small intestinal phase, suggesting that the alginate was not completely dissolved and 
released into the reaction mixture. This could explain why the digestion rate of olive oil was not 






Figure 4.5. Glycerol liberation during the digestion of olive oil alone or in combination with 500 mg of 
alginates in the synthetic model gut. Three alginates: (A) CC01, (B) 1N80, and (C) 1LF80 were added 
separately into samples of 5ml olive oil at the salivary phase of the model gut. Data are shown as mean ± 









4.5.4.3 Sunflower oil 
Sunflower oil is rich in free fatty acids which are products of fat digestion because if the reaction 
solution is saturated with a reaction product, the rate of reaction will be slower. Therefore, 
sunflower oil must be passed through aluminum oxide (8 cm deep in glass chromatography column 
with 1.5-2 cm diameter) to remove the free fatty acids.  
Figures 4.6A, 4.6B, and 4.6C show the digestion of 5 ml of sunflower oil without free fatty acids 
alone as a control and in combination with 500 mg of CC01, 1N80 and 1LF80, respectively.  
During the gastric phase, the amounts of glycerol released from the digestion of sunflower oil alone 
and the oil with alginates (CC01, 1N80 or 1LF80) were very small (≤1 mg). However, after 15 
minutes of the small intestinal phase, there was a gradual increase in the amount of glycerol 
produced from the digestion of oil alone and in combination with CC01, 1LF80 or 1N80. At the 
end of the pancreatic small intestinal phase, the amounts of glycerol released from the digestion of 
sunflower oil treated with CC01 (Figure 4.6, graph A) or 1N80 (Figure 4.6, graph B) were 24.4 
(±4.5) and 24.7(±4.1) mg compared with 21 (±4.4) and 25.3 (±7.5) mg from their control digestions, 
respectively. On the other hand, sunflower oil treated with 500 mg 1LF80 produced 29.7 (±5.2) mg 
of glycerol compared with 25 (±3.6) mg from oil digestion alone (Figure 4.6, graph C).                  
However, considering P>0.05 at all time points, there was no significant difference between the 
digestion of sunflower oil alone or in combination with 500 mg of CC01, 1N80 or 1LF80.               
Furthermore, gel and lumps were observed in the samples treated with alginates at the end of the 
gastric phase and they remained present at the end of the model gut procedure. Gelling of alginate 
could have been responsible for the lack of inhibition in the digestion rate of sunflower oil if the 





Figure 4.6. Glycerol liberation during the digestion of a sample of sunflower oil alone or in combination 
with 500 mg of alginates in the synthetic model gut. Three alginates: (A) CC01, (B) 1N80, and (C) 1LF80 
were added separately into samples of 5ml sunflower oil free from free fatty acids at the salivary phase of 










4.5.5 Digestion of olive oil in combination with 1000 mg CC01 
Data from the digestion of olive oil in combination with 500 mg of alginate (CC01, 1N80, or 1LF80) 
presented in this chapter showed that the alginate had no significant effect on olive oil digestion. 
Therefore, a higher amount (1000 mg) of CC01 alginate, which has the highest content of G blocks, 
was used in an attempt to inhibit olive oil digestion. This alginate was chosen as the inhibition level 
of pancreatic lipase by alginate was dependent on the concentration and the content of G blocks as 
shown in Chapter 2 of this study as well as in earlier research conducted by Wilcox et al. (2014).   
The data in Figure 4.7 demonstrates the gastrointestinal digestion of 5 ml olive oil containing free 
fatty acids alone and olive oil treated with 1000 mg of CC01 in the model gut. It is obvious that 
during the gastric phase (0-60 minutes), no glycerol was released from the digestion of olive oil 
alone and olive oil with alginate. However, during the gastric phase, CC01 alginate precipitated 
and formed a gel which was still observed in the bottom of the beaker at the end of the procedure.  
During the first 30 minutes of the intestinal phase, there was a gradual increase in the digestion rate 
of olive oil alone and the digestion rate of olive oil in combination with CC01 alginate, but no 
significant difference was detected between the two digestion rates. After 90 minutes, there was a 
significant increase in the amounts of glycerol produced from the digestion of both olive oil alone 
and olive oil with CC01, with no significant difference between the amounts of glycerol released 
from their digestion. However, at the end of the small intestinal phase, the amount of glycerol 
released from the digestion of olive oil treated with CC01 (43 (±3) mg) was significantly higher 
(P<0.005) than that released from the digestion of olive oil alone (35 (±2.8) mg). This suggests that 
1000 mg CC01 may have activated pancreatic lipase digestion of olive oil. Another possibility is 
that the high levels of alginate were interfering with the glycerol assay. However, additional 






Figure 4.7. Glycerol liberation during the digestion of olive oil containing free fatty acids alone or in 
combination with 1000 mg CC01 in the synthetic model gut. Data are shown as mean ± SD, (n=3). P 
values < 0.005 are represented by**. 
 
4.5.6 Digestion of olive oil free from free fatty acids in combination with 1000 mg CC01 
Previous data demonstrated that 1000 mg of CC01 may have activated olive oil digestion, leading 
to the hypothesis that this occurs because olive oil contains large amounts of free fatty acids, which 
are the product of triglyceride breakdown. Therefore, if the reaction solution is saturated with 
reaction product, it will slow down the rate of reaction. However, if the alginate binds these free 
fatty acids, it effectively removes them from the reaction mixture and the reaction is able to proceed 
at a faster rate. Therefore, the effect of CC01 alginate was studied using free fatty acid-free olive 
oil to investigate whether removing free fatty acids from the olive oil accelerates its reaction rate. 
The oil was passed through aluminum oxide (8 cm deep in glass chromatography column 1.5-2 cm 
diameter) to remove free fatty acids. 
The data in Figure 4.8 show the digestion of 5 ml free fatty acid-free olive oil alone and in 




released from the digestion of the olive oil alone or olive oil treated with 1000 mg CC01. In addition, 
CC01 alginate showed some gel and precipitations. However, data from the pancreatic small 
intestinal phase suggested that alginate activated olive oil digestion where the amounts of glycerol 
liberated from olive oil treated with CC01 alginate were higher than those liberated from the olive 
oil alone. At the end of the pancreatic small intestinal phase, the amounts of glycerol released from 
olive oil treated with 1000 mg of CC01 was 45 (±10.6) mg, while the glycerol released from the 
olive oil alone was 26.6 (±3.8) mg. The differences in the amounts of glycerol released at 90, 150, 
and 180 minutes of the pancreatic phase from the olive oil alone and the olive oil treated with 
alginate were statistically significant (p≤0.05), providing evidence that alginate binding of free 
fatty acids was not the reason for the apparent increase in digestion of olive oil treated with alginate.  
 
 
Figure 4.8. Glycerol liberation during the digestion of olive oil without free fatty acids alone or in 
combination with 1000 mg CC01 in the synthetic model gut. Data are shown as mean ± SD, (n=3). P 
values < 0.005 are represented by** and <0.0005 are represented by ****. 
4.5.7 Gelling of alginate added at the salivary phase 
The data just described above showed that alginate did not inhibit the digestion of fat. However, 




sample passed through the gastric phase, indicating that the alginate underwent gelation in the 
gastric phase (Figure 4.9). The gels and lumps were still seen at the bottom of the beaker at the end 
of model gut, showing that the gel did not dissolve, and the alginate was not released in the reaction 
mixture, which could explain the ineffectiveness of alginate in reducing the fat digestion. 
Furthermore, it was noticed that 1000 mg of alginate produced a large amount of gel, double (by 
observation) that formed from the 500 mg of alginate, suggesting a correlation between the amount 
of gel formed and the amount of alginate added to the solution.  
 On the other hand, when the samples containing alginate in combination with glyceryl trioctanoate 
were passed through the gastric phase, gels, lumps, and precipitation were formed and still seen at 
the end of the gastric phase. However, no gels, lumps or precipitation were seen at the end of the 
small intestinal phase (at-180 minute), suggesting that the gel was dissolved, and the alginate was 
released in the reaction mixture to reduce the triglycerides hydrolysis. This was supported by the 
previous data obtained from digestion of glyceryl trioctanoate in combination with alginate which 





                                                       
 
Figure 4.9. Gel formed during alginate passage through the gastric phase of the model gut system. A and B show the gel at the end of gastric phase (T60) 




4.5.8 Effect of alginate added during the small intestinal phase on fat digestion 
Earlier results showed that there was no significant reduction in the digestion of olive oil treated 
with alginates, and this may occur because the CaCl2 in saliva and acidic pH caused alginates to 
form gels which would affect their efficiency in reducing fat digestion. Therefore, the effect of 
alginates on olive oil digestion in the synthetic model gut was investigated as described previously, 
but the alginates (CC01, 1N80, and 1LF80) were added 10 minutes after the start of the pancreatic 
small intestinal phase (at 70-minute of the model gut procedure) to allow bile and pancreatic juice 
to provide a rather less acidic environment and avoid gel formation. 
 
4.5.8.1 Olive oil alone and in combination with 500 mg of alginate 
Graphs A, B, and C in Figure 4.10 illustrate the in vitro digestive processes of olive oil alone as a 
control and olive oil with 500 mg of CC0, 1N80 and 1LF80 in the synthetic model gut, respectively. 
During the gastric phase, the amount of glycerol released from the digestion of olive oil alone or 
in combination with CC01 were negligible (≤1 mg) (Figure 4.10, graph A). After 15 minutes of the 
pancreatic intestinal phase, there was a gradual increase in glycerol release from the digestion of 
olive oil alone and olive oil treated with 500 mg CC01. However, at 120, 150, and 180 minutes, 
there were significant differences (P<0.05) between the amounts of glycerol released from 
digestion of olive oil alone, 11(±3), 22.4 (±6.7), 35(±5.3) mg, respectively, and those released from 
digestion of olive oil with CC01, 3.12 (±3.9), 12.1 (±4.9), and 21 (±4.8) mg, at 120, 150, and 180 
minutes, respectively (Figure 4.10, graph A).   
The data shown in graph B of Figure 4.10 indicate that during the gastric phase, only small amounts 
of glycerol (≤ 1mg) were released from the digestion of olive oil alone and olive oil in combination 
with 500 mg 1N80. During the small intestinal phase, there was an increase in mean glycerol 
released from olive oil alone and olive oil in combination with 500 mg 1N80. At 150 and 180 
minutes, the amounts of glycerol released from the digestion of olive oil alone were 22.8 (±2.4) 
and 37.2 (±5.4) mg, respectively, and these amounts of glycerol were significantly greater (P<0.05) 
than those released from the digestion of olive oil treated with 1N80, which were 14.3 (±3.3) and 
28.6 (±5.8) mg, respectively, showing that 500 mg of 1N80 alginate added at the small intestinal 




There was no significant difference (P>0.05) between the amounts of glycerol released from the 
digestion of olive oil alone and olive oil treated with 500 mg of 1LF80 alginate, demonstrating that 
500 mg of 1LF80 alginate introduced during the small intestinal phase did not affect olive oil 















Figure 4.10. Glycerol liberation during the digestion of olive oil alone or in combination with 500mg 
alginates added during the small intestinal phase of the model gut. 500mg of alginates (A) CC01, (B) 
1N80 and (C) 1LF80 were added separately into samples of 5ml olive oil. Data are shown as mean ± SD 
(n=3). P values < 0.05 are represented by *, < 0.01 are represented by **, and <0.001 are represented by 







4.5.8.2 Olive oil alone and in combination with 1000 mg of alginate  
The data in Figure 4.11 illustrate digestion of 5 ml of olive oil alone and with 1000 mg CC01, 1N80, 
and 1LF80 in the gastric and pancreatic small intestinal phases of the synthetic model gut, 
respectively.  
The data in graph A of Figure 4.11 compare olive oil digestion in the presence and absence of 1000 
mg CC01. During the gastric phase, small amounts of glycerol (≤1 mg) were released from 
digestion of the olive oils. During the first 10 minutes of the small intestinal phases, there was an 
increase in the digestion rate of the two samples (Figure 4.11, graph A), after which 1000 mg CC01 
alginate was added to the olive oil. The digestion rates of olive oil alone and treated with CC01 
increased, and at 90 and 180 minutes, there were significant differences (P<0.05) in mean glycerol 
released from the olive oil with CC01 (5.2 (±1.9) mg and 39 (±6) mg) and mean glycerol released 
from digestion of olive oil alone (1 (±1.3) mg and 28.1 (±1.7)) mg, respectively, demonstrating 
activation in olive oil digestion by 1000 mg CC01 alginate.   
Data shown in Figure 4.11 (graph B) compare olive oil digestion in the presence and absence of 
1000 mg 1N80 and this shows that only small amounts of glycerol (≤ 1mg) were released from 
digestion of the two samples during the gastric phase (0-60 minutes). However, during the small 
intestinal phase (60-180 minutes), the digestion rates for olive oil alone or in combination with 
1000 mg 1N80 alginate increased with no significant difference during the first 60 minutes of the 
small intestinal phase (60-120 minutes). However, there was a significant difference (P<0.05) at 
150 and 180 minutes between glycerol liberated from digestion of olive oil treated with 1000 mg 
1N80 and digestion of olive oil alone, where the glycerol liberated from digestion of olive oil 
treated with 1000 mg 1N80 at 150 and 180 minutes was 27.2 (±1.4) and 42 (±7.2) mg, respectively, 
compared to 19.4 (±7.6) and 32.5 (±8.5) mg released from digestion of olive oil alone at 150 and 
180 minutes, respectively, indicating that 1N80 could activate olive oil digestion. 
The data in Figure 4.11 (graph C) compare digestion of olive oil in the presence and absence of 
1000mg 1LF80. The amounts of glycerol released from digestion of olive oil during the gastric 
phase were negligible (<1 mg). Unlike the gastric phase, during the small intestinal phase higher 
amounts of glycerol were released from digestion of olive oil alone and olive oil in combination 




mg 1LF80 appeared higher than the digestion rate of olive oil alone at all time points of the small 
intestinal phase, Bonferroni’s test indicated a significant difference (P<0.05) only at the end of the 
small intestinal phase where the mean glycerol released from digestion of olive oil treated with 
1LF80 was 42.7 (±11.4) mg, compared to 29 (±5.8) mg of glycerol released from digestion of olive 












Figure 4.11. Glycerol liberation during the digestion of olive oil alone or in combination with 1000mg 
alginates added during the small intestinal phase of the model gut. 1000mg of alginates (A) CC01, (B) 
1N80, and (C) 1LF80 were added separately into samples of 5ml olive oil. The dotted arrow indicates that 
alginate was added at T70 of the model gut procedure. Data are shown as mean ± SD (n=3). P values < 
0.05 are represented by *, < 0.01 are represented by **, <0.001 are represented by ***, and <0.0005 are 








4.5.8.3 Olive oil alone and in combination with 250 mg of CC01 alginate  
Results from the turbidity assay discussed in Chapter 2 of this thesis showed that alginates could 
inhibit the activity of pancreatic lipase. The highest level of lipase inhibition was caused by CC01 
alginate, which is rich in G block, and the level of inhibition of lipase by CC01 was dose-dependent. 
In addition, earlier results presented in this chapter showed that 500 mg of alginate added at the 
small intestinal phase could reduce the digestion of olive oil in the synthetic model gut whereas 
1000 mg alginate appeared to increase it. Therefore, the effect of 250 mg of CC01 alginate on olive 
oil digestion was tested to investigate whether the level of lipase inhibition by alginate is 
concentration-dependent. 
Figure 4.12 shows the in vitro gastrointestinal digestion of 5 ml of olive oil alone and in the 
presence of 250 mg CC01 alginate. During the gastric phase, glycerol production from digestion 
of olive oil was undetected. During the small intestinal phase (CC01 alginate added at 70-minute), 
the digestion rate of olive oil alone was greater than that of olive oil in combination with CC01. 
The glycerol release from digestion of olive oil alone at 150 and 180 minutes, 28 (±4.1) and 47.1 
(±7.2) mg, was significantly (P<0.05) higher than the glycerol amounts produced from digestion 
of olive oil treated with CC01, 17.3 (±3.6) and 33.4 (±4) mg, respectively.  
Moreover, at the end of the small intestinal phase, the amount of glycerol released from the 
digestion of olive oil treated with 250 mg of CC01 alginate (33.4 (±4) mg) (Figure 4.12) was 
significantly higher (P<0.05) than the amount of glycerol released from the digestion of olive oil 
treated with 500 mg of CC01 added at the small intestinal phase (21 (±4.8) mg) (Figure 4.10, graph 







Figure 4.12. Glycerol liberation during the digestion of olive oil alone or in combination with 250 mg 
CC01 added during the small intestinal phase of the synthetic model gut. The dotted arrow indicates that 
alginate was added at T70 of the model gut procedure. Data are shown as ± SD, (n=3). P values <0.001 are 
represented by ***, and <0.0005 are represented by ****.  
 
4.5.8.4 Olive oil alone and in combination with 250 mg of CC01 alginate added at the salivary 
phase 
As the effect of 250 mg CC01 alginate added during the salivary phase was not tested previously 
due to 500 mg CC01 having no effect on olive oil digestion, it was now also tested.  
As seen in Figure 4.13, during the gastric phase, only small amounts of glycerol were released from 
digestion of both olive oil alone and olive oil treated with 250 mg CC01 added at the salivary phase. 
During the small intestinal phase, the amount of glycerol released from the digestion of olive oil in 
combination with 250 mg of CC01 at the 180-minute was 38.1 (±4.7) mg compared to 34.5 (±2.5) 
mg of glycerol produced from the digestion of olive oil alone. No significant difference was 
detected between the intestinal digestion of olive oil alone and that of olive oil treated with 250 mg, 
demonstrating that unlike 250 mg CC01 added at the small intestinal phase, 250 mg of CC01 





Figure 4.13. Glycerol liberation during the digestion of olive oil alone or in combination with 250 mg 
CC01 added at the salivary phase of the synthetic model gut. Data are shown as mean ± SD (n=3).  
 
4.5.8.5 Glyceryl trioctanoate alone and in combination with 500 mg CC01 added at the small 
intestinal phase  
Figure 4.14 demonstrates in vitro digestion of 5 ml glyceryl trioctanoate alone and in the presence 
of 500 mg CC01 alginate added after 10 minutes of the pancreatic small intestinal phase (T70). As 
expected, insignificant amounts of glycerol (≤1 mg) were released from digestion of glyceryl 
trioctanoate during the gastric phase. However, during the pancreatic intestinal phase, the digestion 
rates of both glyceryl trioctanoate alone and glyceryl trioctanoate treated with CC01 rose sharply 
at the same level, and no significant difference (P>0.05) was seen between mean glycerol released 
from their digestion at all time points, showing that 500 mg CC01 added at the pancreatic phase 






Figure 4.14. Glycerol liberation during the digestion of glyceryl trioctanoate alone or in combination with 
500 mg CC01 added during the small intestinal phase of the synthetic model gut.Data are shown as mean 
± SD (n=3). The dotted arrow indicates that alginate was added at T70 of the model gut procedure. 
 
4.5.9 Digestion of olive oil alone and in combination with alginate added at salivary phase using 
a buffered synthetic salivary diluent  
Results obtained from the model gut experiments for digestion of olive oil in combination with 
CC01 added at the salivary phase showed that CC01 did not inhibit olive oil digestion. Also, some 
precipitation and gel formation were observed in the bottom of the beakers containing alginate 
samples, which might be because the pH in the gastric phase ranged between 2 and 3, values which 
are below the pKa values for guluronate (3.65) and mannuronate (3.38) monomers of alginate 
polymer and this could lead to acid gel formation.  
However, olive oil digestion was reduced when CC01 was added at the small intestinal phase (T70) 
where the pH values were above 4.5, and no gels or precipitations were observed at the end of the 
small intestinal phase. Therefore, an attempt was made to avoid alginate precipitation and gelling 
during the gastric phase through buffering the synthetic salivary diluent. 




containing a higher amount of NaHCO3, 372mM, could reduce gel formation and precipitation. 
Also, pH measurements showed that the buffered salivary diluent could provide pHs in the stomach 
phase higher than those for a normal salivary diluent. Consequently, the effect of alginate (CC01) 
on olive oil digestion within the model gut using the buffered salivary diluent was examined to 
ascertain whether producing less acidic pHs in the stomach enables alginate to reduce olive oil 
digestion.  
The synthetic salivary diluent (pH 7.4) was prepared as described in the methods (section 4.3.1) of 
this chapter but using 372mM NaHCO3 instead of 62mM NaHCO3. The samples were passed 
through salivary, gastric and small intestinal phases of the model gut. The collected samples were 
treated as described earlier in section 4.3.3.1 of this chapter. 
Figure 4.15 shows the digestion of olive oil alone using normal and buffered salivary diluents 
containing 62mM NaHCO3 and 372mM NaHCO3, respectively. It is obvious that during the gastric 
phase, the amounts of glycerol produced from olive oil digestion using either normal or buffered 
salivary diluent were small (≤ 1 mg). During the first hour of the small intestinal phase, the amounts 
of glycerol produced from the digestion of olive oil treated with normal salivary diluent and that 
produced from olive oil treated with buffered salivary diluent increased with no significant 
difference between their digestion rates. However, at 150 and 180 minutes of the small intestinal 
phase, the amounts of glycerol produced from digestion of olive oil treated with normal salivary 
diluent were 22.1 (±7.7) mg and 35.4 (±8.0) mg, compared to 17.4 (±5.2) mg and 27.9 (±5.3) mg 
produced from the digestion of olive oil treated with buffered salivary diluent, with P values 
<0.0005, at 150 and 180 minutes, respectively, indicating that the digestion rate of olive oil treated 
with normal saliva was significantly higher than that of olive oil treated with buffered saliva,   








Figure 4.15. Glycerol liberation during the digestion of olive oil alone using normal salivary diluent (●) or 
buffered salivary diluent (■) in the synthetic model gut. Data are shown as mean ± SD, (n=9). P values 
<0.0005 are represented by *** and <0.0001 are represented by ****.  
 
Graphs A, B, and C in Figure 4.16 show digestion of olive oil alone using a buffered salivary diluent 
and the digestion of olive oil in combination with 250, 500, and 1000 mg CC01 alginate added at 
the salivary phase using a normal synthetic salivary diluent containing 62mM NaHCO3 or buffered 
salivary diluent containing 372mM NaHCO3, respectively. 
As shown in graph A of Figure 4.16, during the gastric phase, the amounts of glycerol released 
from the digestion of olive oil alone using buffered salivary diluent, the digestion of olive oil treated 
with 250 mg of CC01 alginate and normal salivary diluent or the digestion of olive oil treated with 
250 mg CC01 and buffered salivary diluent were negligible (≤1 mg of glycerol). During the first 
hour of the small intestinal phase, the digestion rates of olive oil alone using buffered salivary 
diluent, olive oil treated with 250 mg CC01 in combination with normal salivary diluent, and olive 
oil treated with 250 mg CC01 in combination with buffered synthetic salivary diluent increased 
equally. However, at the end of the small intestinal phase (at 180-minute), the digestion rate of 




(P<0.001) than that for olive oil alone using buffered diluent where the amount of glycerol released 
from the digestion of olive oil in combination with 250 mg CC01 was 29.41 (±3.4) mg compared 
to 25.1 (±2.4) mg released from olive oil alone. Additionally, a small amount of gel was observed 
at the end of the small intestinal phase in the samples containing 250 mg CC01 and buffered 
salivary diluent, but this was less than the gel produced from 250 mg CC01 in combination with 
normal salivary diluent containing 62mM NaHCO3.  
Data in Figure 4.16 (graph A) also shows that at 150 and 180 minutes, the digestion rate of olive 
oil treated with 250 mg CC01 and normal salivary diluent was significantly higher (P<0.05) than 
the digestion rate of olive oil treated with 250 mg CC01 and buffered diluent where the amounts 
of glycerol liberated from digestion of olive oil treated with 250 mg CC01 and normal salivary 
diluent were 25.2 (±4.9) mg and 41.5 (±5.8) mg, compared to 16.1 (±1.7) and 29.4 (±3.4) mg of 
glycerol released from digestion of olive oil treated with 250 mg CC01 and buffered salivary 
diluent, respectively, indicating that the 250 mg of CC01 alginate added at the salivary phase in 
combination with buffered salivary diluent containing 372mM NaHCO3 could significantly reduce 
the digestion rate of olive oil, compared to 250 mg CC01 in combination with normal salivary 
diluent containing 62mM NaHCO3.  
Data in graph B of Figure 4.16 show that during the gastric phase, the amounts of glycerol released 
from the digestion of olive oil alone, the digestion of olive oil treated with 500 mg CC01 and 
normal salivary diluent, or the digestion of olive oil treated with 500 mg CC01 and buffered 
salivary diluent was small (<3 mg). During the small intestinal phase, no significant difference 
(P>0.05) was detected between the amount of glycerol released from digestion of olive oil alone 
and that released from the digestion of olive oil in combination with 500 mg CC01 and buffered 
salivary diluent, suggesting that the 500 mg CC01 in combination with buffered salivary diluent 
had no effect on olive oil digestion (Figure 4.16, graph B). Also, a small amount of gel was 
observed at the end of the small intestinal phase, which was less than (by observation) the gel 
produced from 500 mg of CC01 alginate treated with (62mM NaHCO3) normal saliva.  
Data in Figure 4.16 (graph B) also shows that during the small intestinal phase, there was a 
difference between the digestion rate of olive oil treated with 500 mg CC01 and buffered salivary 




all time points of the small intestinal phase. However, this difference was statistically significant 
(P<0.05) only at 150 and 180 minutes, where the amounts of glycerol released from digestion of 
olive oil treated with 500mg CC01 and buffered salivary diluent were 14.3 (±8.3) and 32 (±9.3) 
mg compared to 30.8 (±3.9) and 41.4 (±4.6) mg produced from the digestion of olive oil treated 
with 500mg CC01and normal salivary diluent at 150 and 180 minutes, respectively. This shows 
that 500 mg CC01 in combination with buffered synthetic salivary diluent could significantly 
reduce the digestion rate of olive oil compared to 500 mg of CC01 in combination with normal 
salivary diluent.   
Data presented in Figure 4.16 (graph C) demonstrate that during the gastric phase, the amounts of 
glycerol released from the digestion of olive oil alone, the digestion of olive oil in combination 
with 1000 mg and normal salivary diluent, or the digestion of olive oil in combination with 1000 
mg CC01 and buffered salivary diluent were small (≤3 mg). However, after 15 minutes from the 
start of the small intestinal phase, there was an increase in the digestion rate for both olive oil alone 
and olive oil in combination with 1000 mg CC01 and buffered salivary diluent, with a significant 
difference (P<0.05) between digestion rates at the end of the small intestinal phase (at 180-minute),  
where the amount of glycerol released from digestion of olive oil in combination with 1000 mg 
CC01 and buffered salivary diluent was 41.14 (±2.76) mg, compared to 27.59 (±2.89) mg from 
digestion of olive oil alone, showing that 1000 mg CC01in combination with a buffered salivary 
diluent may activate olive oil digestion. Moreover, some gels and lumps were observed at the end 
of the small intestinal phase, but these were half than (by observation) those observed upon the 
addition of 1000 mg CC01 alginate to olive oil at the salivary phase using the normal salivary 
diluent containing 62 mM NaHCO3. 
Additionally, as can be seen in Figure 4.16 (graph C), during the small intestinal phase, no 
significant difference was detected between the amount of glycerol liberated from digestion of 
olive oil treated with 1000 mg CC01 and buffered salivary diluent and that liberated from digestion 
of olive oil treated with 1000 mg CC01 and normal salivary diluent. This shows that unlike 250 
and 500 mg CC01 in combination with a buffered salivary diluent, 1000 mg CC01 in combination 





The data presented above suggested that that the reduction shown in the digestion of olive oil is 
caused by buffering the salivary diluent and not by alginate, and that can be supported by the 
digestion rate of olive oil alone treated with buffered diluent which was significantly lower than 
that of olive oil alone treated with normal olive oil (Figure 4.15).  Buffering the salivary diluent 
may cause changes in the pH which in turn affect the activity pancreatic lipase. Therefore, the effect 




















Figure 4.16. Glycerol liberation during the simulated digestion of olive oil alone using a buffered salivary 
diluent (●), olive oil treated with different amounts of CC01 using a normal (■) or buffered salivary 
diluent (▲) in the synthetic model gut. (A) 250, (B) 500 and (C) 1000 mg of CC01 were added the 
salivary phase of the model gut procedure. Data are shown as mean ±SD (n=3). P values <0.05 are 
represented by * < 0.001 are represented by ***, and < 0.0005 are represented by ****. The dotted line 







4.5.10  pH measurements during simulated digestion of fat in the model gut system 
4.5.10.1 Olive oil alone and in combination with CC01 alginate added at the salivary phase 
It has been reported that pancreatic lipase must remain stable over a broad pH range during the 
small intestinal phase of digestion to avoid irreversible denaturation [163]. The same paper states 
that although pancreatic lipase is produced as a component of pancreatic secretions at pH 8, it is 
exposed within the small intestine to pH ranging from approximately 6.5 in the duodenum to over 
7 in the distal ileum. Furthermore, based on figure 1 from Brownlee et al. (2010) study, it has been 
shown that although the activity of pancreatic lipase is stable between the pH 6 and 7.5, there was 
a significant reduction in the pancreatic lipase activity when the pH is reduced below 6 or above 
7.5. For example, changing pH from 5.5 to 6 increased the level of turbidity reduction from 0.15 
to 0.45 (arbitrary units), indicating a significant increase in lipase activity by 200%. Also, there 
was an increase in the activity of pancreatic lipase by about 18% when pH was changed from 6 to 
6.5. In contrast, there was a significant decrease by about 74% in the activity of pancreatic lipase 
when pH was altered from 7.5 to 8 [163]. To investigate if the effects of CC01 alginate on 
pancreatic lipase are due to pH changes resulting from its addition, the pH of olive oil alone or in 
combination with CC01, added at the salivary or small intestinal phase, across the range of 
concentrations was measured. Also, the effect of buffering the salivary diluent on the pH of 
pancreatic lipase was investigated.  
Graphs A, B, and C in Figure 4.17 shows pH measurements at different time points for olive oil 
alone and olive oil in combination with 250, 500, and 1000 mg of CC01 alginate added at the 
salivary phase of the model gut system, respectively.  
As seen in Figure 4.17 (graph A), during the gastric phase, the pH values for olive oil in 
combination with 250 mg CC01 alginate were higher than those for olive oil alone, but this 
difference was only significant (P<0.05) at 15 and 30 minutes, where the pH values for olive oil in 
combination with 250 mg of CC01 were 2.63 (±0.23) and 2.59 (±0.20), compared to 2.08 (±0.03) 
and 2.07 (± 0.06) for olive oil alone, respectively. However, during the small intestinal phase (60-
180 minutes), there was no significant difference in the pH values between the olive oil alone and 




During the gastric phase, the pH values for olive oil alone at 15, 30, and 60 minutes were 2.08 
(±0.03), 2.07 (± 0.06), and 2.06 (± 0.04), respectively, and these values were significantly higher 
than those for olive oil in combination with 500mg CC01 which were 2.8 (±0.45) 2.9 (±0.46), 2.8 
(±0.35), respectively (Figure 4.17, graph B). However, during the small intestinal phase, there was 
no significant difference at any time point between the pH values for the olive oil alone and olive 
oil in combination with 500 mg CC01 alginate.  
There was a significant difference in pH values (P<0.05) for olive oil alone and those for the olive 
oil treated with 1000 mg CC01 alginate at all time points of the gastric phase. The pH values for 
the olive oil treated with 1000 mg CC01 alginate at 0, 15, 30, and 60 minutes of the gastric phase 
were 3.8 (±0.05), 3.7 (±0.1), 3.6 (±0.11), and 3.2 (±0.66), respectively, compared to 2.08 (±0.03), 
2.076 (±0.03), 2.07 (± 0.06), and 2.06 (± 0.04) for olive oil alone. However, during the small 
intestinal phase (60-180 minutes), there was no significant difference (P>0.05) in the pH values 






Figure 4.17. pH changes during simulated digestion of olive oil alone or in combination with different 
amounts of CC01 alginate. (A) 250, (B) 500, and (C) 1000 mg CC01 were added at the salivary phase of 
the synthetic model gut system. Data are shown as mean ±SD (n=3). P values <0.05 are represented by *, 







4.5.10.2 Olive oil alone and in combination with CC01 alginate added at the small intestinal 
phase  
Figure 4.18 demonstrates the pH measurements at different time points of the gastric and small 
intestinal phases within the synthetic model gut system for olive oil alone and olive oil in 
combination with 250, 500, and 1000 mg CC01 alginate added after 10 minutes of the small 
intestinal phase (at T70 of the model gut procedure). Expectedly, during the gastric phase (0-60 
minutes) the pH values were highly acidic, ranging between 2 and 1.97 at the end of the gastric 
phase. Also, since the alginate was not yet added, the samples were identical to olive oil alone, 
therefore, the pH values were also identical. After 60 minutes, the bile was added to start the small 
intestinal phase, resulting in an increase in pH for all samples, reaching values of approximately 
4.5. The pH increased further over time due to pumping of the pancreatic juice into the samples. 
At 70-minutes, when CC01 was added, no significant difference (P>0.05) was observed between 
the pH values for olive oil alone and those for the olive oil in combination with CC01 alginate (250, 
500 or 1000 mg), indicating that the addition of alginate at the small intestinal phase did not affect 
the pH of the mixture, hence, the inhibition observed in olive oil digestion by 500 and 250 mg 
CC01 alginate, presented earlier in this chapter (Figure 4.10A and Figure 4.12, section 4.5.7), was 





Figure 4.18. pH changes during simulated digestion of olive oil alone or in combination with different 
amounts of CC01 alginate. (A) 250, (B) 500, and (C) 1000 mg CC01 were added during the small 
intestinal phase of the synthetic model gut system. Values are shown as mean ± SD (n=3). The dotted 









pH data presented in Figures 4.17 and 4.18 of this chapter have been combined to allow comparison 
between the pH values of olive oil in combination with 250, 500, and 1000 mg of CC01 alginate 
added at the salivary phase and those for olive oil in combination with 250, 500, and 1000 mg of 
CC01 alginate added after 10 minutes of the small intestinal phase (Tables 4.5-4.7). 
There was no significant difference (P>0.05) between the pH values for the olive oil treated with 
250 mg CC01 added at the salivary phase and those for olive oil treated with 250 mg CC01 added 
at the small intestinal phase.  
Comparison of the pH values for olive oil in combination with 500 mg of CC01 alginate added 
either at the salivary phase or small intestinal phase showed that at 15, 30, and 60 minutes of the 
gastric phase, the pH values for olive oil treated with 500 mg of CC01 alginate were significantly 
higher (P<0.05) than those for olive oil treated with 500 mg CC01 added at the small intestinal 
phase (Table 4.6). However, during the small intestinal phase (60T-180 minutes), there was no 
significant difference between the pH values for olive oil in combination with 500 mg CC01 added 
at the salivary phase and those for olive oil in combination with 500 mg CC01 added at the small 
intestinal phase.  
The pH data presented in the Table 4.7 indicates that the pH values for olive oil treated with 1000 
mg CC01 alginate added at the salivary phase were significantly higher (P<0.05) than those for 
olive oil in combination with 1000 mg of CC01 alginate added at the small intestinal phase at all 
time points of the gastric phase. However, during the small intestinal phase (60T-180 minutes), no 
significant difference (P>0.05) was observed between the pH values for olive oil in combination 
with 1000 mg CC01 added either at the salivary or small intestinal phases.  
Adding alginate into the model gut system either at the start of the salivary phase or the small 
intestinal phase had no effect on the pH of samples removed from the model gut during the small 
intestinal phase. However, as shown in Figure 4.17, the presence of alginate during the salivary 





Time      
(minute) 
250mg CC01 alginate added at 
the salivary phase 
250mg CC01 alginate added at the 




pH ± SD pH ±SD 
0 2.50 ± 0.26 2.11 ± 0.04 ns 
15 2.60 ± 0.22 2.1 ±0.03 ns 
30 2.59 ± 0.20 2.09 ±0.03 ns 
60 2.43 ± 0.23 1.99 ±0.14 ns 
60T 4.96 ± 0.37 4.62 ±0.11 ns 
75 5.40 ± 0.67 5.88 ±0.16 ns 
90 5.92 ± 0.25 6.31 ±0.07 ns 
120 6.48 ± 0.18 6.64 ±0.05 ns 
150 6.72 ± 0.20 6.88 ±0.01 ns 
180 6.99 ± 0.03 7.05 ±0.04 ns 
Table 4.5. Comparison between the pH values for olive oil treated with 250 mg CC01 alginate added at the 
salivary phase and the pH values for olive oil with 250 mg CC01 added at the small intestinal phase. The 
gastric phase lasted for 1 hour (0-60 minutes) and the small intestinal phase lasted for 2 hours (60T-180 
minutes). 60T indicates the zero time of small intestinal phase. Data are shown as mean ± SD, (n=3), P 









Time          
(minute) 
500 mg CC01 alginate added at the 
salivary phase 
500 mg CC01 alginate added at the 




pH ± SD pH ±SD 
0 2.30 ± 0.03 2.11 ± 0.04 ns 
15 2.89 ± 0.45 2.06 ±0.05 * 
30 2.99 ± 0.46 2.04 ±0.05 * 
60 2.89 ± 0.35 2.02 ±0.05 * 
60T 4.79 ± 0.33 4.60 ±0.02 ns 
75 5.26 ± 0.02 5.20 ±0.21 ns 
90 6.16 ± 0.10 5.99 ±0.53 ns 
120 6.57 ± 0.09 6.48 ±0.19 ns 
150 6.79 ± 0.18 6.80 ±0.12 ns 
180 6.98 ± 0.10 6.97 ±0.04 ns 
Table 4.6. Comparison between the pH values for olive oil treated with 500 mg CC01 alginate added 
at the salivary phase and the pH values for olive oil with 500 mg CC01 added at the small intestinal phase. 
The gastric phase lasted for 1 hour (0-60 minutes) and the small intestinal phase lasted for 2 hours (60T-180 
minutes). 60T indicates the zero time of small intestinal phase. Data are shown as mean ± SD, (n=3). P value 
<0.05 was taken to detect the significant difference in pH values where P values < 0.05 are represented by 










Time      
(minute) 
1000 mg CC01 alginate added at 
the salivary phase 
1000 mg CC01 alginate added at the 




pH ± SD pH ±SD 
0 3.88 ± 0.05 2.14 ± 0.06 **** 
15 3.71 ± 0.10 2.12 ±0.05 **** 
30 3.66 ± 0.11 2.03 ±0.13 **** 
60 3.20 ± 0.66 1.97 ±0.15 **** 
60T 5.05 ± 0.14 5.79 ±0.06 ns 
75 5.88 ± 0.07 6.18 ±0.20 ns 
90 6.15 ± 0.60 6.49 ±0.10 ns 
120 6.60 ± 0.05 6.48 ±0.08 ns 
150 6.70 ± 0.20 6.84 ±0.05 ns 
180 7.01 ± 0.08 7.05 ±0.04 ns 
Table 4.7. Comparison between the pH values for olive oil treated with 1000 mg CC01 alginate added at 
the salivary phase and the pH values for olive oil with 1000 mg CC01 added at the small intestinal phase. 
The gastric phase lasted for 1 hour (0-60 minutes) and the small intestinal phase lasted for 2 hours (60T-180 
minutes). 60T indicates the zero time of small intestinal phase. Data are shown as mean ± SD, (n=3). P value 
<0.05 was taken to detect the significant difference in pH values where P values <0.0005 are represented by 








4.5.10.3 Glyceryl trioctanoate alone and in combination with 500 mg CC01 added at the salivary 
phase and in the small intestinal phase 
Table 4.8 shows the pH values for glyceryl trioctanoate alone (as a control) and glyceryl 
trioctanoate in combination with 500 mg CC01 added either at the salivary phase or 10 minutes 
after the start of the small intestinal phase (at T70 of the model gut procedure).  
During the gastric phase, the pH values for glyceryl trioctanoate in combination with 500 mg CC01 
added at the salivary phase were significantly higher than (P<0.05) those for glyceryl trioctanoate 
alone. However, during the small intestinal phase, no significant difference (P>0.05) was detected 
between the pH of glyceryl trioctanoate alone and those of glyceryl trioctanoate in combination 
with 500 mg CC01 added at the salivary phase. 
Table 4.8 also shows the pH values for glyceryl trioctanoate alone and in combination with 500 mg 
of CC01 added 10 minutes after the start of the small intestinal phase. As expected, during the 
gastric phase where the alginate was not present, no significant difference (P>0.05) was seen in pH 
values between the samples. During the small intestinal phase, there was no significant difference 
between the pH values for glyceryl trioctanoate alone and those for glyceryl trioctanoate in 
combination with 500 mg CC01. 
Data from Table 4.8 also shows that at 15, 30, and 60 minutes of the gastric phase (0-60 minutes), 
the pH values for glyceryl trioctanoate treated with 500 mg CC01 added at the salivary phase were 
significantly higher (P<0.05) than those for glyceryl trioctanoate where CC01 was not yet added 
to the sample. However, when 500 mg CC01 was added 10 minutes after the start of the small 
intestinal phase (60T-180 minutes), there was no significant difference (P>0.05) in the pH values 
for glyceryl trioctanoate in combination with 500 mg of CC01 added at the small intestinal phase 
and those for glyceryl trioctanoate in combination with 500 mg of CC01 added at the salivary 
phase. 
During the small intestinal phase (60T-180 minutes) where the majority of triglyceride digestion 
occurs, the pH values for glyceryl trioctanote alone were not significantly different to the pH values 
for glyceryl trioctanoate in combination with 500 mg of CC01 added at the salivary phase nor the 
pH values for glyceryl trioctanoate added at the small intestinal phase (T70). Also, no significant 




added at the salivary phase and those for glyceryl trioctanoate treated with 500 mg CC01 added at 
the small intestinal phase (T70). Consequently, changes in pH could not account for any inhibition 




Glyceryl trioctanoate alone 500mg CC01 added at the 
salivary phase 
500mg CC01 added at the 
small intestinal phase 
 pH ±SD Signif pH ±SD Signif pH ±SD Signif 
0 1.95 (±0.23) ns 2.21 (±0.29) ns 1.98 (±0.23) ns 
15 1.93 (±0.25) c 2.50 (±0.48) ab 1.97 (±0.22) C 
30 1.92 (±0.26) c 2.54 (±0.56) ab 1.96 (±0.25) C 
60 1.90 (±0.28) c 2.47 (±0.50) ab 1.93 (±0.24) C 
60T 4.47 (±0.33) ns 4.45 (±0.15) ns 4.45 (±0.16) ns 
75 5.35 (±0.50) ns 5.11 (±0.46) ns 5.41 (±0.34) ns 
90 5.69 (±0.09) ns 5.81 (±0.13) ns 5.55 (±0.33) ns 
120 6.08 (±0.12) ns 6.03 (±0.14) ns 5.98 (±0.07) ns 
150 6.21 (±0.01) ns 6.20 (±0.02) ns 6.22 (±0.04) ns 
180 6.51 (±0.06) ns 6.46 (±0.05) ns 6.46 (±0.03) ns 
Table 4.8. pH measurements for glyceryl trioctanoate alone and in combination with 500 mg CC01 alginate 
added either at the salivary phase or the small intestinal phase of the model gut system.Values are shown as 
mean ± SD, (n=3). P value < 0.05 was used for comparison between the pH values for glyceryl trioctanoate 
alone and those for the alginate samples to determine the significance difference (signif.). Letters a, b and c 
represent a significant difference (P<0.05) from the control, a significant difference (P<0.05) from the 
samples of alginate added at the small intestinal phase and a significant difference (P<0.05) from alginate 
added at the salivary phase, respectively. P values >0.05 are represented by ns (non-significant difference). 
60T represents the zero-minute of the small intestinal phase. CC01 was added 10 minutes after the start of 




4.5.10.4 Olive oil alone and in combination with alginate added at the salivary phase using a 
buffered synthetic salivary diluent 
Figure 4.19 illustrates the pH measurements within the synthetic model gut system for olive oil 
alone as a control and olive oil in combination with 250, 500, and 1000 mg CC01 alginate added 
at the salivary phase using buffered salivary diluent containing 372mM NaHCO3.  
The pH values for the olive oil in combination with 250 mg of CC01 at 0, 15, 30, and 60 minutes 
of the gastric phase were 5.39 (±0.16), 4.32 (±0.24), 3.59 (±0.15), and 3.03 (±0.11), and these 
values were significantly higher (P<0.05) than the pH values for olive oil alone at 0, 15, 30, and 60 
minutes which were 4.89, 2.88, 2.32, and 1.97, respectively (Figure 4.19, graph A). However, 
during the small intestinal phase, there was no significant difference (P>0.05) between the pH 
values of the olive oil alone or in combination with 250 mg of CC01 at any time point. 
The pH measurements for olive oil alone and in combination with 500 mg CC01 (Figure 4.19, 
graph A) shows that the pH of olive oil treated with 500 mg of CC01 at 0, 15, 30, and 60 minutes 
of the gastric phase was 5.25 (±0.08), 4.38 (±0.23), 3.85 (±0.13), and 3.44 (±0.15), respectively, 
compared to 5.3 (±0.19), 3.40 (±0.06), 2.75 (±0.07), and 2.29 (±0.10) for olive oil alone at 0, 15, 
30, and 60 minutes, respectively. The pH values for olive oil in combination with 500 mg of CC01 
were significantly higher (P<0.05) than those for olive oil alone at 15, 30, and 60 minutes, but not 
at 0-minute. During the small intestinal phase, no significant difference was observed between the 
pH values for olive oil alone and those for olive oil treated with 500 mg CC01. 
The pH values for olive oil in combination with 1000 mg CC01 at 0, 15, 30, and 60 minutes of the 
gastric phase were 5.9 (±0.19), 5.14 (±0.58), 4.16 (±0.19), and 3.67 (±0.03), compared to 5.6 
(±0.15), 3.06 (±0.12), 2.42 (±0.08), and 2.08 (±0.10) for olive oil alone, respectively (Figure 4.19, 
graph C). The difference in gastric pH values for olive oil alone and olive oil in combination with 
1000 mg CC01 became significant (P<0.05) at 15, 30, and 60 minutes. During the small intestinal 
phase (60-180 minutes), there was no significant difference between the pH values of olive oil 
alone and the pH of olive oil in combination with 1000 mg CC01. 
Based on the pH data from the graphs A, B, and C of Figure 4.19, all three concentrations (250, 
500 and 1000 mg) of alginate could significantly increase the pH in the gastric phase. However, 




gastric phase were the highest, indicating that the change in pH is a concentration dependent.  
Although the gastric pH of olive oil treated with CC01 (250, 500 or 1000 mg) in the intestinal 
phase were significantly higher (P<0.05) than those for olive alone, the pH values for olive oil 
treated with CC01 in the small intestinal phase, where the majority of triglyceride digestion occurs, 
were not altered from those for olive oil alone, indicating that the shift in pH cannot explain the 










Figure 4.19. pH changes during the digestion of olive oil alone using buffered salivary diluent and olive 
oil in combination with different amounts of CC01 alginate using buffered salivary diluent. (A) 250, (B) 
500 and (C) 1000 mg CC01 were added at the salivary phase within the model gut system. Data are shown 
as mean ± SD, (n=3). The significant difference was determined based on P value <0.05 where * 







4.5.10.5 Olive oil in combination with CC01 using a buffered salivary diluent and olive oil in 
combination with CC01 using normal salivary diluent 
Table 4.9 shows the pH measurements for olive oil alone using either normal saliva containing 
62mM NaHCO3 or buffered saliva containing 372mM NaHCO3. During the gastric phase (0-60 
minutes), the pH values for the olive oil treated with buffered saliva appeared higher than those for 
olive oil treated with normal saliva, but the difference in pH values was significant only at zero-
minute of the gastric phase. However, during the small intestinal phase (60T-180 minutes), there 
was no difference between the pH values for olive oil treated with buffered saliva and those for 
olive oil treated with normal saliva, indicating that the reduction in the digestion rate of olive oil 
treated with buffered saliva compared with that of olive oil treated with normal saliva was 
independent of pH. 
Tables 4.10, 4.11 and 4.12 demonstrate pH values for olive oil treated with 250, 500, and 1000 mg 
CC01 added at the salivary phase using either normal synthetic saliva containing 62mM NaHCO3 
or buffered synthetic saliva 372mM NaHCO3, respectively.                                                                                                                                                                             
It is obvious from Table 4.10 that during the gastric phase (0-60 minutes), the pH values for olive 
oil treated with 250 mg CC01 and buffered saliva were significantly higher than (P<0.05) those for 
olive oil treated with 250 mg CC01 and normal saliva at all time intervals. However, during the 
small intestinal phase (60T-180 minutes), although the pH values for olive oil treated with 250 mg 
CC01 and buffered saliva were higher than those for olive oil in combination with 250 mg CC01 
and normal saliva at all time points, Bonferroni’s test indicated a significant difference (P<0.05) 
only at 75 and 90 minutes.  
Data in Table 4.11 show that during the gastric phase (0-60 minutes), the pH values for olive oil in 
combination with 500 mg CC01 and buffered saliva were significantly higher (P<0.05) than those 
for olive oil treated with 500 mg CC01 and normal saliva at 0, 15, and 30 minutes, but not at 60-
minute. However, during the small intestinal phase (60T-180 minutes), although the pH values for 
olive oil treated with 500 mg CC01 and buffered saliva were higher than those for olive oil treated 
with 500 mg CC01 and normal saliva, Bonferroni’s test showed a significant difference in pH 





The pH measurements in Table 4.12 demonstrate that during the gastric phase (0-60 minutes), the 
pH values for olive oil in combination with 1000 mg CC01 alginate and buffered saliva were higher 
than those for olive oil in combination with 1000 mg CC01 and normal saliva. However, 
Bonferroni’s test indicates a significant difference between the gastric pH values only at 0 and 15 
minutes. During the small intestinal phase (60T-180 minutes), however, the pH values for olive oil 
treated with buffered saliva and 1000 mg CC01 were higher than those for olive oil treated with 
normal saliva and 1000 mg CC01, but no significant difference (P>0.05) was observed between 
pH values at any time point of the small intestinal phase.  
Unlike alginate added at the salivary phase with saliva containing 62mM NaHCO3, when the 
alginate was added at the salivary phase in combination with salivary diluent containing 372mM 
NaHCO3, less gel was formed in the samples and this could be because the buffered saliva produced 
a higher pH in the gastric phase which prevents or reduces acid gel formation. 
It is obvious that the digestion rate of olive oil alone in the presence of buffered saliva was slower 
than its digestion rate in the presence of normal saliva, but no significant difference was detected 
between their pH values in the small intestinal phase, therefore that the reduction in the digestion 
of olive oil treated with buffered saliva was independent of the pH, suggesting that this reduction 
might be because of calcium binding with bicarbonate through cation exchange.   
The pH changes in the gastric and pancreatic phases might account for the change in the levels of 
pancreatic lipase activity which might provide an explanation for the reduction in the digestion rate 
of olive oil treated with buffered saliva and CC01 alginate compared with the digestion rate of olive 










Time        
(minute) 
Olive oil with normal       
salivary diluent 






pH ± SD pH ±SD 
Zero 2.08 ± 03 4.51 ± 0.17 <0.0001 **** 
15 2.07 ± 0.03 3.03 ±0.38 >0.05 ns 
30 2.06 ± 0.06 2.59 ±0.16 >0.05 ns 
60 2.03 ± 0.04 2.27 ±0.17 >0.05 ns 
60T 4.59 ± 0.07 5.32 ±0.33 >0.05 ns 
75 5.62 ± 0.26 6.06 ±0.57 >0.05 ns 
90 6.41 ± 0.08 6.29 ±0.52 >0.05 ns 
120 6.65 ± 0.07 6.78 ±0.27 >0.05 ns 
150 6.89 ± 0.09 6.99 ±0.27 >0.05 ns 
180 7.00 ± 0.09 7.20 ±0.22 >0.05 ns 
Table 4.9. pH changes during simulated digestion of olive oil alone using normal or buffered salivary diluent 
within the synthetic model gut system. The normal salivary diluent contained 62mM NaHCO3, whereas the 
buffered salivary diluent contained 372mM NaHCO3. Data are shown as mean ± SD, (n=3). P values 
<0.0001 are represented by ****, whereas P values >0.05 are represented by ns (non-significant difference). 
The gastric phase lasted for one hour (0-60 minute) whereas the small intestinal phase lasted for two hours 







Time      
(minute) 
Olive oil with 250 mg CC01 
using normal salivary diluent 
Olive oil with 250 mg CC01 using 





pH ± SD pH ±SD 
Zero 2.50 ± 0.26 5.39 ± 0.16 <0.0001 **** 
15 2.60 ± 0.22 4.32 ±0.25 <0.0001 **** 
30 2.59 ± 0.20 3.59 ±0.15 <0.005 *** 
60 2.43 ± 0.23 3.03 ±0.12 <0.05 * 
60T 4.96 ± 0.30 5.49 ±0.21 >0.05 ns 
75 5.40 ± 0.67 6.46 ±0.12 <0.005 *** 
90 5.83 ± 0.24 6.65 ±0.16 <0.005 *** 
120 6.48 ± 0.18 7.04 ±0.11 >0.05 ns 
150 6.72 ± 0.20 7.27 ±0.17 >0.05 ns 
180 6.99 ± 0.03 7.50 ±0.12 >0.05 ns 
Table 4.10. pH changes during simulated digestion of olive oil in combination with 250 mg CC01 added at 
the salivary phase using normal or buffered salivary diluent within the model gut system.Data are shown as 
mean ± SD, (n=3). P values < 0.05 are represented by *, <0.0005 are represented by ***, and <0.0001 are 
represented by ****, whereas P values >0.05 are represented by ns (non-significant difference). The gastric 
phase lasted for one hour (0-60 minute) whereas the small intestinal phase lasted for two hours (60T-180 








Time      
(minute) 
Olive oil with 500 mg CC01 
using normal salivary diluent 
Olive oil with 500 mg CC01   





pH ± SD pH ±SD 
Zero 2.30 ± 0.03 5.26 ± 0.08 <0.0001 **** 
15 2.89 ± 0.45 4.38 ±0.23 <0.0001 **** 
30 2.99 ± 0.46 3.85 ±0.12 <0.005 ** 
60 2.89 ± 0.35 3.44 ±0.16 >0.05 ns 
60T 4.79 ± 0.33 5.51 ±0.12 <0.05 * 
75 5.26 ± 0.02 6.32 ±0.06 <0.0005 *** 
90 6.16 ± 0.10 6.43 ±0.04 >0.05 ns 
120 6.57 ± 0.09 6.75 ±0.03 >0.05 ns 
150 6.79 ± 0.18 7.04 ±0.01 >0.05 ns 
180 6.98 ± 0.10 7.20 ±0.02 >0.05 ns 
Table 4.11. pH changes during simulated digestion of olive oil in combination with 500 mg CC01 added at 
the salivary phase using normal or buffered salivary diluent within the model gut system.Data are shown as 
mean ± SD, (n=3). P values < 0.05 are represented by *, <0.005 are represented by **, <0.0005 are 
represented by ***, and <0.0001 are represented by ****. P values >0.05 are represented by ns (non-
significant difference). The gastric phase lasted for one hour (0-60 minute) whereas the small intestinal 










Time   
(minute) 
Olive oil with 1000 mg of CC01     
using normal salivary diluent 
Olive oil with 1000 mg of CC01     







pH ± SD pH ±SD 
Zero 3.88 ± 0.05 5.92 ± 0.19 <0.0001 **** 
15 3.71 ± 0.10 5.14 ±0.58 <0.0001 **** 
30 3.66 ± 0.11 4.16 ±0.19 >0.05 ns 
60 3.20 ± 0.66 3.67 ±0.03 >0.05 ns 
60T 5.05 ± 0.14 5.46 ±0.21 >0.05 ns 
75 5.88 ± 0.07 6.19 ±0.04 >0.05 ns 
90 6.15 ± 0.60 6.56 ±0.07 >0.05 ns 
120 6.60 ± 0.05 7.00 ±0.02 >0.05 ns 
150 6.70 ± 0.20 7.31 ±0.04 >0.05 ns 
180 7.01 ± 0.08 7.57 ±0.11 >0.05 ns 
Table 4.12. pH changes during simulated digestion of olive oil in combination with 1000 mg CC01 added 
at the salivary phase using normal or buffered salivary diluent within the model gut system.Data are shown 
as mean ± SD, (n=3. P values <.0001 are represented by * and ****, respectively, whereas P values >0.05 
are represented by ns (non-significant difference). The gastric phase lasted for one hour (0-60 minute) 
whereas the small intestinal phase lasted for two hours (60T-180 minute). 60T represents the zero-minute 









In this chapter, three different fat substrates, glyceryl trioctanoate, olive oil and sunflower oil, were 
run alone or in combination with alginates in a synthetic model gut system to investigate alginates 
as potential lipase inhibitors. The data presented here showed that all the fat substrates were 
digestible in the synthetic model gut with different rates of digestion, suggesting that the digestion 
rate of fat substrates is dependent on fatty acid chain length and their degree of saturation. 
During the gastric phase of the model gut system, only trace amounts of glycerol were released 
from digestion of glyceryl trioctanoate, olive oil and sunflower oil, showing that little digestion of 
fat takes place in the gastric phase. These observations agree with earlier studies which reported 
that only 20% of triglyceride intake undergoes hydrolysis in the stomach by the action of gastric 
lipase which is resistant to denaturation by pepsin and thus can function even in an acidic 
environment [164]. Furthermore, it has been stated that approximately 10-30% of fat intake is 
digested in the stomach, releasing free fatty acids and 2-monoglycerides. The digestion process of 
fats in the stomach enables their full hydrolysis in the small intestine due to formation of these 
hydrolysis products which in turn promote triglyceride solubility and accelerate binding of colipase 
to the substrate interface [54, 165-167]. As hydrolysis is only partial in the stomach, then little 
glycerol will be released as this requires complete hydrolysis. This fatty acid release results in the 
activation of cholecystokinin (CCK), a hormone which sequentially stimulates the pancreas to 
produce digestive enzymes including pancreatic lipase and procolipase [165, 167]. Moreover, Mu 
& Høy (2004) reported that triglycerides are partially hydrolysed in the stomach by gastric or 
lingual lipase depending on the species considered, and both lipases tend to break down the sn3-
ester bond, producing sn1, 2-diacylglycerides and fatty acids [110]. The lipases tendency to attack 
the ester bond at sn3 is two times higher than the sn1-ester bond. In addition, it has been stated that 
lingual and gastric lipases can hydrolyse short- and medium-chain triglycerides more effectively 
than long-chain triglycerides [64, 168]. Also, Borel et al (1994) demonstrated that in the rabbit, 
pure gastric lipase hydrolysed medium-chain triglycerides three times faster than long-chain 
triglycerides [169]. 
The data presented here based on glycerol release from glyceryl trioctanoate, olive oil and 
sunflower oil digestion at the end of small intestinal phase showed that higher amounts of glycerol 




This is as expected as triglyceride hydrolysis occurs mainly in the small intestinal phase by the 
action of pancreatic lipase. Embleton, & Pouton (1997) and Mu & Høy (2004) reported that 
pancreatic lipase shows a high preference to attack the ester bonds at sn1 and sn3, but not the sn2 
ester bond, producing 2-monoacylglyceride and free fatty acids as the main products of small 
intestinal hydrolysis [110, 170]. However, they stated that 2-monoacylglyceride may be rearranged 
to 1-monoacylglyceride via slow and non-enzymatic isomerisation under alkaline pH, resulting in 
complete hydrolysis for triglyceride into glycerol and free fatty acids [64, 110, 170]. It has been 
reported that the relative quantities of the various products arising from triglyceride hydrolysis in 
a normal human are mostly as follows: 22% glycerol, 72% 2-monoglycerides and 6% 1-
monoglycerides [170] . 
It is clear from the data presented in this chapter that the digestion rate of glyceryl trioctanoate was 
the highest among the three fat substrates, and that may occur because of the difference in length 
of the fatty acids and the degree of unsaturation. Glyceryl trioctanoate consists of pure saturated 
medium-chain triglycerides containing octanoic acids (C8:0) at the 1, 2 and 3 positions. Olive oil 
is a mixture of monounsaturated long- medium chain triglycerides consisting of monounsaturated 
oleic acids (C18:1) and saturated palmitic acids (C16: 0), while sunflower oils are long-chain 
triglycerides containing polyunsaturated linoleic acids (C18: 2) and monounsaturated oleic acids 
(C18: 1) at 1 and 3 positions. Olive oil triglycerides contain oleic (55-83%), palmitic (7.5-20%), 
linoleic (3.5-21) %, linolenic (0.01-1%), stearic (0.5-5%), and palmitoleic (0.3-3.5%) acids [171]. 
Although olive oil is composed of different fatty acids, oleic acid is the most abundant, forming up 
to 68-80% of the fatty acids present in olive oil, whereas palmitic acid forms 9-12% of olive oil 
fatty acids [172] . According to Orsavova et al (2015), sunflower oil triglycerides contain different 
fatty acids, however, oleic acid (28%) and linoleic acids (62%) are the predominant fatty acids in 
the oil [173].  
All lipases responsible for triglyceride digestion attack the ester bonds of triglycerides specifically 
at the 1 and 3 positions, and these enzymes have tendency to hydrolyse short- and medium-chain 
triglycerides more than long-chain triglycerides [174]. Additionally, pancreatic lipase tends to 
hydrolyse medium-chain triglycerides more than long-chain triglycerides, and the intraluminal 
breakdown of these medium-chain triglycerides occurs very rapidly in the small intestine [175]. 
Another study on rats reported that the hydrolysis rate of medium-chain fatty acid triglycerides is 




glycerol produced at T180, the digestion of olive oil alone was quicker than the sunflower oil, and 
this might occur because triglycerides of olive oil includes saturated palmitic acid (C16:0) and 
monounsaturated fatty acids (oleic acid, C18:1), while sunflower oil triglycerides contain 
monounsaturated fatty acids (oleic acid, C18:1) and polyunsaturated fatty acids (linoleic acids, 
C18:2) at the 1 and 3 positions, respectively. Triglycerides containing polyunsaturated fatty acids 
are more rigid (less flexible) than those with saturated and monounsaturated fatty acids. Therefore, 
these two triglycerides may differ in the way that they insert to the active site of enzymes especially 
considering that the rotation around the double bond is restricted, while the rotation around the 
single bond is free.  
The data obtained from digestion of fat substrates in combination with 500 mg alginate added at 
the salivary phase was unexpected. Glyceryl trioctanoate treated with either 500 mg CC01 or 1N80 
showed a significant reduction in digestion (P< 0.05) compared with the relevant control (glyceryl 
trioctanoate alone), while 500 mg 1LF80 had no significant effect on glyceryl trioctanoate digestion. 
The ability of the alginates to inhibit digestion of octanoic acid (C8:0) containing triglycerides may 
relate to the fact that trioctanoate hydrolysis is more rapid than triglycerides containing palmitic 
acid (C16:0) and oleic acid (C18:1) or linoleic acid (C18:2). In addition, when the alginate was 
added to glyceryl trioctanoate at T70, it did not inhibit digestion, suggesting for the alginate to be 
active, it must pass through the low gastric pH phase. It may be that some substrate/inhibitor 
interaction in the gastric phase is necessary to allow inhibition of pancreatic lipase.  
There was no significant reduction in digestion rates of either olive oil or sunflower oil treated with 
500 mg CC01, 1N80 or 1LF80. During the model gut experiments, it was noticed that once the 
alginate (CC01, 1N80 or 1LF80) had been added to glyceryl trioctanoate, olive oil or sunflower oil 
at the salivary phase, the pH ranged between 7 and 7.3, and once the synthetic gastric juice was 
added to start the gastric phase, some gelatinous precipitates were observed. However, at the end 
of the pancreatic phase, there were some gelatinous pieces in the olive oil and sunflower oil 
chambers beakers, but not in the glyceryl trioctanoate chamber. 
 The alginate may precipitate and form an acid gel due to the rapid decrease in pH to 2-2.5 when 
the gastric juice is added. Draget and his colleagues, in 2006, demonstrated that the rapid decrease 
in the pH of an alginate solution from pH 7 will result in the precipitation of alginate, however, 




decreased slowly. Furthermore it has been reported that at low pH, -CCO− ions of the alginate chain 
are protonated to -COOH, thus the electrostatic repulsion between alginate chains decreases and 
the chains become closer to each other, leading to formation of hydrogen bonds and increasing 
viscosity, and when a further decrease in the pH occurs, a gel will form at pHs between 3 and 4 
[177]. However, Cuibal and his colleagues reported that alginates lack the ability to form gels and 
they tend to precipitate at pHs < 3.5 [178]. Imeson (2012) stated that at low pH, less than or around 
the pKa of alginic acid (3.5), foods and beverages containing alginates will be unaffected by the 
stability and thickening properties of alginates, and when a further decline in pH occurs, the 
alginate will undergo a partial protonation, losing its net negative charge and the alginic acid begins 
to precipitate [179]. Furthermore, the presence of calcium chloride in saliva and pancreatic juice 
may result in alginate precipitation and gel formation. Even though sodium alginate immediately 
precipitates or forms gel in the presence of CaCl2, small amounts of sodium alginate are unable to 
form a homogenous gel (without any lumps) in the presence of calcium ions even with high-speed 
stirring because of the strong, quick and permanent formation of junctions in the gel and the high 
rate of gelation [103].  
It has been reported that alginate usually forms hydrogels in the presence of cross-linking agents 
such as CaCl2, where the calcium ions bind only to G-blocks of alginate chains because of their 
structural features, which provide a suitable distance between COO− and OH− groups, hence 
allowing a high level of coordination with calcium ions [100, 180]. The G-block of one polymer 
links with G-blocks of neighbouring polymer chains making a gel structure with a shape referred 
to as the egg-box structure (shown in Figure 2.10, Chapter 2 of this thesis) [100]. Additionally, it 
has been reported that G-block regions possess a pleated conformation due to the presence of 
diaxial linkages which restrict rotation around the glycosidic bonds, hence producing a stiff and 
extended chain while MG-blocks are softer and more flexible [181]. Furthermore, the 
mannuronate/guluronate (M/G) ratio has been reported by many studies as a crucial factor in 
determining the quality of an alginate gel where the alginate with a high content of G-block forms 
strong stiff gels, while alginate with high M-block content produces soft and flexible gels [159, 
160]. 
A key difference in the model gut experiments with glyceryl trioctanoate was the pancreatic juice 
used contained a higher amount of sodium bicarbonate (322.8 mM) compared with the pancreatic 




may arise from fatty acid release especially because glyceryl trioctanoate triglycerides produce 
fatty acids with a low pKa (4.9). The higher concentration of sodium bicarbonate may provide a 
more alkaline environment which could degrade the gel, thus releasing the alginate which then 
inhibited glyceryl trioctanoate digestion.  
Experimental results from the model gut digestion of olive oil treated with alginate added after 10 
minutes of the pancreatic small intestinal phase showed that both 250 and 500 mg CC01 
significantly reduced olive oil digestion. Additionally, 500 mg 1N80 significantly decreased olive 
oil digestion at 150-minute, while 500 mg 1LF80 had no effect on olive oil digestion. It is apparent 
that unlike glyceryl trioctanoate where passage through the gastric phase is necessary for alginate 
inhibition, passage of alginate through the gastric phase prevents alginate inhibition of olive oil. 
This could be explained by a lack of alginate substrate interaction in the gastric phase which cannot 
then form in the more alkaline small intestinal phase.  
The amount of glycerol released from the digestion of olive oil treated with 500 mg CC01 in the 
small intestinal phase was significantly lower than the amount of glycerol released from the 
digestion of olive oil treated with 250 mg CC01, showing that the inhibitory effect of alginate is 
dependent on concentration. This result is in agreement with the results obtained from the turbidity 
microplate assay presented in Chapter 2 of this thesis which showed that alginate potency as a 
pancreatic lipase inhibitor is influenced by concentration where the higher concentrations of 
alginate could inhibit pancreatic lipase activity in vitro to level much greater than the lower 
concentrations. Wilcox et al (2014) reported that there is a positive correlation between inhibition 
of pancreatic lipase activity and alginate concentration. They found that increasing LFR5/60 
alginate concentration from 0.21 mg/ml to 0.86 mg/ml increased the reduction of pancreatic lipase 
activity by 75% and increasing alginate concentration from 0.86 to 3.43 mg/ml increased the 
reduction by a further 56% [72].   
The data presented here showed that the digestion rates of glyceryl trioctanoate and olive oil treated 
with CC01 were slower than the digestion rates when they were treated with 1N80, and the 
variation in inhibition may relate to the structural features of the alginates. 1H NMR data for the 
alginates, shown in Chapter 2, revealed that CC01 possesses the highest content of G- 
homopolymeric blocks (GG and GGG-blocks) compared to 1N80, hence CC01 had the ability to 




no impact on fat digestion and that might be because of its high content of M- blocks, (MM, and 
MMM residues). These results are in agreement with the earlier results in Wilcox et al 2014 which 
demonstrated that alginates with high content of guluronic acid are considered to be strong 
inhibitors of lipase. In the presence of divalent cations such as calcium ions, alginate rich in G 
blocks produces a stiff and brittle hydrogel where the G blocks bind to each other through diaxial 
linkages, creating cavities where the ions can bind to these sites, producing the egg-box 
conformation [182].   
The reduction in olive oil digestion achieved by CC01 (250 or 500 mg) and 500 mg 1N80 added 
at the small intestinal phase could also be explained by the relatively high pH in the small intestinal 
phase compared to the low pH in the gastric phase. At an acidic pH of less than the pKa of guluronic 
acid (3.5), alginate forms a highly viscus acid-gel due to protonation of carboxylic acids which 
accept protons and lose their net negative charge [179, 183]. However, the data obtained from 
experiments of alginate added at the small intestinal phase showed that pH after adding the bile 
and pancreatic juice ranged between 4.5 and 4.7. Therefore, an alginate gel will not form, allowing 
the alginate to be free in solution to inhibit the pancreatic lipase. 
A confounding result is that addition of 1000 mg alginate at the salivary phase to olive oil 
containing free fatty acids and olive oil free from free fatty acids resulted in a significant increase 
(P<0.05) in the digestion rates of both. A possible explanation for the apparent increase in digestion 
rate might be that alginate gelling reduces the volume for reaction, increasing the relative enzyme-
substrate concentration, and therefore, increasing activity.  
Model gut experiments with alginate added at the small intestinal phase (T70) showed that unlike 
500 mg, using 1000 mg alginate unexpectedly increased olive oil digestion. Also, 1000 mg 1LF80 
added at T70 caused a significant increase in olive oil digestion although 500 mg 1LF80 added at 
T70 did not affect olive oil digestion. Consequently, simple experiments with alginate and glycerol 
using the glycerol assay, which is described in the method sections of this chapter, were carried out 
to investigate whether there was any interference by alginate in the glycerol assay, causing an 
apparent increase in glycerol release. Alginate in DH2O at three different concentrations, 8, 4, and 
2 mg/ml, were prepared. These concentrations were chosen because they are almost identical to the 
used alginate concentrations (1000, 500 and 250 mg in volume 120 ml, respectively) at the zero 




from the experiments indicated interference from alginate in the glycerol assay. The interference 
effect was corrected for the samples by subtracting the absorbance of alginate obtained from 
glycerol assay from the absorbance of the samples, however, the digestion rate of olive oil treated 
with 1000 mg of alginate still showed an increased rate, indicating that the interference effect could 
not explain all of the increase. 
An additional possible explanation for the apparent increase in olive oil digestion by 1000 mg 
alginate might be found in solubility issues. Samples of olive oil treated with 500 mg alginates 
added at the small intestinal phase did not show any gelation or precipitation, however, some 
precipitation and formation of gel lumps were seen in the samples treated with 1000 mg alginate. 
Thus, it is possible that 500 mg alginate dissolves more efficiency than 1000 mg and becomes 
released into the solution, binds the pancreatic lipase and reduces its activity. Another possible 
explanation is when olive oil is present alone, lipases interact differently with triglycerides 
containing different fatty acid chain length and degree of saturation. In the presence of 1000 mg 
alginate, triglycerides containing long and unsaturated fatty acids could bind preferentially with 
the alginate, thus preventing reaction with lipases and allowing them to hydrolyse saturated 
triglycerides with shorter fatty acids, and thus increasing the reaction rate. Further investigation of 
these potential effects is required.  
A previous study found that low methylic ester pectin (LM pectin) at a concentration 1.5 g/100 ml 
could reduce the activity of trypsin, lipase, and amylase in vitro by 86, 96, and 100% respectively 
through lowering the pH of duodenal juice from 5.7 to 3.9 [141].  Also, it has been reported that 
activity of pancreatic lipase is influenced by the intestinal pH. The approximate pH in the small 
intestine ranges from 6.5 in the duodenum to above 7 in the distal ileum (Brownlee et al., 2010). 
The data obtained from pH measurements for olive oil alone or in combination with alginate added 
either at the salivary phase or small intestinal phase (T70) indicated that the pH values for olive oil 
in combination with alginate added at the salivary phase were significantly higher than those for 
fat substrate alone or in combination with alginate added at the small intestinal phase. As mentioned 
earlier, the salivary pH of alginate containing olive oil solution experienced a rapid sudden drop to 
below the pKa for uronic acids (3.5) when the gastric juice was added, producing gel and 
precipitation, and reducing the free release of alginate into the reaction mixture, thus, the inhibitory 
effect of alginate on triglyceride digestion would be affected.  On the other hand, during the small 




in pH neither between the fat substrate alone or fat substrate in combination with alginate added at 
the salivary phase, nor between the pH values for fat substrate alone and those for fat substrate in 
combination with alginate added at the T70 of small intestinal phase, demonstrating that unlike the 
LM pectin which inhibited pancreatic lipase through reducing the pH of duodenal juice, adding 
alginate either at the salivary or small intestinal phase did not change the pH within the small 
intestinal phase. Therefore, it is likely that for the alginate added to olive oil, the regulatory affect 
(activation or no effect) was influenced by the gel formed at low pH in the gastric phase, but, for 
the reduction in olive oil digestion produced by alginate added at the small intestinal phase, the 
alginate effect on fat digestion seemed dependent on pH in term of the gelling effect. However, as 
was shown previously in this work, the gelling effect of alginate at low pH in the gastric phase was 
not observed when glyceryl trioctanoate in combination with alginate was passed through the 
gastric phase, also, no significant difference was observed between the small intestinal pH values 
for olive oil alone, olive oil with alginate added at the salivary phase, and olive oil with alginate 
added at the T70 of small intestinal phase, indicating that  the regulatory effect of alginate is 
independent of pH. Obviously, unlike LM pectin, the inhibitory effect of alginate added either at 
the salivary phase or at the small intestinal phase to glyceryl trioctanote did not rely on a reduction 
of small intestinal pH.  
A buffered synthetic salivary diluent containing 372mM NaHCO3 was used to produce less acidic 
pH in the gastric phase, hence, avoiding or reducing the amount of gel and precipitation produced 
from alginate due to acidic pH in the gastric phase of model gut. The data obtained from the 
digestion of olive oil in combination with CC01 alginate added at the salivary phase using buffered 
saliva showed no change in the digestion rate of olive oil treated with CC01 alginate. However, in 
the small intestinal phase, where triglyceride digestion mainly takes place, no significant difference 
was shown between the pH levels for olive oil in combination with alginate and buffered saliva, 
and the pH levels for olive oil in buffered saliva without alginate. This indicates that the regulatory 
effect of alginate added at the salivary phase in combination with buffered saliva on olive oil 
digestion was independent of small intestinal pH.  
Furthermore, the data presented here showed that the digestion rate of olive oil alone treated with 
buffered saliva containing 372mM NaHCO3 was significantly lower than the digestion rate of olive 
oil treated with normal saliva containing 62mM NaHCO3. The reduction in digestion rate of olive 




explained by Ca++ ions binding bicarbonate through cation exchange, producing insoluble calcium 
bicarbonate which cannot dissociate. Therefore, lower concentration of calcium ions would be 
present in the reaction mixture, consequently, the activity of pancreatic lipase is affected.  Previous 
studies showed that calcium ions are important for lipase activity. Armand et al, (1992) reported 
that calcium ions can modulate the activity of lipase until the enzyme reaches its maximum activity. 
It has been suggested that calcium ions may reduce the electrostatic repulsion, which takes place 
at the emulsion/water interface due to the binding of bile salts, allowing the penetration of lipase 
to the substrate interior, and reducing the duration of lag phase (i.e. the time required for activation 
of the pancreatic lipase) [55-57]. 
The digestion rate of olive oil treated with CC01 alginate and buffered saliva was significantly 
lower than that of olive oil in combination with 250 mg CC01 and normal saliva. Also, the amount 
of gel formed in samples of olive oil treated with alginate and buffered saliva was lower than that 
formed in samples of olive oil treated with alginate and normal saliva. As described above this 
could be because of the binding of calcium with bicarbonate through cation exchange, reducing the 
concentration of Ca2+ in the reaction mixture and therefore the interaction between Ca2+ and 
alginate.   
The data presented here showed that the gastric pH values for alginate in combination with buffered 
saliva were significantly higher than those for alginate in combination with normal saliva. These 
high pH values in the gastric phase likely explain the lower amounts of gel, lumps and precipitate 
seen in the samples of alginate treated with the buffered saliva. This would allow more alginate to 
be present in the reaction mixture compared to the alginate present in the reaction mixture treated 
with normal saliva. This might explain the reduction in the digestion rate of olive oil treated with 
alginate and buffered saliva compared to the digestion rate of olive oil treated with alginate and 
normal saliva.   
In this chapter, model gut experiments for CC01, 1N80 and 1LF80 alginates, as pancreatic lipase 
inhibitors, showed different results from those of the microplate assay for the same alginates, 
however, this variation in results between the microplate assay and model gut system may occur 
for many reasons. Lipase microplate assay experiments conducted by Wilcox et al were carried out 
in well-controlled conditions where a single enzyme (pancreatic lipase) was used, thus the 




the synthetic model gut has been developed to imitate the human gastro-intestinal tract, therefore, 
the model gut system is more complicated than the lipase microplate assay since the model gut 
system involves several types of chemicals, digestive secretions and enzymes. Alginate may 
interact with other enzymes of the synthetic diluents within the model gut system such as pepsin  
instead of pancreatic lipase as previous studies reported that alginate could inhibit pepsin activity 
in vitro by 52% where the direct binding of alginate to pepsin has been suggested as one of the 
inhibition mechanisms [107]. Moreover, in the model gut system, bile and pancreatin from pig 
were used, where the bile is made up of bile salts, mucus, phospholipids, cholesterol, and bilirubin, 
and the pancreatin involves all the digestive enzymes present in pancreatic secretions. Previous 
studies have shown that dietary fibres such as alginate can interact with bile salts [184, 185]. Also, 
a further difference between the model gut and microplate assay is stirring. The stirring applied 
within the model gut system may change the possible interaction between alginate and the 
pancreatic lipase or fat substrate [162]. The synthetic model gut system was stirred at 0.05 Hz in 
an attempt to mimic the motion of the gastro-intestinal tract in human body. The motion of the 
model gut system does not exactly imitate shearing, mixing and stirring produced by gastric 
motility and peristaltic movement within the gastrointestinal tract of human body [162], hence it is 
obvious that the digestion within the model gut does not take place in the complete in vivo 
environment. Furthermore, lipase microplate assays were performed at a constant pH (7.3), while 
the model gut system was carried out at different pH conditions. During the gastric phase, the pH 
was acidic, and once the gastric phase ended and the small intestinal phase started, bile and 
pancreatin from pig were added, hence the pH increases gradually and becomes neutral or more 
alkaline. As mentioned earlier, pH affects alginate properties since alginate at acidic pH produces 
gel due to protonation of uronic acids and the gel formation may affect alginate’s capacity as a 











The data obtained from digestion of fat substrates within the synthetic model gut system revealed 
that  tiny amounts of the fat substrate were digestible within the gastric phase, however, the majority 
of fat substrates were digestible in the small intestinal phase, confirming previous studies which 
reported that although triglyceride digestion starts in stomach, it occurs mostly in the small intestine, 
proving the capacity of the synthetic model gut in representing in vivo digestion from the mouth to 
small intestine. However, the digestion rate of fat substrate was dependent on length of fatty acids 
as well as saturation degree of these fatty acids. The model gut did not digest olive oil and sunflower 
oil to the same level. A possible explanation for the difference in olive oil and sunflower oil 
digestion is that in enzymatic reactions, the rate of end product production is governed by their 
concentrations where the accumulation of these products may slow the enzymatic reaction; 
however, under some circumstances of high product concentration, the reaction may be driven in 
reverse back toward reactants [186], meaning if there is high concentration of products then this 
will slow the rate of end product production (glycerol and free fatty acids). Since the synthetic 
model gut lacks absorption capability, the end products may accumulate and slow the rate of 
production, however, the product production rate is unaffected in vivo since the products of 
triglycerides digestion would be absorbed.  
The regulatory effect of alginate added at the salivary phase in combination with normal saliva 
containing 62mM NaHCO3 was influenced by the gastric pH within the synthetic model gut system 
where passage of alginate through the gastric phase produced a gel, some lumps and precipitation 
which might prevent solubility and free release of alginate in the small intestinal phase where 
triglyceride digestion occurs mainly. However, the regulatory effect of alginate added at the small 
intestinal phase was independent of pH. Moreover, the regulatory effect of alginate passed through 
the stomach phase in combination with buffered saliva containing 372mM NaHCO3 was 






Chapter 5: Digestion of alginate bread in the synthetic model gut system  
5.1 Aims 
 In this chapter, 4% (w/w wet dough) powdered CC01 alginate, which previously inhibited 
pancreatic lipase activity in the turbidity assay and reduced fat digestion in the synthetic model gut 
(data presented in Chapters 2 and 3 of this thesis), was incorporated into bread, known as alginate 
bread (AB). Alginate-free bread was used as a control bread (CB), glyceryl trioctanoate and olive 
oil were used as fat substrates. This chapter aims to: 
 Investigate whether AB will be completely digestible within the synthetic model gut, and 
if the alginate released from bread digestion can be measured using an improved version of 
the Periodic Acid-Schiff (PAS) assay [187].  
 Evaluate the efficiency of the PAS assay as a method in measuring alginate in model gut 
solutions (MG) taken from the gastric and small intestinal phase of the synthetic model gut 
system.    
 Study effect of AB on digestion of both glyceryl trioctanoate and olive oil in vitro using the 
synthetic model gut to assess wither the AB can reduce in vitro fat digestion. 
 
5.2 Introduction 
Prospective studies have stated that diets rich in dietary fibres could reduce body weight and 
obesity development [28, 188]. Furthermore, human intervention studies in overweight subjects 
indicated that consuming dietary fibres or fibre-based supplement in combination with caloric-
limited diets decreases body weight and reduces energy intake [189-191].  Moreover, Wilcox et al. 
(2014) and Houghton et al. (2015) showed that some alginates could reduce pancreatic lipase 
activity in vitro and the inhibition level depends on alginate content of G- and M-blocks and 
concentration [72, 192]. Further work conducted by Chater et al. (2015) demonstrated that alginate 
inhibits pepsin activity in vitro, and this finding was in agreement with earlier work of Sunderland 
et al. (2000) who presented that alginate diminishes pepsin activity [193]. Furthermore, 
incorporating dietary fibres into food could reduce obesity and its related metabolic diseases. 




polysaccharide) fibres decreases fasting cholesterol level in blood and changes the ratio of HDL: 
LDL cholesterol in plasma [194-197].  
Jenkins et al. 1980 reported that guar gum, which is unabsorbed polysaccharide, possesses 
beneficial effects in treating diabetes over about one year. Jenkins and his colleagues informed that 
a significant decrease (40-50%) in glucose level was found in 2h urine samples collected from 
diabetic subjects after consumption of bread, soup, and either fruit juice or mashed potatoes 
containing 25g guar/day [198]. Additionally, it has been found that incorporating guar gum into 
foods containing carbohydrates reduces hyperglycaemia and insulinaemia in normal and diabetic 
individuals [198, 199]. Furthermore, Shah et al. (1986) reported that water soluble polysaccharides, 
pectin and guar gum, reduce pepsin activity in vivo by 57 and 44%, respectively [200]. Shah and 
his colleagues reported that the reduction in pepsin activity is associated with the fibres capability 
to form viscous solutions in the stomach which in turn attenuates the stirring process in stomach, 
hence limiting binding of enzyme to substrate.  Moreover, Seal and Mathers (2001) reported that 
NSP fibres alginate (SA) and guar gum (GG) may be used to reduce the risk of hypercholestrileamia 
since their study on male rats feeding with cholesterol-free diets containing SA alginate (50 or 
100g/kg) for 21 days decreased the cholesterol level in plasma and increased the amounts of bile 
acids excreted in faeces, hence they suggested that alginate could be used as a dietary supplement 
to reduce the development of hypercholestrileamia [201].  
Alginate can form both an acidic gel at low pH in stomach (pH<3.5), and an ionic gel in the 
presence of divalent cations [202], and its content of guluronate acid residues affects its gelling 
capability, gel strength, and viscosity [203]. Alginate viscosity/gel plays a crucial role in the 
gastrointestinal signals that moderate hunger, promote satiety and reduce caloric intake [82, 202]. 
Many studies have revealed that incorporating alginate into beverages or cereal bars reduces body 
weight, suggesting that alginate could be used in obesity treatment. The beneficial health effects 
stated in these studies include decreasing blood glucose and insulin [114], increasing excretion of 
fat and bile acids [106], promoting weight loss [83], enhancing satiety and reducing energy intake 
[202].   
Bread is a very acceptable and popular basic food which is consumed regularly in all parts of the 
world [204]. It is a staple constituent in diets of many Western countries. Archeology and history 




civilization was significantly more developed, Greek, and Roman civilization, bread was a 
consistent component of diets consumed every day [205]. In the UK, bread is the most predominant 
basic food among starch foods. About 12 million loaves and packs are produced daily, also, bread 
is one of the major sectors in food industry in the UK (Federation of Bakers, 2005, cited in Burton 
& Lightowler, 2008 [206]). Furthermore, white bread constitutes over 70% of all sold breads in the 
UK ([206]). It has been reported that bread is an excellent source of macronutrients (carbohydrates, 
proteins and fats), and micronutrients (minerals and vitamins) important for human health [204]. 
Alginates, which are polysaccharides, can be quantified using many methods such as 
polyhexamethylenebiguandinium chloride (PHMBH+ Cl-), 1,9-dimethyl methylene blue (DMMB), 
Safranin-O (S-O), Toludine Blue (T-B), and Periodic Acid-Schiff (PAS) assay [207-209]. However, 
Houghton et al’s study (2014) indicated that the PAS assay was more sensitive in detecting low 
concentrations of alginate with a wide range of absorbance and an excellent linearity compared 
with the cationic dyes DMMB, S-O, and T-B.  
PAS assay is a simple and sensitive staining technique used to detect polysaccharides which 
undergo oxidation on exposure to periodic acid. PAS assay technique involves preparing Schiff 
reagent following by linking the Schiff reagent with oxidised sugars which are already oxidised by 
periodic acid [187].  
Many types of carbohydrates, including monosaccharides, polysaccharides, glycogen, and 
mucoproteins, are PAS positive substances [210]. Therefore, the polysaccharide content and 
position within constituents of plant and animal are frequently determined through PAS staining 
assay [211]. In Periodic Acid-Schiff reaction, periodic acid (HIO4) is used as an oxidising agent to 
oxidise hydroxyl (-OH) groups on neighbouring carbon atoms where the C-C bond is cleaved, and 
aldehydes are produced. Then, the resulting aldehydes are detected using a colourless Schiff 
reagent which gives a colour ranged between magenta and purple at the sites of oxidisable 






Figure 5.1. Mechanism of Periodic Acid-Schiff (PAS) reaction. A, Schiff reagent interacts with aldehydes 
producing a purple complex. The Schiff reagent may be used to distinguish polysaccharides following 
treatment with periodic acid (HIO4). B, Periodic acid reacts with 1, 2-diol groups inside polysaccharides, 
and then oxidises them into a dialdehyde compound. Adapted from Fernandes et al., (2006) [211]. 
 
Data from the olive oil turbidity assay presented in Chapter 2 of this thesis revealed that CC01 
significantly reduced in vitro pancreatic lipase activity by 69.8 (± 11.7) %. Also, 1H NMR 
neighbour analysis (Chapter 2) showed that CC01 is rich in guluronic acid. These results agree 
with the Wilcox et al. study in 2014 which indicated that alginate rich in guluronate reduces 
pancreatic lipase activity more than alginate rich in mannuronic acid [72]. Moreover, the data from 
the model gut experiments presented in Chapter 4 of this thesis shows that free CC01, which was 
used as a powder in model gut experiments, reduced digestion of glyceryl trioctanoate and olive 
oil. Additionally, previous in vivo studies mentioned in the introduction of this chapter, reported 
that adding alginate into diets reduces energy intake, and ultimately controls body weight. 
Therefore, in this chapter, digestion of fat substrates was assessed using alginate bread containing 






All chemicals, materials and enzymes used in the current synthetic model gut experiments were 
identical to those used in Chapter 4. The alginate sample CC01 was provided by Coca-Cola. The 
fluids of synthetic model gut (saliva, gastric and pancreatic juices) were prepared as described in 
Chapter 4, and they were used as stock solutions, whereas the enzymes were added before passing 
the sample through the model gut.  
For the PAS assay, periodic acid HIO4.2H2O, acetic acid CH3COOH, sodium metabisulphate 
Na2S2O5 and Schiff fusion-sulphite reagent were purchased from Sigma-Aldrich, UK. 
For bread preparation, strong white bread flour, skimmed milk powder, rape seed oil, sugar, salt, 
and fast acting yeast were purchased from a local supermarket (Cooperative Food, UK) 
 
5.3.2 Model gut equipment 
Model gut equipment, procedure, sampling, and glycerol quantification were as described in 
Chapter 4. 
 
5.3.3 Periodic Acid-Schiff (PAS) assay 
The PAS assay used was a modified version of Mantle and Allen (1978) to be performed in 96-well 
microplate. In the assay, 10 µl of 50% (v/v) HIO4.2H2O was added into 5 ml of 7% (w/v) 
CH3COOH in DH2O and mixed. Then, 20 µl of the mixture from the previous step was added into 
wells of a 96-well microplate containing 200µl of sample in duplicate.  Next, 87.8 mM Na2S2O5 in 
Schiff fusion-sulphite reagent was prepared and mixed. After that, both 96-well microplate and 
Schiff fusion-sulphite mixture were incubated at 37 ºC for one hour. Then, 20 µl of Schiff fusion-
sulphite mixture was added to each well and the plate incubated for 30 minutes at room temperature 





5.3.4 Standard curves for mucin and alginate 
Standard curves for mucin and alginate were prepared using the modified version of the PAS assay 
(Mantle and Allen, 1978) described above. For a mucin standard curve, purified porcine gastric 
mucin was dissolved in DH2O at a concentration of 1 mg/ml. Then, the mucin solution was diluted 
further in DH2O to create a mucin standard curve over concentration range of 0-2 mg/ml. The 
mucin standard curve was used here as a positive control to assess the validity of the PAS assay in 
detecting the polysaccharides. For the standard curve of alginate released in the gastric phase of 
the model gut (0-60 minutes), the model gut (MG) solution from 60 minutes was titrated to pH 7 
using 1M NaOH. Then, alginate was dissolved in the titrated MG solution at a concentration of 2 
mg/ml which was then diluted further in DH2O to produce a standard curve over concentration 
range of 0-0.25 mg/ml. For the standard curve of alginate released in small intestinal phase, 5 
mg/ml alginate in MG solution taken at 180-minute was prepared. This was further diluted by 50% 
in methanol to produce 2.5 mg/ml alginate in methanol which was placed at -20 ºC for 30 minutes. 
After that, the alginate in methanol was centrifuged at 12,000 rpm for 30 minutes at 4 ºC, the 
supernatant removed, and the pellet freeze dried. The expected weight of isolated alginate 
following freeze drying should be 2.5 mg for each ml of alginate in methanol. Following freeze 
drying, the alginate sample was re-suspended in 5ml of DH2O to give a concentration of 0.5 mg/ml. 
This was then diluted further in DH2O to generate a standard curve over concentration range of 0-
0.25 mg/ml. The colour of MG solution may affect the accuracy of PAS assay in quantifying 
alginate; therefore, the colour effect of MG solution was removed through precipitation and 
dilution processes as described above. MG solutions alone from 60 and 180 minutes of the model 
gut with the same dilution used to dilute alginate in the gastric and small intestinal phase were used 
as controls for measuring alginate released in gastric and small intestinal phase of model gut, 
respectively. Next, 200 µl of different concentrations of mucin in DH2O, alginate in MG solutions 
from 60 and 180 minutes of the model gut, and their controls were added to 96 well plate in 
duplicate and the PAS assay was performed. The absorbance of DH2O was subtracted from mucin, 
whereas the absorbance of controls for alginate in gastric and pancreatic phase was deducted from 





5.3.5 Preparation of control and alginate bread 
Control and alginate bread were prepared in a home bread making machine (Morphy Richards) 
following the manufacturer’s instructions for a 2lb loaf. Control bread contained standard 
ingredients (Table 5.1). Alginate bread additionally contained 208 mg alginate and the preparation 
procedure was adjusted to accommodate this. Briefly, skimmed milk powder, rape seed oil, and 
sugar were added to a pan containing water. Salt was dissolved in an additional 150 ml water. The 
salt-water solution was added gently to the pan ingredients with continuous mixing using a fork to 
allow hydration of the dry ingredients. After that, half of the total quantity of flour (300g) and half 
of the alginate were added to the pan, followed by addition of half of the rest of the flour (150g) 
and the remaining alginate, and then the remaining amount of flour (150g). Finally, the yeast was 
placed on the top of flour and the programme started. Both AB and CB were baked at Newcastle 
















Ingredient Control Bread (CB) Alginate Bread (AB) 
Water (Warm ῀ 30 °C) 360ml 360ml 
Skimmed Milk Powder 30g 30g 
Rape Seed Oil 40g 40g 
Sugar (Granulated) 20g 20g 
Salt 10g 10g 
Strong White Bread Flour 600g 600g 
Fast Acting Yeast 7g 7g 
Alginate (CC01) - 50g 
Additional Water - 150ml 
Total Weight 1067g 1267g 
Weight after Baking 933g 1064g 
Percent of Alginate (Wet Weight) - 3.9% (w/w) 
Percent of Alginate (Dry Weight) - 4.7% (w/w) 
Table 5.1. Quantity of ingredients involved in CB and AB preparation.  
 
5.3.6 Isolation and quantification of alginate released from the alginate bread vehicle 
To determine the amount of alginate released from alginate enriched bread, the bread was placed 
within the synthetic model gut system which mimics in vivo digestive process from the mouth to 
small intestine. Thus, the alginate bread was digested, allowing the release of alginate which was 
subsequently measured.  




the model gut system, whereas the synthetic gastrointestinal fluids (gastric juice and pancreatic 
juice) and porcine bile were placed in water bath 1 (Figure 5.2). The bread was cut into small pieces 
ranging between 2 and 4 cm since this size of bread and conditions imitates that of bread masticated 
in human mouth. The AB sample contained 5.2 g of AB, 5 ml saliva, and 10 ml DH2O, CB sample 
contained 5.2 g CB, 5 ml saliva, 10 ml DH2O, while MG solution contained 5 ml saliva and 10 ml 
DH2O. These three samples were passed through the gastric and small intestinal phases of synthetic 
model gut as described in Chapter 4.  During the gastric phase of model gut digestion, 500 μl of 
MG solution alone and MG solution with either CB or AB was collected at different time points. 
Then, the samples taken from the gastric phase were titrated to pH 6-7 using 1M NaOH to stop 
enzymatic reactions. Following titration, the samples were centrifuged at 13,500 rpm for 10 
minutes to remove insoluble materials. After that, 500μl of the supernatant was added to 500μl 
deionised water and mixed. During the small intestinal phase, 500μl of the three samples were 
added to Eppendorf tubes containing 500μl methanol and vortexed. Next, the samples were placed 
in a freezer at -20 ºC for 30 minutes, and then centrifuged at 4100 rpm for 30 minutes at 4 ºC. The 
supernatant was removed, and the pellet was re-suspended in 4ml of DH2O. After that, 200μl of 
the samples was added to 96 well plates, and the PAS assay performed as described earlier. The 
absorbance of MG was subtracted from CB and AB absorbance. Then, the remaining CB 
absorbance was subtracted from the remaining AB absorbance. The amount and concentration of 
CC01 alginate that would be released from the complete digestion of 5.2g AB at the end of synthetic 
model gut was calculated as in equation 5.1. 
 
5.2g AB contains 4% by weight of CC01 alginate powder 
(5.2x4)/100= 0.208g x 1000= 208 mg at 180 minutes (the end of model gut) 
Total volume of solution at 180 minutes= 180 ml 
Concentration of alginate at 180 minutes = 208 mg/180ml = 1.16 mg/ml 
 





Figure 5.2. Bread digestion in the synthetic model gut system. Taken from Houghton, D., (2013)Water 
bath 1 contained gastric juice, porcine bile, and pancreatic juice. Water bath 2 contained three samples 
with saliva: alginate bread (AB), control bread CB, and model gut solution (MG). Gastric juice was added 
to each sample and then pumped into the samples via peristaltic pump for one hour. At the small intestinal 
phase, porcine bile was added to the samples, then the pancreatic juice was pumped into the samples for 
two hours. 
 
5.3.7 Digestion of fat substrates in combination with CB and AB in the synthetic model gut 
In this set of model gut experiments, two fat substrates (glyceryl trioctanoate and olive oil), and 
four samples (AB in combination with fat substrate, AB alone, CB in combination with fat substrate, 
and CB alone) were used. As described earlier in this chapter, the bread was cut into small pieces 
ranging between 2 and 4 cm, and the model gut samples were prepared as the following:  
 AB in combination with fat substrate consisted of 5.2 g AB, 5 ml saliva, 5 ml DH2O, and 
5 ml fat substrate (glyceryl trioctanoate or olive oil).   
 AB alone. It consisted of 5.2 g AB, 5 ml saliva, and 10 ml DH2O. 
 CB in combination with fat substrate consisted of 5.2 g CB, 5 ml saliva, 5 ml DH2O, and 
5 ml fat substrate (glyceryl trioctanoate or olive oil). 




Briefly, the samples were passed through the model gut system for three hours as described in 
Chapter 4 of this thesis, and 500 µl of each sample was taken at different time points of the gastric 
(0-60 minutes) phase and small intestinal phase (60-180 minutes) and added into Eppendorf tubes 
containing 500 µl of 10% (w/v) TCA (trichloroacetic acid) to stop enzymatic reactions. Then, the 
samples were kept at 4 ºC overnight. After that, the samples were centrifuged at 10,000 rpm for 10 
minutes, and the supernatants analysed using the glycerol assay as described in Chapter 4 to assess 
the glycerol liberated from fat digestion. The experiment was repeated six times. 
 
5.4 Statistical analysis 
The effectiveness of alginate incorporated into bread (AB) on  fat digestion in the model gut was 
assessed using Two-way Repeated ANOVA followed by a Post-Hoc Bonferroni test at a 
significance level (α) below 0.05 to compare between the alginate released from bread digestion at 
the gastric phase and small intestinal phase, to compare between the pH of the AB, CB and MG, 
and to compare between the amount of glycerol released from the digestion of fat substrates in 
combination with CB and the glycerol amount released from fat substrates in combination with 
AB. Data is shown as mean and standard deviation (SD), and the number of replicates is revealed 












5.5.1 Standard curve for mucin  
The standard curve of mucin in DH2O which was used as a positive control in the modified PAS 
assay is shown in Figure 5.3. The absorbance range was between 0-1.27 OD for 0-0.2 mg/ml mucin, 
with good linearity (R2=0.99). 
 
 
Figure 5.3. Standard curve for mucin in DH2O using the modified PAS assay. The values are mean ±SD 
(R2=0.99; n=6).  
5.5.2 Standard curve for alginate released in stomach and small intestine  
Graphs A and B of Figure 5.4 illustrate standard curves of alginate in MG solutions taken at 60 
minutes and 180 minutes of the gastric and small intestinal phases, respectively. The absorbance 
range for alginate in MG solution of gastric phase was between 0 and 0.52 OD for 0-0.25 mg/ml 
alginate with good linearity (R2=0.99), while the absorbance range for alginate in MG solution of 
small intestinal phase was between 0 and 0.23 OD for 0-0.25 mg/ml alginate with good linearity 





Figure 5.4. Standard curves for CC01 alginate in MG solution of (A) the gastric phase and (B) small 
intestinal phase using the PAS assay. The MG solutions were taken at 60 minutes (end of gastric phase) 
and 180 minutes (end of small intestinal phase) minutes of the model gut procedure to represent alginate 







5.5.3 Recovery of freeze-dried alginate in MG solution taken at the end of model gut 
The predicted and measured weights of freeze-dried alginate isolated at the end of the model gut 
are shown in Table 5.2. To test the efficiency of alginate recovery during the freeze dry process, 
5mg/ml alginate in MG solution taken at 180 minutes was prepared. This was diluted 1in 2 with 
methanol and freeze dried, following the procedure described in section 5.3.5, and the amount of 
recovered alginate weighed. For each ml of alginate solution, the expected yield after freeze drying 
would be 2.5 mg/ml if the process is 100% efficient. However, the mean measured weight of freeze-
dried alginate was 3.6 mg, higher than the predicted weight by 1.1 mg, and suggesting that other 
materials could be precipitated with the alginate. 
 
Replicate Predicted weight (mg) Measured weight (mg) Difference in weight (mg) 
First 2.5 3.1 + 0.6 
Second 2.5 3.7 + 1.2 
Third 2.5 4.0 + 1.5 
Mean 2.5 3.6 + 1.1 
Table 5.2. Predicted weight, measured weight, and the difference between predicted and measured 
weights for 5 mg/ml alginate in MG solution. The MG solution was taken at the end of small intestinal 
phase of model gut (at 180 minutes). 
5.5.4 Alginate released from bread digestion in the synthetic model gut 
Data from the digestion of AB within the synthetic model gut system is shown in Figure 5.5. It is 
obvious from the figure that the bread was digestible within the synthetic model gut, and the greater 
amount of alginate was released from digestion of bread in the small intestinal phase. According to 
the total amount of alginate (208 mg) that would be released if the AB was completely digested, 
10.6% (22 mg), 12.6% (26.2 mg), and 73.1% (152 mg) of the total alginate was liberated at 0.5, 
60, and 180 minutes, respectively. There was no significant difference between the amounts of 
alginate produced from AB digestion at 0.5 and 60 minutes of the gastric phase (P>0.05), however, 




that produced at 0.5, 30 and 60 minutes (P<0.05). 
 
 
Figure 5.5. Alginate produced from AB digestion in the stomach and small intestinal phases of the 
synthetic model gut. Values are mean ± SD (n=3), * shows that there was a significant difference between 
mean alginate produced from AB digestion at 180 minutes of the small intestinal phase and those 
produced at 0.5, 30, and 60 minutes of the stomach phase, P<0.05. The horizontal dotted line at 208 mg 
shows total amount of CC01 alginate present within the bread, while vertical dotted line shows stomach 
and small intestinal phases within the model gut system. 
 
5.5.5 pH measurements for CB, AB, and MG solution alone within the model gut system 
Figure 5.6 demonstrates the pH for AB, CB, and MG alone within the synthetic model gut system. 
The pH in the mouth was 7.8 (±0.22), 7.2 (±0.21), and 8.3 (±0.09) for AB, CB, and MG, 
respectively. In the mouth, the pH for MG was significantly higher (P<0.05) than those for AB and 
CB, also, the pH for AB was significantly higher than that for CB. However, after adding the gastric 
juice to start the stomach phase, there was a significant reduction (P<0.05) in the pH for all the 
three samples compared to the pH in the mouth where the pH reached 2.9 (±0.3), 2.6 (±0.06), and 
1.8 (±0.17) for AB, CB, and MG, respectively. During the first 15 minutes of stomach phase, there 




2.5 (±0.06) and 1.7 (±0.06) at 15 minutes, respectively. Then, the pH for the three samples 
decreased further for all samples reaching to 2.7 (±0.13), 2.2 (±0.09), and 1.6 (±0.07) at the end of 
the stomach phase (60-minute) for AB, CB, and MG, respectively. Also, Bonferroni’s test showed 
a significant difference (P<0.05) in mean pH values between AB and MG, and between CB and 
MG at 0.5 minutes of the stomach phase. In addition, there were significant differences between 
AB and CB, between AB and MG, and between CB and MG at 15, 30, and 60 minutes of the 
stomach phase (P<0.05). During the small intestinal phase, there was a significant increase in pH 
levels for all the three samples, reaching to 7.8 (±0.11), 7.7 (±0.06), and 8 (±0.06) for AB, CB, and 
MG, respectively, at the end of small intestinal phase (180-minute). However, there were no 




Figure 5.6. Mean pH for AB, CB, and MG throughout their digestion within the model gut system. The 
error bars are the standard deviation of three replicates (± SD; n=3), * indicates significant differences in 
pH. Horizontal lines show the stomach and small intestinal phases of the model gut system, P<0.05. 
5.5.6 Digestion of glyceryl trioctanoate in the presence of control and alginate bread 




synthetic model gut. During the gastric phase, only small quantities of glyceryl trioctanoate with 
either CB or AB were digestible. During the small intestinal phase, there was a gradual increase in 
the digestion of glyceryl trioctanoate with CB and AB reaching to 38.5 (±21.8) mg and 40 (±58) 
mg glycerol released at 180 minutes (the end of small intestinal phase), respectively. However, 
there was no significant difference (P>0.05) at any time points between the mean glycerol released 
from digestion of glyceryl trioctanaote with CB and that released from digestion of glyceryl 
trioctanoate with AB.   
 
 
Figure 5.7. Glycerol liberated during the digestion of glyceryl trioctanoate with either CB or AB in the 
synthetic model gut system. For the digestion within the model gut system, 5.2g of either CB or AB was 










5.5.7 Digestion of olive oil in the presence of control and alginate bread 
Figure 5.8 demonstrates the digestion of olive oil with CB and AB in the synthetic model gut. 
During the gastric phase, the amount of glycerol released from digestion of olive oil with AB was 
higher than that released from olive oil with CB, however, no significant difference was seen at 
any time point. During the small intestinal phase, higher amounts of olive oil with either CB or AB 
were digestible compared with the gastric phase, however, there was no significant difference 
between the amount of glycerol released from digestion of olive oil with AB and olive oil with CB 




Figure 5.8. Glycerol liberation during the digestion of olive oil with either CB or AB in the synthetic 
model gut system. For the digestion within the model gut system, 5.2g of either CB or AB was added to 









The results of the olive oil turbidity assay presented in Chapter 2 of this thesis shows that alginate 
CC01 inhibited pancreatic lipase enzyme activity in vitro by 75.6% (± 10.6) suggesting that CC01 
alginate could be used as a potential inhibitor for pancreatic lipase in vivo [122]. Additionally, the 
data from kinetic assay for pancreatic lipase presented in Chapter 3 showed that although all the 
tested alginates reduced the rate of lipase-catalysed reaction, showing these alginates as pancreatic 
lipase inhibitors, the highest inhibition was by CC01. Moreover, the data from model gut 
experiments of fat substrate digestion presented in Chapter 4 showed a significant reduction in 
digestion of fat substrates treated with CC01 alginate as compared with digestion of fat substrates 
alone. Additionally, earlier studies have reported that adding alginate into food showed beneficial 
effects (described in the introduction section of this chapter). Therefore, in this chapter, bread which 
is a very popular, acceptable and staple food consumed regularly in all parts of the world, was used 
as a delivery vehicle for alginate.  
Bread containing CC01 (AB) was passed through the synthetic model gut and the amount of 
alginate released measured using a modified version of PAS assay [187]. Furthermore, the pH for 
AB (alginate bread), CB (control bread), and MG (model gut) solution were measured at the 
salivary phase and at different time points of the gastric and small intestinal phases of model gut 
system to determine if the addition of bread significantly altered the pH particularly in the small 
intestinal phase as a change in pH could modify lipase activity. The effect of AB on digestion of 
fats containing triglycerides with different fatty acid chain length using the synthetic model gut 
was also investigated.  
Houghton et al. (2014) reported that quantifying alginate released in vitro using a synthetic model 
gut could be difficult due to the wide range of materials involved in the model gut system which 
may interfere with the technique used for alginate measuring and affect its efficiency in detecting 
alginate. Besides, it has been stated that alginate at pH less than pKa of the uronic acid residue 
(3.38 for mannuronic acid and 3.65 for guluronic acid) undergoes protonation and an acidic gel 
(alginic acid) could be formed [159, 212, 213]. The gel formation may affect coupling of alginate 
with any dye used, hence, reducing the amount of alginate bound to the dye [161]. In human, the 
pH ranges between 5-7 in mouth, while stomach pH ranges between 1 and 3. The gastric pH 




food ingestion. The pH in small intestine ranges between 6 and 7.5 [214]. Moreover, in the model 
gut, both porcine bile and pancreatic juice had been added at the small intestinal phase, thus, the 
colour of MG solution changed from transparent to a dark green/brown solution and that may 
influence the coloumertic assay used for alginate quantification [161].  
In this chapter, AB was used as a delivery vehicle for alginate. AB has to be digested to release the 
alginate and reduce fat digestion; therefore, AB was passed through the model gut at 37 °C and at 
optimum pH conditions identical to pH conditions in human body to enable bread digestion and 
alginate release. Wickham et al. (2009) reported that validity of any model gut in studying in vitro 
digestion requires ability of this model to mimic in vivo conditions and processing present in the 
mouth, stomach (cumulative to the mouth), and the duodenum (cumulative of mouth and stomach) 
[215]. The predominant ingredient of ingested bread is carbohydrates, and most of ingested 
carbohydrates are in the form of starch [216]. Starch digestion starts in the mouth by the action of 
salivary amylase, however, the role of salivary amylase in starch digestion is limited due to its 
inactivation by the acidic pH of gastric contents. The complete digestion of starch occurs in the 
small intestine by the action of pancreatic α-amylase and brush-border enzymes. Pancreatic α-
amylase cleaves interior 1-4 glycosidic bonds in starch, releasing three disaccharide molecules: α-
limited dextrins, maltose, and maltotriose. These disaccharides undergo further hydrolysis by α-
dextrinase, maltase, and sucrase to glucose (monosaccharides) which is then absorbed via epithelial 
cells of small intestine [217]. If the AB was digestible within the model gut, then, the alginate 
would be released, and an improved version of PAS assay [187] could be used here to measure it.  
Data presented here showed that the standard curve of mucin in DH2O, which was used as a positive 
control in PAS assay, was linear with an excellent linearity (R2=0.99), confirming a previous study 
in which the PAS assay was suggested as a simple, repeatable and sensitive method for detecting 
mucin and polysaccharides (Mantle & Allen, 1978). In addition, the data presented here indicated 
that standard curves of alginate in MG solution taken from the end of either gastric phase or small 
intestinal phase of the model gut both had excellent linearity (R2=0.99) with absorbance ranging 
between 0-0.52 OD and 0-0.23 OD for 0-25 mg/ml of alginate in MG solutions of gastric and small 
intestinal phases, respectively,  
 Mantle and Allen’s study in 1987 used the PAS staining method on glycogen and glycoproteins 




were PAS-positive, however, they noticed that sensitivity per mg of these substances relied on the 
level of oxidation by periodic acid. Among the three tested substances, glycogen was the most 
positive substance for PAS since all residues within glycogen were oxidizable by periodic acid, 
whereas the gastric glycoprotein positivity for PAS was the lowest because most of the sugar 
residues within the gastric glycoprotein linked via 1-3 glycosidic bonds are not oxidizable via 
periodic acid due to the absence of adjacent –OH groups. For the sugars to be oxidizable by periodic 
acid, they require the presence of adjacent -OH groups within their structure. In the PAS assay, the 
intensity of the red- magenta colour, which appears at the oxidizable carbohydrate sites where 
aldehydes are present, following the addition of Schiff reagent, relies on the number of neighboring 
–OH groups. Therefore, the higher quantities of glycoproteins will produce higher absorbance 
values.   
 Alginate is a polysaccharide consisting of two uronate sugars residues (D-mannuronic (M) acid 
and L-guluronic (G) acid) which are linked together via 1-4 glycosidic bonds. These uronate sugar 
residues are relatively comparable to the sugar residues of glycoprotein where both sugar residues 
of glycoprotein and uronate sugars of alginate have adjacent -OH groups in their structure. Uronate 
sugars of alginate have adjacent –OH groups at C1, C2, C3, and C4, suggesting that the PAS 
techniques may be used to measure amount of alginate in solution within the synthetic model gut 
system.  
The modified version of PAS assay (Mantle & Allen, 1978) was an accurate assay for alginate 
detection since the assay was able to measure alginate at relatively low concentrations [187]. 
Furthermore, data from the standard curves of alginate in MG solutions taken from the end of 
gastric and pancreatic phases presented in this chapter illustrated that the absorbance of alginate in 
MG solution of the gastric phase at any alginate concentration was higher than that of alginate in 
MG solution of the small intestinal phase. The lower absorbance of alginate in MG solution of 
small intestine could be because of alginate binding with other materials within the model gut 
system such as bile salts and acids which in turn reduces free release of alginate. Another reason 
for the low absorbance values for alginate in MG solution of small intestine compared to those for 
alginate in MG solution of gastric phase could be alginate degradability in acid condition, hence, 
the alginate in MG solution of gastric phase may become more PAS positive. The PAS results 
presented here confirmed data from a 2014 study by Houghton et al. which showed that the 




throughput method for alginate quantification compared with other cationic dyes DMMB, T-B, and 
S-O. In the original work, standard curves for alginate in deionised water using different 
concentrations of DMMB, S-O, and T-B in DH2O, and PAS assay were created to measure alginate 
[218] . It was found that only the PAS assay had the ability to measure alginate in DH2O at relatively 
low concentrations (0.0-0.5mg/ml), with a varied range of absorbance (0-0.45 OD) within the linear 
absorbance scale (0-1), showing the efficiency of the PAS assay in detecting alginate despite the 
possibility of interference that may arise from some materials within the model gut. However, 
Houghton stated that despite the ability of DMMB, S-O, and T-B cationic dyes to measure alginate, 
using these methods for measuring free alginate released from bread digestion within the model 
gut would be inappropriate since the standard curves of these methods showed either poor linearity 
or absorbance outside linear absorbance scale (0-1) [161, 218].  
The data presented here showed that the weight of recovered freeze dried alginate (3.6 mg) was 
higher than the predicted weight (2.5 mg) by 1.1 mg, indicating that even with the attempts to 
remove contaminating material by precipitation, centrifugation, and dilution processes as described 
in the method section of this chapter, some materials, possibly bile components (bile acids and 
salts), remain attached to the alginate. It has been reported that dietary fibres have high affinity to 
bind bile salts and acids [184, 185, 219]. Moreover, a study by Wang et al. in 2001 investigated the 
binding capability of soluble and insoluble dietary fibres from seaweeds with bile salts and found 
that although both types of dietary fibres had the ability to bind bile salts, the binding affinity of 
soluble dietary fibres with bile salts was higher than that of insoluble dietary fibres. Therefore, if 
the binding between alginate (soluble dietary fibre) and bile acids happened here, then this could 
be responsible for the lower absorbance of alginate in MG solution of small intestinal phase 
compared with absorbance of alginate in MG solution of stomach phase and could be also 
responsible for the excess weight of freeze-dried alginate. 
Furthermore, the data presented here showed a significant difference (P<0.05) in the amount of 
alginate released at 180 minutes (152 mg) and that released at 0.5 (22 mg) and 60 (26.2 mg) minutes, 
demonstrating that the AB was digestible within the synthetic model gut, and greater amounts of 
CC01 alginate were released from bread matrix in the small intestinal phase compared with the 
gastric phase. It is well-known that the digestion of carbohydrate, namely starch, which is the major 
form of carbohydrate, predominantly occurs in the small intestine by the action of pancreatic 




intestinal phase (73.1%) compared to the gastric phase (10.6%). The alginate incorporated into 
bread was 208 mg, however, only 73.1% of the alginate was released from AB digestion. The partial 
release of alginate could be because of alginate degradation and fragmentation due to high 
temperature during the cooking process. These alginate fragments might not be precipitated by 
methanol which was used here to precipitate the alginate as methanol has the ability to precipitate 
large polymers such as alginate. As a result, these small molecules (fragments) might not precipitate 
and therefore would be lost when the supernatant was removed.  
The effect of AB containing 4% of powdered alginate by weight (208 mg) on the digestion of fat 
substrates containing medium- and long- chain triglyceride was investigated in attempt to reduce 
triglyceride digestion. The amount of glycerol released here from fat digestion was assessed using 
the glycerol assay described in Chapter 4. 
The data presented here from glyceryl trioctanoate and olive oil in combination with either CB or 
AB showed that the amounts of glycerol released from digestion of glyceryl trioctanoate and olive 
oil in combination with CB during the gastric phase (0-60 minute) were negligible, however, during 
the small intestinal phase, higher amounts of glycerol were released, suggesting that triglyceride 
digestion predominantly takes place in the small intestine. This observation agrees with Carey et 
al. (1983) who reported that although triglyceride digestion starts in the stomach, 80-90% of its 
digestion takes place in the small intestine [220]. Also, Klein et al., (2006) stated that only 20% of 
triglyceride hydrolysis occurs in the stomach [164] . Moreover, Mu & Hoy (2004) reported that 
triglycerides are partially hydrolysed in the stomach by the action of gastric or lingual lipases which 
tend to breakdown ester bond at sn-3 producing 1, 2-diacylglycerides and fatty acids [110]. In 
addition, it has been reported that although triglyceride hydrolysis occurs predominantly in the 
lumen of the small intestine, triglycerides undergo  partial hydrolysis in stomach [221] , however, 
this would not be detected in the model gut system as it does not generate the free glycerol which 
is detected by the assay used here.  
As expected, digestion of glyceryl trioctanoate containing pure saturated medium-chain 
triglycerides was quicker than the digestion of olive oil containing a mixture of long to medium 
chain triglycerides with saturated and unsaturated fatty acids, a result that is consistent with 
previous studies showing that the digestion rate of fat substrates is dependent on fatty acid chain 




on triglyceride digestion rates were discussed in detail in Chapter 4 of this thesis.  
The data presented here also showed that  amounts of glycerol released from digestion of glyceryl 
trioctanoate (38.5 mg) and olive oil (17.1 mg) in combination with CB bread at the end of the small 
intestinal phase were lower than those released from digestion of glyceryl trioctanoate (59.6 mg) 
and olive oil (35.4 mg) alone (data presented in Chapter 4). The reduction in digestion of glyceryl 
trioctanoate and olive oil in combination with CB could be due to interaction of pancreatic lipase 
with some ingredients of bread, preventing substrate binding to the enzyme, or interaction of the 
substrate with the bread, preventing enzyme access to oil/water interface. Both interactions would 
slow enzyme-substrate binding and reduce triglyceride digestion rate.  
Additionally, the data available here indicated that AB did not reduce either glyceryl trioctanote or 
olive oil digestion. However, it was shown in Chapter 4 of this thesis that the dry powder CC01 
alginate (250 and 500 mg) added at the small intestinal phase, could significantly reduce olive oil 
digestion, and 500 mg of dry powder CC01 alginate added at the salivary phase could significantly 
decrease glyceryl trioctanoate digestion. Failure of alginate incorporated into bread in reducing fat 
digestion here could be due to alginate degradation, alginate concentration, or alginate binding with 
other substances within the model gut system. 
Triglyceride digestion occurs mainly in the small intestine by the action of pancreatic lipase.  The 
expected volume of MG solution at the beginning of small intestinal phase (T60) is 120 ml, and the 
amount of alginate incorporated into bread was 208 mg. Therefore, if the AB was completely 
digestible within the model gut and all the alginate incorporated into bread would be released, the 
predicted concentration of alginate released at the beginning of small intestinal phase would be 
1.73 mg/ml. However, this concentration is lower than the concentrations achieved with 250 and 
500 mg of dry powder alginate added to olive oil and glyceryl trioctanoate which correspond to 
2.08 and 4.16 mg/ml alginate, respectively. However, data available here from quantification of 
alginate released from the digestion of AB using PAS assay showed that about 73.1% of alginate 
incorporated into the bread was released in the small intestinal phase, suggesting that the AB was 
not completely digestible within the model gut system.  Alginate could interact with other substance 
within the model gut such as bile salts and acids, and this binding might be revealed from the excess 
weight of isolated free dried alginate here as shown earlier, and this could reduce free alginate 




Furthermore, alginate incorporated into bread may experience degradation for many reasons. 
Degradation of alginate may affect the essential properties of alginate such as viscosity and 
molecular size; subsequently, the effect of alginate as a pancreatic lipase inhibitor would be affected. 
One possible reason for alginate degradation could be pH.  Haug and his colleagues investigated 
the degradation of alginate extracted from Laminaria digitata at diverse pHs and reported that 
alginate remains stable at pH 5 to 10. The same authors reported that at pH less than 5, alginate 
undergoes degradation via proton-catalysed hydrolysis, while at pH more than 10, alginate 
undergoes degradation through β-alkoxy-elimination [222]. Lee & Mooney (2012) showed a 
negative correlation between alginate viscosity and pH where alginate viscosity increases as pH 
decreases, and the alginate solution becomes highly viscous at pH between 3 and 3.5. However, at 
pH below 3, the carboxyl groups in the alginate backbone undergo protonation and hydrogen bonds 
are formed [100]. The data presented here showed that the pH for AB at the salivary phase was 7.8, 
however, the pH rapidly declined to 2.9 following the addition of gastric juice, and 2.7 at the end 
of the gastric phase, suggesting that alginate may undergo proton-catalysed hydrolysis. 
Subsequently, the glycosidic bond linking alginate sugar monomers together would be broken 
down, hence, the viscosity of alginate will be reduced. Houghton and his colleagues (2015) 
reported that exposing alginate in DH2O to the alterations in pH values over the same time course 
as the model gut system caused a 70% drop in viscosity where the specific viscosity decreased 
from 9.9 to 2.8 [223]. However, the possibility of alginate degradation because of low pH is not 
thought to be reasonable here, as only a slight amount of alginate was released in the gastric phase. 
This observation was expected since the digestion of bread occurs predominantly in the small 
intestine. The pH measurements for AB within the model gut showed that the pH for AB at the 
beginning of the small intestinal phase was greater than 5, indicating the possibility of 
fragmentation of alginate incorporated into bread here due to low pH was not likely to occur.  
Commercially available alginates usually contain trace quantities of phenolic compounds which 
can stimulate oxidative-reductive reactions. Therefore, alginates may experience depolymerisation 
and fragmentation at neutral pH due to the effect of these phenolic compounds [181]. However, 
while this is a possibility, it is unlikely to be the explanation in these experiments because the 1H 
NMR spectra of CC01 alginate within the shaded region show that there is no evidence for the 





The chemical shift in ppm for polyphenol peaks is in the regions from 7.8 to 6 and 4 to 3 [224], 
and the peaks which are used for alginate determination are in the regions between 5.2 and 4.3. 
Therefore, no polyphenolic compounds were detected within the alginate sample.   
Alginate and other polymers can undergo fragmentation by reactive oxygen species (ROS) such as 
the hydroxyl radical (∙OH), which can be formed from oxygen or water molecules. Glycosidic 
bonds linking uronate monomers of alginate polymer can be cleaved by this radical ROS through 
an oxidative-reductive depolymerisation reaction, producing smaller fragments of alginate. Metal 
ions such as Cu++ and Fe++/Fe+++ have great affinity to alginate and may accumulate during the 
production and processing of alginate. These ions can catalyse the formation of ROS through the 
Fenton reaction, therefore, they must be removed from alginate to produce highly pure alginate 
[225]. Alginate incorporated into bread may undergo fragmentation through this type of reaction 
due to the presence of iron (Fe) in the bread flour or alginate itself. Based on the current UK bread 
and flour regulations, iron must be added to several foods including flour where each 100 g must 
have up to 1.65 mg of iron added as powdered iron, ferric ammonium citrate or ferrous sulphate 
[226]. The presence of such catalytic metal in bread flour can stimulate oxidative-reductive 
depolymerisation. 
 Another possible explanation for alginate degradation could be the high temperature during the 
baking process. AB is exposed to temperature up to 120 ºC for 65 minutes during baking process, 
and this may result in degradation of alginate. Hasatani and his colleagues (1991) studied the 
influence of different methods of bread baking and could determine the temperature of different 
parts of bread [227]. They reported that the temperature at the central part of the loaf may only 
range between 70 to 80 ºC, while the temperature of crust may range between 180 to 200 ºC. 
However, the accurate temperature of whole loaf of bread in the present study was not measured 
here. Breaking down alginate polymers into smaller fragments will affect the viscosity of alginate.   
The viscosity of alginate has been suggested as the mechanism by which alginates reduce digestive 
enzyme activity. This viscosity is influenced by many physical factors such as temperature, alginate 
concentration, polymer size, shear rate, the existence of water miscible solvents, and chemical 
factors such as pH, sequestrants, polyvalent cations and monovalent salts [228]. Lacík (2004)  
reported that the viscosity of a polymeric solution can be increased by increasing polymer 




Houghton et al’s study (2015) indicated that the viscosity of free alginate (0.91, ±0.41)1 added as 
a powder at time zero of the model gut, at the same concentration which would be expected to be 
liberated from alginate bread (AB) at the end of digestion in the model gut, was higher than the 
actualviscosity of AB (0.42, ±0.01) after passing through the model gut system, suggesting that the 
bread process decreased the capacity of alginate to form a viscous solution [223]. Moreover, 
Houghton et al compared viscosities of model gut solutions and CB where alginate was added 
either at the start or the end of model gut process. When the alginate was added at the end of the 
process, viscosity was greater in both model gut solution and CB than when it was added at the 
start of the process (viscosity of model gut solution with alginate added at end= 2.96 ±0.71, 
viscosity of model gut solution with alginate added at the start= 0.91 ±0.41; viscosity of CB with 
alginate added at the end= 2.88 ± 0.57, viscosity of CB with alginate added at the end= 0.42 ±0.01. 
Indicating that passing alginate through the model gut system either as free alginate (powder) or 
incorporating into bread attenuates alginate’s ability to form a viscous solution.  
Additionally, the Houghton et al’s study (2015) on the impact of different temperatures on alginate 
viscosity revealed that the viscosity of alginates LFR 5/60, and DM SF200 after heating at 37, 50, 
or 100 °C for 30 minutes was constant [223]. However, the viscosity of alginate solution 
significantly decreased after heating at 150°C for 30 minutes and approached zero after heating at 
200 °C for 30 minutes, demonstrating that alginate chains experienced extensive fragmentation. 







1. The viscosity is expressed in a unitless form as it is viscosity (ηsp) of sample divided by the viscosity (ηsp) 




McDowell (1961) and Leo et al. (1990) have demonstrated that alginate may undergo 
depolymerisation when exposed to temperatures more than 100 ºC. McDowell (1961) showed 
alginate exposed to a temperature around 200°C, will be extensively degraded and CO2 will be 
rapidly produced from the uronic acids [230, 231]. Blackburn (2005) stated that viscosity of 
alginate decreases as the temperature increases, and high temperature may result in 
depolymerisation of alginate [232]. Also, Qin (2018) reported that exposing alginate to 
temperatures of more than 50 ºC for many hours may result in depolymerisation of polymer causing 
a permeant reduction in viscosity and molecular weight [233]. 
Alginate forms acidic gels at pH below the pKa of uronic acid [159, 213], and forms ionic gels in 
the presence of multi-valent cations such as Ca2+ due to the interaction between Ca2+ and guluronate 
in the alginate backbone, producing the egg-box model. Alginate with a high content of G-blocks 
can form stronger gels than that produced by alginate low in G-block, and the gel strength plays a 
crucial role in gastric emptying, gel breakdown and transport of nutrients to small intestine [202, 
234, 235]. Alginate has been used in industry, pharmacology and medicine, and these applications 
are reviewed elsewhere [236]. Although large amounts of seaweeds are eaten in South East Asia, 
alginate and other algal phycocolloids (carrageenan and agar) are used mostly as emulsifying, 
stabilising and thickening agents in the food industry in the Western world (Brownlee et al., 2005). 
It has been reported that consuming meals rich in alginate slows macronutrient digestion and 
decreases appetite due to the high viscosity of alginate produced from its gelation at the acidic pH 
in stomach [10, 85, 103, 201, 237]. Jensen et al’s study in 2012 stated that there is a reduction by 
6.78 (±3.67) kg in body weight of obese subjects following drinking a strong-gelling sodium 
alginate beverage, which is rich in guluronate, in combination with calorie-limited diet before main 
meals compared with a reduction of 5.04 (±3.40) kg in obese subjects who consumed placebo 
beverage in combination with calorie-limited diet [238]. Paxman and her colleagues (2008) and 
Kristensen & Jensen (2011) reported that the mechanisms for the influence of sodium alginate 
fibres in conjunction with calcium involved alterations in critical physical characteristics such as 
viscosity, gel production, and alterations of stomach contents, hence these alterations may decrease 
gastric clearance and attenuate absorption of nutrients in the small intestine, reduce postprandial 
glucose and insulin responses, which ultimately enhance the sense of fullness [10, 85]. The same 
authors stated that capability of alginate to produce both acidic and ionic gels may account for a 




and subsequently, nutrients digestion and absorption will be reduced [85, 238]. It has been stated 
that solid meals may have a considerable influence on satiety more than liquid meals of the same 
size and number of calories because the solid meals can attenuate gastric emptying and expand the 
antrum which will send signal of increased satiety through tension receptors [202]. However, high-
viscosity beverages or beverages containing unbreakable solids (lumps) have an unpleasant taste 
and became unpalatable, therefore, it has been suggested to use a meal which has the capability to 
form a viscous/gel solution immediately in the presence of gastric acid in the stomach [202].   
Even though viscosity has been suggested as the mechanism by which alginate may reduce gastric 
emptying, reduce hunger, increase the sense of satiety, and slow macronutrient digestion and 
absorption, the viscosity may pose a problem for alginate in term of poor acceptability [238]. It has 
been shown that highly viscous meals containing strong-gelling alginate or guar are less acceptable 
since such high molecular weight biopolymers form a viscous solution on hydration which may be 
slimy in the mouth, hence their products become undesirable [202]. It has also been reported that 
consumption of diets containing alginate may cause abdominal pain, nausea, mild diarrhea, and 
unpleasant taste [238], and it has been indicated that adding large amounts of alginate to food may 
slow absorption of some beneficial minerals and nutrients such as calcium, iron, cobalt, chromium, 
and β-carotene [236, 239-241]. Additionally, a study by Jensen, Kristensen, & and Astrup (2012) 
indicated that subjects who ingested diets containing sodium alginate experienced an increase in 
blood pressure compared with the control group [238].  
Although viscosity has been suggested to be the mechanism by which dietary fibres reduce 
digestive enzyme activity in vitro [200, 201], the Wilcox et al. (2014) and Houghton et al. (2015) 
studies reported that viscosity was not responsible for the reduction in pancreatic lipase activity in 
a turbidity assay. Houghton and his colleagues reported that alginate may inhibit pancreatic lipase 
in a similar way to that pectin inhibits pancreatic lipase, in which serine and histidine residues at 
the enzyme active site are protonated, preventing enzyme binding with substrate [144]. In the 
original work, Houghton investigated the effect of temperature and concentration on the inhibitory 
effect of alginate (DM) isolated from alginate bread using a turbidity assay and olive oil as a 
substrate. They observed that despite the significant reduction in viscosity (78%) of isolated 
alginate upon heating at 150°C, this alginate at concentrations 3 and 2 mg/ml was still able to 
decrease pancreatic lipase activity in vitro by 35% and 18%, respectively, compared with 33 and 




significant reduction by 88% in the inhibitory properties of the isolated alginate following heating 
at 200 °C, showing that such high temperature (200°C) seems to induce a significant change in 
alginate structure which is crucial for gel formation and inhibitory effects [218, 223]. Houghton et 
al also showed that freeze-dried alginate isolated from alginate bread was able to reduce pancreatic 
lipase activity in vitro, indicating that the cooking and baking processes did not affect the inhibitory 
properties of alginate as a pancreatic lipase inhibitor. In contrast, the AB used in this study did not 
inhibit pancreatic lipase activity. The AB used here was cooked using an alternative method of 
baking in which the AB was cooked for 65 minutes. However, the AB used in Houghton et al. study 
was made by Greggs, a commercial baker, using the Chorleywood bread process in which the AB 
was cooked for a shorter time (17-25 minutes), Therefore, less breakdown of the alginate would be 
expected. This was an unexpected result. It was not anticipated that changing the production 
method would alter the inhibitory properties of alginate and the mechanism requires investigation. 
For alginate to be a useful additive to foods, how it is altered by food production processes needs 
to be known. 
Alginate rich in G-blocks reduces pancreatic lipase activity in vitro more than alginate rich in M-
block [72, 223]. In addition, alginate with a high content of G-block forms stronger gel than alginate 
with low content of G-blocks, and the gel strength is essential in gastric clearance, gel breakdown, 
and food transport into small intestine [202, 234, 242].  
Another potential explanation for the failure of alginate incorporated into bread in reducing 
triglyceride digestion could be that alginate degradation reduces the steric hindrance effect which 
in turn affects the inhibitory effect of alginate. Large alginate polymers may bind to the substrate 
binding site of the enzyme or to the oil/water surface of the substrate, blocking the substrate access 
to the enzyme or the enzyme entry to the substrate, preventing the formation of the E-S complex, 
subsequently, inhibiting triglyceride digestion (Figure 5.9A). However, if the alginate undergoes 
degradation, smaller fragments of alginate would be produced which in turn reduces the steric 
hindrance, where these small fragments can easily diffuse in and out of the active site of the enzyme, 
hence, the substrate can bind to the enzyme forming the E-S complex.  Also, the binding of these 
fragments to the oil/water surface of the substrate will not affect the access of the enzyme to the 






Figure 5.9. Schematic diagram showing the effects of size on the inhibitory properties of alginate as a 
pancreatic lipase inhibitor. Triglycerides substrate consists of glycerol and three fatty acids (FA1, FA2, and 
FA3). A. Alginate as a large polymer can bind to both the enzyme and substrate. Alginate can bind to the 
substrate binding site of the enzyme, blocking the access of the substrate to the enzyme. Alginate can also 
bind to the substrate interface (oil/water interface), preventing the access of the enzyme to the substrate 
interface due to the steric hindrance of alginate. Subsequently, the E-S complex will be inhibited, and the 
products will not be formed. B. Alginate fragments can bind to the enzyme or substrate; however, the 
steric hindrance effect of these small molecules is much less. Thus, the substrate can bind to the enzyme 
and E-S complex can be formed. Also, the binding of these fragments to the substrate interface will not 
prevent the formation of E-S complex.      
 
Even though there is limited data on fibres incorporated into food and their capability to reduce 
pancreatic lipase activity [223], other fibres could significantly reduce pancreatic lipase activity in 
vitro such as pectin [141] and chitosan [150]. The exact mechanism by which alginate can inhibit 
pancreatic lipase activity is still unknown, however, several mechanisms have been suggested and 
some of them involve substrate-enzyme binding [72, 243]. These mechanisms were described in 





The data described in this chapter showed that the modified version of the PAS assay [187] could 
be used to detect alginate produced from AB digestion in the model gut system. Standard curve 
data for alginate in MG solution of stomach phase and alginate in MG solution of small intestinal 
phase confirmed that PAS is an efficient and sensitive protocol in quantifying alginate since the 
linearity for both curves was excellent, and the protocol succeed in measuring alginate at relatively 
lower concentrations, and this finding is in agreement with previous findings [187, 223]. 
Furthermore, the AB used here was digestible within the model gut, supporting the ability of the 
synthetic model gut to mimic the digestive processes in the human body from mouth to small 
intestine. Also, the measured pHs at the salivary, stomach, and small intestinal phases of the 
synthetic model gut were similar to in vivo pHs.  
The majority of alginate released from AB digestion was in the small intestine, however, the 
alginate released from bread digestion did not reduce fat digestion through the synthetic model gut, 
and that could be due to alginate degradation, alginate concentration used, or alginate interacting 
with other materials such as bile. Alginate degradation may result from proton-catalysed hydrolysis 
(pH<3), thermal degradation (high temperature during baking process), or fragmentation due to the 
presence of phenolic compounds in alginate which stimulate oxidative-reductive reactions. Also, 
binding between alginate and other substances within the model gut such as bile may affect the 
amount of alginate available in the solution. In addition, failure of alginate in reducing fat digestion 
could be associated with the presence of bread in the model gut system. Alginate degradation may 
even induce some alterations in alginate structure which in turn impact alginate capability in gel 
formation and inhibiting digestive enzymes activity in vitro. All these factors may affect regulatory 









Chapter 6:  General Discussion 
Obesity has become a serious and common problem which potentially threatens public health and 
increases health care expenditure in the developed and developing countries. Some chronic 
diseases such as heart disease, type 2 diabetes, hypertension, non-alcoholic fatty liver disease 
(NFLD), and some types of cancer may develop from obesity [244]. Obesity is due to accumulation 
of body fat in adipose tissue, where individuals with BMI above 30 kg/m2 can be considered as 
obese and that can be confirmed by an increase in the waist circumference [245]. Factors such as 
consumption of large amounts of food, lack of physical activity and some inherited diseases can be 
associated with obesity development.  
It has been reported that the majority of excess caloric intake comes from the digestion and 
absorption of dietary lipids. Therefore, pancreatic lipase which is the main enzyme responsible for 
dietary lipid digestion and absorption becomes a potential target for obesity treatment where many 
anti-obesity drugs that aim to reduce lipid digestion and absorption have been developed to inhibit 
its activity [77].  
Marine seaweeds have numerous beneficial effects on health since they are rich in dietary fibres 
which are indigestible in the upper gut. Marine seaweeds have been considered to form a 
prospective source of bioactive compounds with anti-obesity properties (Hu et al., 2016). The 
majority of these bioactive compounds are extracted from marine algae, mainly brown seaweeds 
[246]. Algal bioactive alginate is an indigestible polysaccharide which exists in the cell wall and 
intercellular space of brown algae (Phyophyceae), also, some bacterial species such as Azotobacter 
and Pseudomonas genii can produce alginate as a constituent of their extracellular matrix [115, 
116].  
Beside the various applications of alginate in medicine and pharmacology as prebiotics, 
antibacterial agents, antiviral agents and non-toxic antioxidants, and in industry as stabilising, 
thickening, and emulsifying agents [94], earlier studies showed that some alginates could be used 
as inhibitors for digestive enzymes responsible for macromolecule digestion such as pepsin [107, 
108, 243] and pancreatic lipase [72, 192, 209]. This suggests a use for alginate as an inhibitor for 
pepsin and pancreatic lipase in vivo to reduce protein and fat digestion and absorption, subsequently, 




In this study, the regulatory effect of alginate on pancreatic lipase and fat digestion were 
investigated using three methods: a turbidimetric assay, a kinetic assay, and a synthetic model gut 
system.   
 
6.1 Lipase regulation by alginate 
In this study, data obtained from the turbidimetric lipase activity assay in which olive oil was used 
as a substrate showed that all the alginates used here could inhibit the activity of pancreatic lipase 
in vitro and the inhibition in lipase activity caused by different alginates was dependent on the 
structure and concentration of these polymers. Data obtained from the turbidimetric assay and 
1HNMR analysis for CC01, 1N80 and 1LF80 alginates showed that CC01, which contained the 
highest number of G blocks, could reduce the activity of pancreatic lipase to the greatest extent 
(75.6%) compared with other alginates, indicating that alginates with high content of G blocks 
could potentially reduce the activity of pancreatic lipase more than alginate with high content of M 
block. Also, higher concentrations of alginate caused a significant reduction in lipase activity 
compared to lower concentrations of alginate. These results are compatible with earlier results from 
Wilcox et al. (2014) who reported that the alginate could reduce activity of pancreatic lipase in 
vitro by 72.2% with DGGR (a synthetic substrate) and by 58% with olive oil (a natural substrate), 
and the extent of inhibition of lipase activity relied on the concentration and chemical structure of 
the alginate [72]. Wilcox and his colleagues found that alginate rich in G blocks could significantly 
inhibit the activity of pancreatic lipase more than alginate rich in M residues. Also, they found that 
the level of inhibition of lipase produced by alginate was dose dependent, where increasing the 
alginate concentration increased the inhibition level of lipase [72]. However, in the same study, 
Wilcox and his colleagues found that inhibitory effect of alginate was unaffected by the viscosity 
and molecular weight of the alginate. The results described herein in addition to previous results 
from the Wilcox et al. study (2014) suggested that alginates could be used as pancreatic lipase 
inhibitors in vivo to reduce triglyceride digestion and absorption, thus, reduce caloric intake and 
manage body weight. Therefore, the activity of pancreatic lipase might be modulated to a variable 





6.2 Kinetic assay of lipase activity 
Kinetic parameters from the Michaelis-Menten plots presented in Chapter 3 of this study indicated 
that the presence of alginate in the reaction mixture allowed the lipase-catalysed reaction to 
approach the Vmax at lower value compared to the Vmax of control reaction in which alginate was 
not present. Also, the reduction in reaction velocity was dependent on the alginate structure, where 
alginate rich in G blocks could significantly decrease the velocity of lipase-catalysed reaction more 
than alginate rich in M blocks, showing that alginate had anti-pancreatic lipase activity which was 
dependent on the chemical structure of alginate.  
In addition, the kinetic information produced from Lineweaver-Burk plots showed all three tested 
alginates acted as mixed inhibitors where they could bind to both the free enzyme and the enzyme-
substrate complex with different binding affinities  
Several mechanisms have been suggested for lipase inhibition by alginate, however, the exact 
mechanism by which alginate can inhibit pancreatic lipase is still unknown. Alginate can interact 
with the free enzyme and the substrate. Alginate has been shown to interact with the protein 
segment of a glycoprotein namely mucin and the presence of G residue is very important factor for 
this interaction where alginate rich in M residue would not interact with the mucin [139]. Alginate 
also may inhibit pancreatic lipase through protonation of hydroxyl (-OH) group of serine residues 
at the active site of the enzyme by the carboxyl (-COOH) group of the G blocks of alginate, 
reducing or stopping the proton shuttle mechanism which is a very important mechanism for the 
catalytic action of pancreatic lipase as described in Chapter 1 (Figure 1.6). This is believed to be 
the mechanism by which pectin inhibits the pancreatic lipase activity. It is therefore important to 
note that the carboxyl groups of pectin are at positions similar to the carboxyl groups of G residues 
of alginate (Figure 2.10 in Chapter 2 of this thesis) [72, 144]. Moreover, alginate could interact 
with the water/oil interface of the substrate, reducing the enzyme access to the substrate and 
decreasing formation of enzyme-substrate complex which in turn decreases the formation of 
product.  This is reported to be the mechanism by which other anti-pancreatic lipase inhibitors such 





6.3 Fat digestion within the synthetic model gut system 
Three different fat substrates (glyceryl trioctanoate, olive oil, and sunflower oil) were passed 
through the synthetic model gut system, and the amount of glycerol, which is a product released 
from fat digestion, was quantified. The data obtained from the digestion of the fat substrate showed 
that all the substrates were digestible within the synthetic model gut, however, the majority of 
substrate digestion occurred in the small intestinal phase by the action of pancreatic lipase. This 
finding is supported by previous finding [110, 164, 165, 167]. The digestion of fat substrates 
showed that the synthetic model gut used here was able to mimic in vivo gastrointestinal digestion 
of fat.  
However, the digestion rates of fat substrates varied depending on the chain length of fatty acids 
of the triglyceride components of the fat substrates as well as the degree of saturation of these fatty 
acids. It has been reported that lipases preferentially hydrolyse short and medium chain 
triglycerides more than long-chain triglycerides [134, 175, 176]. The digestion rate of glyceryl 
trioctanoate containing saturated medium-chain triglycerides (octanoic acid) was the quickest. 
However, digestion of olive oil containing a mixture of triglycerides with medium- and long-chain 
triglycerides containing mostly palmitic acid (C16:0, saturated fatty acid,) and oleic acid (C18:1, 
monounsaturated fatty acid) was quicker than the digestion rate of sunflower oil consisting mainly 
of triglycerides containing long-chain polyunsaturated fatty acids (linoleic acids, C18:2). 
Consequently, these triglycerides may bind differently to the active site of enzyme because unlike 
the free rotation around the single bond, the rotation around the double bond is hindered.  
Furthermore, 500 mg of alginate passed through the gastric phase of model gut was able to reduce 
glyceryl trioctanoate digestion with different levels of inhibition depending on the alginate content 
of G blocks. However, alginate passed through the gastric phase had no effect on olive oil or 
sunflower oil digestion and this appears to be due to alginate gelling caused by acidic pH during 
the gastric phase or because of CaCl2 present in the synthetic saliva, hence, creating an ionic gel 
(calcium-alginate gel). Alginate can produce an acidic gel at low pH [103, 177, 202].  Additionally, 
it has been reported that alginate produces highly viscous acid-gels at pH less than the pKa of its 
uronic acids (3.5) [179, 183]. Besides, alginate produces an ionic gel in the presence of cationic 
ions such Ca2+ [100, 103, 180]. Alginate containing a high fraction of G blocks produces strong 




160]. Gel formation might affect inhibitory properties of alginate since it will reduce the amount 
of free alginate within the reaction mixture, subsequently, the potency of alginate as a pancreatic 
lipase inhibitor will be reduced because the inhibition of pancreatic lipase by alginate is 
concentration-dependent.   
However, alginates added after 10 minutes of the small intestinal phase could inhibit olive oil 
digestion, and that might be because the pH values within the small intestinal phase, which ranged 
between 4.5 and 4.7, was higher than the pKa of uronic acids (3.5) of alginate, hence, no gel was 
formed, allowing the free release of alginate within the reaction mixture to reduce fat digestion. In 
addition, it was found that 500 mg CC01 added at the small intestinal phase could reduce the 
digestion rate of olive oil to level much greater than that caused by 250 mg CC01, showing that 
inhibition effects of alginate are affected by alginate concentration. Wilcox et al. (2014) reported 
that specific alginates could inhibit pancreatic lipase activity in vitro, and the inhibition level of 
lipase caused by alginates were dependent on alginate concentrations [72].   
Higher amounts of alginate (1000 mg) added either at the salivary phase or added after 10 minutes 
of the small intestinal phase appears to activate lipase, increasing the digestion of olive oil. The 
apparent activation in the digestion rate of olive oil treated with 1000 mg of alginate could be due 
to gel formation caused by low pH in the gastric phase (acidic gel) or the presence of Ca2+ ions in 
the saliva (ionic gel). The gel will bind a lot of water which will mean that the remaining solution 
will have less volume, thus, the enzyme-substrate concentrations in solution will be higher, leading 
to activation of triglyceride digestion. The gel produced from 1000 mg of alginate was larger than 
that produced from lower amounts of alginate (500 or 250 mg), thus, the larger the gel, the higher 
potential to bind higher amounts of water, causing more increases in the enzyme-substrate 
concentrations. This could explain the apparent activation in the digestion rate of triglycerides 
treated with 1000 mg alginate added at the salivary phase. Another possible explanation for the 
apparent increase in the digestion rate of olive oil treated with 1000 mg alginate added either at the 
salivary or small intestinal phase could be the effect of different affinity of alginate to triglycerides 
containing fatty acids with different degrees of saturation. Olive oil consists of a mixture of 
saturated and monounsaturated medium- and long- chain triglycerides, and as mentioned early, 
lipases show different binding affinity for different triglycerides containing different fatty acids 
with different chain length and different degrees of saturation. Thus, during the digestion of olive 




Therefore, the digestion rate of olive oil treated with 1000 mg of alginate might be accelerated 
because alginate may prefer binding to triglycerides containing long and unsaturated fatty acids, 
preventing these triglycerides binding with lipases, allowing hydrolysis of saturated triglycerides 
with shorter fatty acids by lipases, and accelerating the reaction rate. Further investigation of this 
hypothesis is needed.  
In other studies, a synthetic saliva containing higher concentration of NaHCO3 (372 mM) instead 
of normal saliva (62 mM) was used in an attempt to buffer the gastric pH in the model gut and 
prevent or reduce the gelling of alginate through the gastric phase. The data showed that the 
digestion rate of olive oil treated with buffered saliva was significantly less than the digestion rate 
of olive oil treated with normal saliva. Also, the pH measurements for olive oil treated with buffered 
and normal saliva showed that the gastric pH values for olive oil treated with buffered saliva were 
significantly higher than the gastric pH for olive oil treated with normal saliva, however, no 
significant difference was detected between the pH values for olive oil treated with buffered saliva 
and the pH for olive oil treated with normal saliva in the small intestinal phase, indicating that 
reduction in the digestion of olive oil treated with buffered saliva was not caused by a pH change. 
A possible reason for the reduction in the digestion of olive oil treated with buffered saliva could 
be the binding of calcium to bicarbonate through a cation exchange. As a result, the concentration 
of calcium ions in the reaction mixture will be reduced, hence, the activity of pancreatic lipase will 
be affected. Previous studies showed that the presence of calcium ions is essential for the activity 
of pancreatic lipase. Calcium ions could decrease the lag phase by reducing the electrostatic 
repulsion between the lipase and the surface of emulsion, facilitating the penetration of the enzyme 
to the emulsion interface [55]. Also, calcium ions can precipitate with free fatty acids, which are 
the products of triglycerides hydrolysis, removing them from the substrate surface and preventing 
the inhibition of pancreatic lipase caused by their accumulation at the substrate surface [56, 59].    
The amount of glycerol released during olive oil digestion treated with alginate in combination 
with buffered saliva containing 372mM NaHCO3 passed through the gastric phase was lower than 
that released from olive oil treated with alginate in combination with normal saliva containing 
62mM NaHCO3. The reduction in digestion of olive oil treated with alginate and buffered saliva 
could be because the buffered saliva provided pH values in the gastric phase higher than the pKa 
of uornic acids (3.5), hence, the gelling effect of alginate caused by acidic pH was reduced. Another 




insoluble calcium bicarbonate, consequently, the amount of free calcium ions in the reaction 
mixture would be reduced, resulting in less binding between the calcium ions and the alginate, thus, 
less gel would be formed. 
 
6.4 Digestion of alginate bread in the synthetic model gut system 
Several in vivo studies indicated that adding alginate into beverages or cereals resulted in valuable 
effects on health such as reducing the levels of glucose and insulin the in blood [114, 247], 
increased excretion of fat and bile acids [106], promoting weight loss [238], increasing satiety and 
reducing caloric intake [202, 238] and decreasing hunger [247]. Alginate can produce both an 
acidic and ionic gel [202, 203]. The ability of alginate to produce a viscous/gel solution is an 
important factor in the gastrointestinal signals that reduces hunger, increases feeling of satiety and 
reduce energy consumption [82, 202]. However, the ability of alginate to form a gel could be 
responsible for the poor acceptability of products containing alginate due the slimy feel in the 
mouth which makes it difficult to consume alginate-contained products every day. However, a 
previous ileostomy study in this lab showed that individuals involved in the study favoured the 
bread rich in alginate (4%) more than the alginate-free bread (control bread), showing that bread 
rich in alginate could abolish the issue of poor acceptability, and suggesting alginate bread as a  
palatable product which may be consumed every day [248] . Due to the worldwide acceptability 
and popularity of bread as a basic food which is consumed on a daily basis [204], bread was chosen 
in this study as a vehicle to deliver the CC01 alginate bioactive, which had the highest inhibitory 
effect based on the data obtained from both turbidimetric and kinetic assays for pancreatic lipase 
in this study, in an attempt to reduce pancreatic lipase activity, and thus triglyceride digestion and 
absorption. Alginate bread used here had to be passed through the synthetic model gut system and 
the alginate released had to be measured to investigate whether the alginate bread was digestible 
allowing the alginate to be released and reduce triglyceride digestion. 
In this study, the standard curves for both alginate in MG solution taken from the end of the gastric 
phase (0-0.25 mg/ml) and alginate in MG solution taken from the end of the small intestinal phase 
(0-0.25 mg/ml) showed the accuracy of the modified PAS assay in measuring alginate in samples 
taken from the model gut even at relatively low concentrations. These results agree with previous 




glycoprotein and alginate [187, 223]. Also, alginate bread (AB) used here was shown to be 
digestible within the synthetic model gut and the bread digestion took place mainly in the small 
intestinal phase where the data from PAS assay showed that 73% of alginate was released in the 
small intestinal phase compared to 11% of alginate released in the gastric phase, demonstrating 
that the synthetic model gut used here could imitate digestive process of the upper part of the 
gastrointestinal tract in vivo. However, the data showed that about 16% of alginate incorporated 
into the bread was not measurable, suggesting that alginate might bind to other materials within 
the model gut system such as bile salts. Previous studies reported that alginates have high binding 
affinity to bile salts and acids [184, 185]. Although 73% of alginate incorporated to bread was 
released in the small intestinal phase where triglyceride digestion mainly occurs, the digestion of 
triglyceride in combination with AB was not reduced, showing that alginate incorporated into bread 
could not reduce the activity of pancreatic lipase. This could be because of alginate fragmentation 
caused by high temperature during the cooking process where the alginate was exposed to a 
temperature around 120 °C for 65 minutes. McDowell (1961) and Leo et al. (1990) reported that 
alginate polymers will experience an intensive fragmentation accompanied with the rapid release 
of CO2 from the uronic acids constituents of alginate when the polymer is subjected to a 
temperature greater than 100°C [230, 231]. Also, the alginate might contain some phenolic 
compounds which could cause degradation and fragmentation of alginate polymer. It has been 
stated that some phenolic compounds could be present in the commercial alginate, and these 
compounds enhance oxidative-reductive reactions which results in alginate fragmentation [181].  
In addition, alginate might undergo fragmentation via proton-catalysed reactions due to low pH in 
the stomach phase. Haug et al., (1963) reported that at pH below 5 alginate polymer experiences 
degradation by proton-catalysed hydrolysis, however, at pH above 10, β-alkoxy-elimination 
reaction occurs, resulting in depolymerisation of alginate polymer [222]. However, the possibility 
of alginate degradation due to low pH in the gastric phase is not accountable for the alginate 
incorporated into bread as little alginate was released from bread digestion in the gastric phase.   
Alginate fragmentation and degradation could reduce the size of alginate, hence, the efficiency of 
alginate as a pancreatic lipase inhibitor would be affected.  
Although the results obtained here which revealed that AB did not reduce the activity of pancreatic 
lipase, the Houghton et al study (2015) showed that alginate incorporated into bread could reduce 
the activity of pancreatic lipase. This discrepancy could be because the bread used in the Houghton 




cooks for 17-25 minutes, therefore, less breakdown of the alginate is likely to have occurred. 
However, the bread used in this study was cooked for a longer time (about 65 minutes), thus, more 
fragmentation of the alginate could be expected. Future studies could determine if this is the cause 
of the difference between this study and that of Houghton et al (2015).  
 
6.5 Future work 
This work has raised many interesting possibilities for future investigations not yet completed due 
to time constraints. In this study, data from both the turbidimetric assay and the synthetic model 
gut system have shown that alginates can potentially inhibit pancreatic lipase activity in vitro. The 
data also indicate that the level of lipase inhibition caused by alginate is affected by alginate 
concentration and structure. The capacity of alginates to inhibit the pancreatic lipase activity in 
vitro supports the future use of alginate, for example as a capsule, in vivo as a pancreatic lipase 
inhibitor to reduce fat digestion and absorption and hence, to treat obesity. The effect of alginate 
on pancreatic lipase activity in vivo could be evaluated by measuring the triglyceride level in the 
plasma. Moreover, this current study has focused on studying the effect of alginate on the fat 
digesting enzyme pancreatic lipase. It would, therefore, be interesting to study the effect of alginate 
on carbohydrate digestive enzymes such as α-amylase, α-glucosidase as well as protein digestive 
enzymes such as pepsin in vitro through α-amylase assay, α-glucosidase assays, pepsin assay and 
trypsin assay, respectively. Also, the regulatory effect of alginate on the activity of these enzymes 
in vivo could be investigated either through measuring the level of carbohydrate digestive enzymes 
(α-amylase and α-glucosidase) and the level of protein digestive enzymes (pepsin and trypsin) in 
saliva and gastric juice samples respectively, or through measuring the level of the end products of 
carbohydrate digestion (glucose) and the end products of protein digestion (amino acids, dipeptides, 
and tripeptides) in the blood after a test meal.  
Regardless of the several mechanisms which have been suggested for pancreatic lipase inhibition 
by alginate, the exact inhibition mechanism is still unknown. Therefore, it would be worthwhile to 
investigate the specific mechanism by which alginate inhibits the pancreatic lipase activity in future 
studies through the use of an x-ray crystallography techniques. In such techniques, a mixture of 
enzyme and inhibitor is crystallised, then the molecular structure of enzyme-inhibitor complex can 




The synthetic data from model gut experiments show that a high amount (1000mg) of alginate 
activates olive oil digestion. This activation could be due to gel formation resulting from either low 
pH in the gastric phase or the presence of Ca2+ ions in the saliva. The gel binds a lot of water, 
decreasing the volume of reaction solution, consequently, the enzyme-substrate concentrations in 
solution becomes higher, leading to activation of triglyceride digestion. Therefore, it would be 
sensible to do further binding studies on samples containing alginate and olive oil to investigate 
the level of enzyme-substrate interaction increases in the presence of high amount of alginate.  
The synthetic model gut data presented in this study also indicate that incorporating alginate into 
bread results in the loss of the inhibitory effect of alginate on pancreatic lipase activity and this 
might occur due to fragmentation of alginate as a result of the high temperatures during the cooking 
process. Alginate fragmentation affects its inhibition properties and reduces alginate capacity as a 
potent pancreatic lipase inhibitor. Therefore, a further study is still required to investigate the effect 
of high temperature on alginate polymer. This might be performed by heating alginate at different 
temperatures ranging from 50 to 200 0C, then the molecular size of alginate can be assessed using 
different techniques such as mass spectrometry, light scattering, analytical ultracentrifugation and 
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Graphs 1-7 - Concentration dependent inhibition of lipase caused by different alginates. Lipase activity (%) 
for olive oil alone (control), olive oil with Orlistat, and olive oil with1.2 and 4.8 mg/ml of (1) CC01, (2) 
1N80, (3) 1LF80, (4) BG3600, (5) BG3610, (6) BG3700 and (7) BG3900 alginates. Values are mean 
percentage lipase activity and the error bars are the standard deviation of three replicates (± SD, n=3), P 
values <0.0005 are represented by ****, whereas P vale >0.05 is represented by ns (non-significant 
difference). Buffer diluent included 0.033 M C6H8O7, 0.033 M H3PO4, 0.343 M KOH, 0.033 M H3BO3, 
and 0.35% sodium taurodeoxycholate (pH 7.0 ± 0.3, at 25˚C). The substrate was prepared by diluting 1% 








Appendix B- 1H NMR Spectrum of  alginates  using 700 and 500 MHz NMR machines.  
The method for preperation of alginates samples for 1H NMR analysis as well as the calculation of 
alginate content of guluronate (G) and mannuronate (M) residues are described in chapter 2 (section 
2.4.3, Figure 2.4 and Table 2.2, pp. 53-54) of this thesis. 1H NMR Data was generated by Dr Corrine 







Graph 1: 1H NMR Spectrum of CC01 alginate using 700 MHz NMR machine.  The spectra were run at 353K. Data was generated by Dr Corrine Wills, 





Graph 2: 1H NMR Spectrum of CC01 alginate using 500 MHz NMR machine.  The spectra were run at 353K. Data was generated by Dr Corrine Wills, 
NMR Officer, SAGE Technical Services, Newcastle University. Peaks in shaded region are relevant peaks to calculate signals A (G, proton1), B1 (GGM, 
proton 5), B2 (MGM, proton 5), B3 (MG, proton 1), B4 (MM, proton 1) and C (GG, proton 5) in order to determine alginate content and sequence of 





Graph 3: 1H NMR Spectrum of 1N80 alginate using 700 MHz NMR machine.  The spectra were run at 353K. Data was generated by Dr Corrine Wills, 







Graph 4: 1H NMR Spectrum of 1N80 alginate using 500 MHz NMR machine.  The spectra were run at 353K. (Carried out by NMR officer, Chemistry 
Department, Newcastle University). Data was generated by Dr Corrine Wills, NMR Officer, SAGE Technical Services, Newcastle University. Peaks in 
shaded region are relevant peaks to calculate signals A (G, proton1), B1 (GGM, proton 5), B2 (MGM, proton 5), B3 (MG, proton 1), B4 (MM, proton 1) 
and C (GG, proton 5) in order to determine alginate content and sequence of guluronate G) and mannuronate (M) residues (Chapter 2, Figure 2.4 and Table 







Graph 5:  1H NMR Spectrum of 1LF80 alginate using 700 MHz NMR machine.  The spectra were run at 353K. Data was generated by Dr Corrine Wills, 






Graph 6: 1H NMR Spectrum of 1LF80 alginate using 500 MHz NMR machine.  The spectra were run at 353K. Data was generated by Dr Corrine Wills, 






Graph 7: 1H NMR Spectrum of CC01, 1N80, and 1LF80 alginates using 500 MHz NMR machine.  The spectra were run at 353K. Data was generated by 
Dr Corrine Wills, NMR Officer, SAGE Technical Services, Newcastle University.  
